

CURRICULUM VITAE

Marc Carrier, MD, MSc, FRCPC

Prior relationships with LEO Pharma

- Research Funding for the [PERIOP-01 trial](#)
- Honoraria for consultancy meetings

Contents

Biography.....	2
Current Positions.....	3
Education	3
Current Hospital Privileges.....	3
Past Positions	4
Active Certification, Licensure and Professional Associations.....	4
Leadership Roles, Memberships and Committees.....	4
Honours and Awards.....	6
Research Salary Support.....	7
Research.....	7
Current Peer Reviewed Research Grants.....	7
Previously Held Peer Reviewed Research Grants.....	9
Industry Sponsored Trials.....	12
Publications.....	13
Book Chapters	13
Articles (peer reviewed)	14
Presentations	42
Invited Presentations – International Conferences	42
Invited Presentations – National/Provincial:	47
Invited Presentations – Local:	52
Abstract Oral Presentations – National Conferences	55
Abstract Oral Presentations – International Conferences.....	55
Poster Presentations – International Conferences	59
Poster Presentations – National Conferences	67
Teaching/Lectures.....	67
Other Academic/Teaching Experience	73
Clinical Electives:.....	76
Supervisory Activities.....	79
Co-Supervision:	79
Supervision:.....	80
Consultations, Workshops, Seminars	82
Peer Reviewer.....	86

Contact Information

University of Ottawa at The Ottawa Hospital, General Campus
Department of Medicine
Division of Hematology, Thrombosis Program
Ottawa Blood Disease Centre
501 Smyth Road, Box 201A
Ottawa, ON Canada, K1H 8L6

Tel: Administrative Assistant: 613-737-8899, Ext 73034
Direct: 613-737-8899, Ext 71393
Cell: 613-608-5203
Pager: 613-274-8110
Fax: 613-739-6102
E-mail: mcarrier@toh.ca

Biography

Dr. Marc Carrier, M.D., MSc, FRCPC, is Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. His clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management.

Current Positions

Head, Division of Hematology, Department of Medicine, University of Ottawa at The Ottawa Hospital	Jul 2019-present
Vice-Chair of Research, Department of Medicine, The Ottawa Hospital	2017-Jun 2019
Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute	2014-present
Professor, Hematology, Department of Medicine, University of Ottawa	2018-present
Cross-Appointment, Faculty of Graduate and Post-Doctoral Studies (FGPS) University of Ottawa	2012-present
Cross-Appointment, Department of Epidemiology and Community Medicine University of Ottawa	2010-present

Education

University of Ottawa

Ottawa, Ontario

Thrombosis Fellowship	2006-2008
Master's degree, Clinical Epidemiology	2006-2008
Doctorate of Medicine	1998-2002

Royal College of Physicians and Surgeons of Canada

Ottawa, Ontario

Fellow, Royal College of Physicians and Surgeons of Canada (FRCPC) – Hematology	2007-present
Fellow, Royal College of Physicians and Surgeons of Canada (FRCPC) – Internal Medicine	2006-present
Clinical Investigator Program	2006-2008

Current Hospital Privileges

The Ottawa Hospital	2008-present
Montfort Hospital	2010-present
Cornwall Community Hospital	2011-present

Past Positions

Associate Professor, Hematology, Department of Medicine, University of Ottawa	2013-2018
Assistant Professor, Hematology, Department of Medicine University of Ottawa	2008-2013
Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute	2011-2014
Associate Scientist, Clinical Epidemiology Program Ottawa Hospital Research Institute	2008-2011
Consultant Hematologist Dynacare laboratories	2008-2010

Active Certification, Licensure and Professional Associations

Royal College of Physicians & Surgeons of Canada Specialist Certificate in Hematology 2007-present	Canadian Medical Protective Association 2002-present
Royal College of Physicians & Surgeons of Canada Specialist Certificate in Internal Medicine 2006-present	Canadian Medical Association 2009-present
College of Physicians & Surgeons of Ontario (CPSO) 2002 to present	Ontario Medical Association 2009-present

Unconscious Bias in Medicine, Stanford University School of Medicine. Sep 28, 2020.

Undergraduate Education, MD Program Learning Environment. University of Ottawa Apr 2, 2015

Training: Food and Drug Regulations, Part C, Division 5, Drugs for Clinical Trials Involving Human Subjects. Ottawa Hospital Research Institute. Jan 17, 2013.

Training: Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans Research Ethics Course (TCPS 2: CORE). Oct. 4, 2011.

Good Clinical Practices, Investigator Training Program. Nov 30, 2009.

Leadership Roles, Memberships and Committees

Scientific Officer, CIHR Project Grant Review for Fall 2020 competition, Canadian Institutes of Health Research	Jan 2021
Member, Patient and Scientific Review Board (Thrombosis), LEO Pharma	2021-present
Director, Area of Focused Competency Fellowship in Adult Thrombosis Medicine, University of Ottawa	2011-2020

Associate Editor, Journal of Thrombosis and Haemostasis	2015-present
SSC Liaison, ISTH Education Core Committee. International Society on Thrombosis and Haemostasis (ISTH)	2020-present
Member, ISTH Scientific Planning Committee Task Force. International Society on Thrombosis and Haemostasis (ISTH)	2020-present
Chairman, Scientific & Standardization Committee (SSC) – Scientific Subcommittee, International Society on Thrombosis and Haemostasis (ISTH)	2019-present
Member, ISTH Scientific Program Committee, International Society on Thrombosis and Haemostasis (ISTH)	2020-present
Faculty Mentor. External Mentorship Pilot Program for non-malignant hematology. American Society of Hematology (ASH).	2020-
Member, ASH VTE Patient Decision Aid Task Force. American Society of Hematology	2020-2021
Member Administrative Board, Institut du Savoir Montfort (ISM)	Oct 2020-pres
Chair, SSC – Scientific Subcommittee on Hemostasis & Malignancy, ISTH	2015-present
Co-Lead, Training and Mentoring platform CanVECTOR, Canadian <u>V</u> enous Thrombosis <u>C</u> linical <u>T</u> rials <u>O</u> Rganisation	2015-2019
Secretary (Executive Member), Thrombosis Canada	2016-present
Member, American Society of Hematology (ASH) Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer. American Society of Hematology	2015-2021
Scientific Officer, Randomized Controlled Trials (RCT) Grant Review Committee, Canadian Institutes of Health Research	2017-present
Member, Postgraduate Medical Education Awards Evaluation Committee, University of Ottawa	2015-present
Member, Editorial Board, Thrombosis Research	2011-present
Member, Academic Evaluation Committee, Department of Medicine – The Ottawa Hospital	2011-present
Member, Vertical Mentorship Program, University of Ottawa Faculty of Medicine	2011-present
Member, Canadian Hematology Society (CHS)	2010-present
Member, Hematology Residency Training Committee, University of Ottawa	2009-present
Member, Hematology Residency Selection Committee, University of Ottawa	2009-present

Executive Member, <u>V</u> enous Thrombosis <u>C</u> linical <u>T</u> rials <u>O</u> Rganisation (VECTOR)	2008-present
Member, ISTH	2006-present
Member, ASH	2001-present
Reviewer, ISTH 2013 abstract program, XXIV Congress of the International Society on Thrombosis and Haemostasis.	2013
Member, Specialty Committee in Hematology, Royal College of Physicians and Surgeons of Canada	2011-2012
Member, Pediatric Hematology Residents Training Committee, University of Ottawa	2011-2012
Chair, VECTOR	2010-2011
Member, RCT Grant Review Committee, Canadian Institutes of Health Research	2010-2016
Member, Scientific Review Committee VI – Thrombosis, lipids and lipoproteins, and fundamental Nutrition research, Heart and Stroke Foundation of Canada	2009-2014

Honours and Awards

Recipient, Best presentation. Department of Medicine Grand Rounds, Dalhousie University.	2020
Distinguished Editorial Service Award, Research and Practice in Thrombosis and Haemostasis (RPTH).	2020
New Investigator Award – Heart and Stroke Foundation of Canada (\$300,000)	2012-2017
Dr. Michel Chrétien Researcher of the Year Award, Ottawa Hospital Research Institute	2015
Recipient, 2015 CHS Paper of the Year Award, Canadian Hematology Society	2015
Faculty of Medicine Distinguished Young Professor Award, University of Ottawa	2012
Canadian Institutes of Health Research Fellowship (\$50,000)	2007-2008
Fellowship for New Faculty Award – University of Ottawa (\$120,000)	2007-2008
Award for Excellence in Research, Internal Medicine Resident Research Day The Ottawa Hospital (\$1,000)	2006-2007
John H. Crookston Travel Award, Canadian Hematology Society (\$3,000)	2006

Travel Award, American Society of Hematology (\$1,000)	2006
Resident Research Award - Canadian Institutes of Health Research (\$1,000)	2006
Clinical Research Training Institute Scholarship – American Society of Hematology (\$5,000)	2006

Research Salary Support

University of Ottawa Tier 1 Research Chair :2020-2025 (\$2,000,000)
Venous Thromboembolism in Cancer

University of Ottawa Tier 2 Research Chair: 2011-2020 (\$1,000,000)
Venous Thromboembolism in Cancer

Heart and Stroke Foundation of Canada New Investigator Award: 2012-2017 (\$300,000)
Screening for occult cancer in patients with unprovoked venous thromboembolism.

Canadian Institutes of Health Research (CIHR) Mentoring Award: 2009-2011
(\$160,000).

Role: Principal Investigator. Screening for previously undiagnosed cancer in patients with venous thromboembolism.

Canadian Institutes of Health Research (CIHR) fellowship: 2007-2008 (\$100,000).

Principal Investigator. Screening for previously undiagnosed cancer in patients with venous thromboembolism. A Pilot Study.

R&D Health Research Foundation Summer Research Scholarship: 2000 (\$5,000).

Research

Current Peer Reviewed Research Grants

1. **Canadian Institutes of Health Research – ICRH Community Development Program.** 2015-2021 (\$1,500,000).
CanVECTOR (Canadian Venous Thrombosis Clinical Trials Outcomes Research) Network
Role: Co-Lead Training, mentoring, and early career development network. Co-Lead: Dr. Sudeep Shivakumar. PI's: Dr. Susan Kahn and Dr. Marc Rodger.
2. **Canadian Institutes of Health Research – Operating Grant: Clinical Research Infrastructure Support for COVID-19.** Jun 2020-Nov 2020 (\$150,000).
CanVECTOR (Canadian Venous Thrombosis Clinical Trials Outcomes Research) Network
Role: Co-Investigator. PI's: Dr. Susan Kahn and Dr. Marc Rodger.

3. **Canadian Institutes of Health Research – Project Grant: 2021-2026 (\$1,383,745).** Role: Co-Principal Investigator with Dr. Rick Ikesaka. Primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters: TRIM-Line.
4. **Canadian Institutes of Health Research – Project Grant: 2019-2024 (\$895,050)**
Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Aurélien Delluc. Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism: a Randomized Controlled Trial using 18F-Fluorodeoxyglucose Positron Emission Computed Tomography. (SOME-2)
5. **Canadian Institutes of Health Research – COVID-19 Rapid Research Funding Operating Grant.** Jul 2020-Jun 2021 (\$303,658). Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Deborah Siegal. Venous Thrombosis Virtual Surveillance in COVID (VVIRTUOSO).
6. **Physician’s Services Incorporated Foundation (PSI) – Jul 2020-Jun 2022 (\$100,000).**
Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Joseph Shaw. Global assessment of hemostatic TGA indices following the use of prothrombin complex concentrates for major bleeding or urgent surgery in patients treated with factor Xa inhibitors GAUGE - a prospective observational cohort study.
7. **TOHAMO – The Ottawa Hospital Academic Medical Organization – Innovation Fund:** Mar 2019-Mar 2022. (\$95,581). Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Rebecca Auer. Creation and implementation of risk-stratified patient decision aid to improve the appropriateness of postoperative extended thromboprophylaxis in patients undergoing abdominal surgery for cancer.
8. **CanVECTOR – Canadian VENous Thrombosis CLinical TRials ORganisation – Pilot Trial Funding:** Oct 2019-Sep 2021 (\$71,000) and **Canadian Hematology Society – RK Smiley Research Grant (\$20,000).** Role: Co-Principal Investigator with Dr. Miriam Kimpton. Thromboprophylaxis with apixaban in polycythemia vera and JAK2-positive essential thrombocythemia patients: A pilot randomized controlled trial assessing feasibility.
9. **Canadian Institutes of Health Research – COVID-19 Rapid Research Funding Operating Grant:** Jul 2020-Jun 2021 (\$3,573,336). Role: Co-Applicant. Principal Investigator: Dr. Ryan Zarychanski. Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): A randomized, international, multi-centre, adaptive, controlled clinical trial.
10. **Canadian Institutes of Health Research – COVID-19 Rapid Research Funding Operating Grant:** Jul 2020-Jun 2021 (\$2,176,566). Role: Co-Applicant. Principal Investigators: Drs. Alexis Turgeon and Ryan Zarychanski. Anticoagulation and convalescent plasma ICU trials in REMAP-CAP.

11. **Canadian Institutes of Health Research – Project Grant: 2021-2023 (\$179,776)**
Role: Co-Applicant. Principal Investigator: Dr. Deborah Siegal. Post-Bleed Management of Antithrombotic Therapy after Gastrointestinal Bleeding (PANTHER-GI): A Mixed-Methods Study of Patient Values and Preferences.
12. **The Heart and Stroke Foundation of Canada – 2020/2021 Bridge Grant. Jul 1, 2020-Jun 30, 2021 (\$50,000).** Co-Applicant. Principal Investigator: Dr. Manish Sood. Reducing bleeding with newer anticoagulants: the STOP-BLEED Study.
13. **Canadian Institutes of Health Research – Project Grant: 2019-2024 (\$4,482,900)**
Role: Co-Investigator. Principal Investigator: Dr. Sudeep Shivakumar. Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty (EPCAT III).
14. **Swiss National Science Foundation – Investigator Initiated Clinical Trials (IICT): Jul 2019-Apr 2024 (1,315,113 CHF).** Role: International Partner, Steering Committee member. Principal Investigator: Prof. Drahomir Aujesky, University of Bern, Switzerland. Clinical surveillance vs. anticoagulation for low-risk patients with isolated subsegmental pulmonary embolism: a multicenter randomized placebo-controlled non-inferiority trial.

Previously Held Peer Reviewed Research Grants

1. **Hamilton Academic Health Sciences Organization (HAHSO) - AFP Innovation Grant 2019/20 (\$94,570).** Role: Co-Investigator. Principal Investigator: Dr. Deborah Siegal. A population cohort study to evaluate the risk of ischemic stroke, stroke treatments and post-stroke outcomes among individuals with cancer compared to matched cancer-free controls.
2. **CanVECTOR – Canadian Venous Thrombosis Clinical Trials ORganisation – Pilot Trial Funding: Oct 2017-Sep 2019 (\$52,224).** Role: Co-Principal Investigator with Dr. Rick Ikesaka. A pilot study assessing the feasibility of a randomized controlled trial investigating primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters (TRIM-Line).
3. **CanVECTOR – Canadian Venous Thrombosis Clinical Trials ORganisation – Pilot Trial Funding: Oct 2017-Sep 2019 (\$38,819).** Role: Co-Principal Investigator with Dr. Noémie Kraaijpoel. Tumour-educated platelets to detect cancer in patients with unprovoked venous thromboembolism.
4. **CanVECTOR – Canadian Venous Thrombosis Clinical Trials ORganisation – Clinical Trials and Shared Research Platforms: 2017-2018 (\$58,957) and **Calgary Centre for Clinical Research (CCCR) Clinic Research Fund (CRF (\$30,000).** Role: Co-Investigator. Principal Investigator: Dr. Deepa Suryanarayan. Apixaban versus low molecular weight heparin for treatment of catheter related thrombosis in cancer patients - A pilot study to assess feasibility of a randomized controlled trial.**

5. **Canadian Institutes of Health Research – Operating Grant (\$2,039,985): 2014-2017 and Heart and Stroke Foundation of Canada (\$238,598) (Total: \$2,278,583).** Role: Co-Investigator. Principal Investigator: Dr. James Douketis. Perioperative New Oral Anticoagulant Study (PAUSE Study).
6. **The Heart and Stroke Foundation of Canada 2014/15 Grant-in-Aid (GIA): 2014-2017 (\$235,312).** Role: Co-Investigator. Principal Investigator: Dr. Grégoire Le Gal. Clinical predictors for venous thromboembolism in patients with a history of Thrombosis (PREDICTORS).
7. **Canadian Institutes of Health Research – Operating Grant: 2013-2016 (\$742,083).** Role: Co-Investigator. Principal Investigator: Dr. Clive Kearon. D-dimer testing, tailored to clinical pretest probability, to minimize initial and follow-up ultrasound testing in suspected deep vein thrombosis. A management study. 4D Study.
8. **Heart & Stroke Foundation of Ontario – Operating Grant: 2012-2015 (Total: \$141,648 plus \$70,000).** Role: Principal Investigator. The Management of Subsegmental Pulmonary Embolism: A Prospective Cohort Study (SSPE).
9. **Heart & Stroke Foundation of Canada – Multi-Provincial Grant-In-Aid: 2011-2014 (\$601,659); and Multi-provincial Operating Grant: 2009-2011 (\$160,000).** Role: Principal Investigator. Screening for previously undiagnosed cancer in patients with venous thromboembolism. The SOME Trial.
10. **The Ottawa Hospital, Department of Medicine – Operating Grant: 2009 (\$30,000).** Role: Principal Investigator. The Use of Extended Perioperative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Pilot Randomized Controlled Trial.
11. **Canadian Institutes of Health Research – Operating Grant: 2012-2015 (\$836,840) and Bristol-Myers Squibb/Pfizer Alliance 2016-2018 (\$524,380).** Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Phil Wells. New Oral Anticoagulants for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial (AVERT).
12. **Canadian Institutes of Health Research - Operating Grant: 2010-2014 (\$816,176) and LEO Pharma Inc. 2015-2018 (\$363,550).** Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Rebecca Auer. The Use of Extended Perioperative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Randomized Controlled Trial (PERIOP I).
13. **Canadian Foundation for Innovation: 2011-2014 (Total: \$155,357, my share \$44,778).** Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Rebecca Auer. Innovative Cancer Therapies – Targeting the Perioperative Period – A Translational Research Program.

14. **Canadian Institutes of Health Research – Operating Grant:** 2012-2015 (\$460,462).
Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Susan Kahn. Randomized controlled trial of anticoagulation vs. placebo for a first symptomatic isolated distal deep-vein thrombosis (IDDVT): The CACTUS-PTS Trial.
15. **The Ottawa Hospital, Department of Medicine – Developmental Research Grant:** 2013 (Total: \$7,761). Role: Co-Principal Investigator with Co-Principal Investigator: Dr. Rakesh Patel. Determining the Safety of Enoxaparin Prophylaxis in Critically Ill Adults with Severe Renal Insufficiency.
16. **The Physician’s Services Incorporated Foundation (PSI):** 2005 (\$20,000).
Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Greg Knoll. Antibodies to the heparin-platelet factor 4 complex and hemodialysis vascular access thrombosis. Grant #R05-28.
17. **Canadian Institutes of Health Research - Operating Grant:** 2013-2017 (\$981,033). Role: Co-Investigator. Principal Investigator: Dr. Clive Kearon. D-dimer testing, tailored to clinical pretest probability, to reduce use of CT pulmonary angiography in suspected pulmonary embolism: A management study. (PE Graduated D-dimer [PEGeD] Study).
18. **Heart and Stroke Foundation of Canada – Grant-in-Aid:** 2013-2016 (\$166,336).
Role: Co-Investigator. Principal Investigator: Dr. Mark Crowther. Rivaroxaban for the secondary prevention of thromboembolism in patients with the antiphospholipid antibody syndrome (RAPS).
19. **Canadian Institutes of Health Research – Operating Grant:** Oct 2012-Sep 2016 (\$3,044,877). Role: Co-Investigator. Principal Investigator: Dr. David Anderson. Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II).
20. **Canadian Institutes of Health Research - Rapid Funding for Drug Safety and Effectiveness Network (DSEN) Targeted Research:** Oct 2014-Mar 2015 (\$119,896).
Role: Co-Investigator. Principal Investigators: Dr. George Wells and Dr. Barnaby Reeves. New Oral Anticoagulants for the Treatment and Prevention of Venous Thromboembolism: A Systematic Review and Network Meta-Analysis.
21. **Heart and Stroke Foundation - Operating Grant:** 2012-2015 (\$161,217).
Role: Co-Investigator. Principal Investigator: Dr. Phil Wells. Analysis of Pro-coagulant Markers for the prediction of therapeutic failure during anticoagulation in cancer patients at high-risk for recurrence of Venous Thromboembolism: A pilot study. (REMARK).
22. **Canadian Institutes of Health Research – Operating Grant:** 2011-2013 (\$100,000).
Role: Co- Investigator. Principal Investigators: Dr. Ryan Zarychanski and Dr. Dean Fergusson. A pilot randomized controlled trial to evaluate the efficacy of unfractionated Heparin in septic shock.

23. **Canadian Institutes of Health Research – Operating Grant:** 2012-2014 (\$288,152). Role: Co- Investigator. Principal Investigators: Dr. Ryan Zarychanski and Dr. Dean Fergusson. Heparin Anticoagulation to improve Outcomes in septic shock: The HALO pilot.
24. **Heart and Stroke Foundation of Canada – Grant-in-Aid:** 2012-2013 (\$140,245). Role: Co-Investigator. Principal Investigator: Dr. Sam Schulman. Prospective cohort study on the safety of peri-operative management of dabigatran.
25. **Heart and Stroke Foundation of Canada – Operating Grant:** 2009-2013 (\$392,598); and **Canadian Institutes of Health Research – Operating Grant-PA: Bridge Funding:** 2000 (\$95,982). Role: Co-Investigator. Principal Investigator: Dr. Marc Rodger. REcurrent VEnous Thromboembolism Risk Stratification Evaluation, Long Term Follow-up (REVERSE LTF).
26. **Canadian Institutes of Health Research – Operating Grant:** 2010-2011 (\$46,243). Role: Co-Investigator. Principal Investigator: Dr. Marc Rodger. Gene-Gene Interactions and Recurrent Venous Thromboembolism (GENErVTE).

Industry Sponsored Trials

1. **Canadian National Lead Investigator and Site Principal Investigator:** Sep 2014-May 2018. Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER). Sponsor: Janssen Research & Development LLC (JNJ-39039039).
2. **Site Principal Investigator:** Mar 2015-Dec 2017. A Phase 3B, prospective, randomized, open-label, blind evaluator study evaluating the efficacy and safety of (LMW) heparin/edoxaban vs dalteparin in venous thromboembolism associated with cancer (DU176b-DU311) (PROBE). Sponsor: Daiichi Sankyo, Inc.
3. **Site Principal Investigator:** Nov 2014-Dec 2017. A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban with Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis (OCOG-2013-RASET) (The RASeT Trial). Sponsor: Bayer
4. **Site Principal Investigator:** Sep 2014-Sep 2016. An observational multicenter cohort study on efficacy and safety of Unactivated Prothrombin complex concentrate for reversal of oral, direct factor Xa inhibitors Rivaroxaban or Apixaban in Treatment of major bleeding Events (UPRATE). Sponsor: Octapharma Canada Inc.
5. **Site Principal Investigator and Member, National Coordinator Council:** Aug 2014-Dec 2016. Prospective, multi centre, international registry of treatment and long-term outcomes in patients with acute symptomatic venous thromboembolic events in the real world (GARFIELD-VTE). Sponsor: Bayer, Thrombosis Research Institute, London (TRI).

6. **Site: Principal Investigator.** Principal Investigator: Sam Schulman: May 2014-May 2016. An Observational multicentre cohort study of efficacy and safety of activated prothrombin complex concentrate (FEIBA NF) for reversal of dabigatran (Pradaxa) in major bleeding (FRED). Sponsor: Baxter Healthcare Corporation
7. **Nominated Principal Applicant:** Nov 2012-Apr 2013. Working Group to standardize the management of new oral anticoagulants throughout The Ottawa Hospital and Champlain LHIN.
8. **Site Principal Investigator:** 2011-present. A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/apixaban versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism (AMPLIFY). Sponsor: Bristol Myers-Squibb.
9. **Site Principal Investigator:** Jun 2009-Jun 2013. FRAG-A001-401. Dalteparin sodium injection (Fragmin), multicenter, open label, single-arm, controlled long term (52 weeks) study for understanding safety and efficacy in subjects with malignancies and symptomatic venous thromboembolism. (DalteCAN) Sponsor: Pfizer.
10. **Site Co-investigator:** 2010-present. A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism (HOKUSAI VTE). Sponsor: Daiichi Sankyo.
11. **Site Co-investigator: Apr** 2008-May 2011. A phase III randomized, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg BID) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with parenteral anticoagulant approved for this indication (RE-COVERII). Sponsor: Boehringer Ingelheim.
12. **Site Principal Investigator and National Coordinator:** Jun 2008-Nov 2010. A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy (SAVE-ONCO). Sponsor: Sanofi Aventis.

Publications

Book Chapters

1. Shivji S, **Carrier M.** Screening for Cancer in Unprovoked Venous Thromboembolism. HemaSphere Educational Updates in Hematology Book. 2019, 3(S2). pp 22-23. Publisher: Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

2. **Carrier M**, Cushman M. Chapter 50: Epidemiology and Prognosis of Venous Thromboembolic Disease. In *Vascular Medicine: A Companion to Braunwald's Heart Disease*, 3rd Edition. Jun 2019. Publisher Elsevier.
3. **Carrier M, Soff GA, Le Gal G**. Chapter 7: Treatment of venous thromboembolism in cancer. Historical perspective and evolving role of the direct oral anticoagulants. In *Thrombosis and Hemostasis in Cancer*. 2019. pp 103-115. Publisher: Springer Nature Switzerland. Editors: Gerald Soff and Nicole Kuderer.
4. **Carrier M**, Moretto P. Chapter 4: Deep Vein Thrombosis and Cancer in Current Approaches to Deep Vein Thrombosis. Publisher FutureMedicine.com. Editors: Henri Bounameaux and Grégoire Le Gal). 2013.

Articles (peer reviewed)

Published

1. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. *N Engl J Med*. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25. PMID: 33631065
2. Caiano LM, Riva N, **Carrier M**, Gatt A, Ageno W. Treatment of portal vein thrombosis: an updated narrative review. *Minerva Med*. 2021 Apr 9. doi: 10.23736/S0026-4806.21.07526-1. Online ahead of print. PMID: 33832217.
3. Thachil J, Khorana A, **Carrier M**. Similarities and Perspectives on the two C's - Cancer and COVID-19. *J Thromb Haemost*. 2021 May;19(5):1161-1167. PMID: 33725410.
4. Ladha D, Mallick R, Wang TF, Caiano L, Wells PS, **Carrier M**. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. *Thromb Res*. 2021 Mar 21;202:151-154. doi: 10.1016/j.thromres.2021.03.013. Online ahead of print.

5. Aziz D, Skeith L, Rodger MA, Sabri E, Righini M, Kovacs MJ, **Carrier M**, Kahn SR, Wells PS, Anderson DR, Chagnon I, Solymoss S, Crowther MA, White RH, Le Gal G. Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. *J Thromb Haemost*. 2021 Mar 16. PMID: 33724705. Online ahead of print.
6. Sholzberg M, Tang GH, Negri E, Rahhal H, Kreuziger LB, Pompilio CE, James P, Fralick M, AlHamzah M, Alomran F, Tseng E, Lim G, Lillicrap D, **Carrier M**, Ainle FN, Beckett A, da Costa BR, Thorpe K, Middeldorp S, Lee A, Cushman M, Jüni P. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2021 Mar 10;22(1):202. PMID: 33691765.
7. Lyman GH, **Carrier M**, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood Adv*. 2021 Feb 23;5(4):927-974. PMID: 33570602.
8. Schaefer JK, Li M, Wu Z, Basu T, Barnes GD, **Carrier M**, Griggs JJ, Sood SL. Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. *J Thromb Thrombolysis*. 2021 Feb 5. PMID: 33544284. Online ahead of print.
9. You D, Xu Y, Ponich B, Ronksley P, Skeith L, Korley R, **Carrier M**, Schneider PS. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. *Bone Joint J*. 2021 Feb;103-B(2):222-233. PMID: 33517730.
10. Michalowski M, Wilk S, Michalowski W, **Carrier M**. MitPlan: A planning approach to mitigating concurrently applied clinical practice guidelines. *Artif Intell Med*. 2021 Feb;112:102002. PMID: 33581823. Epub 2020 Dec 16.
11. Becattini C, Cimini LA, **Carrier M**. Challenging anticoagulation cases: A case of pulmonary embolism shortly after spontaneous brain bleeding. *Thromb Res*. 2021 Jan 26;200:41-47. PMID: 33529872. Online ahead of print.
12. Schaefer JK, Li M, Wu Z, Basu T, Dorsch MP, Barnes GD, **Carrier M**, Griggs JJ, Sood SL. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. *J Thromb Haemost*. 2021 Jan;19(1):212-220. PMID: 33104289.
13. Knoll W, Mallick R, Wells PS, **Carrier M**. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. *Thromb Res*. 2021 Jan;197:13-15. PMID: 33160115.
14. Chibane S, Gibeau G, Poulin F, Tessier P, Goulet M, **Carrier M**, Lanthier S. Hyperacute multi-organ thromboembolic storm in COVID-19: A case report. *J Thromb Thrombolysis*. 2021 Jan;51(1):25-28. PMID: 32506364.

15. Le Gal G, **Carrier M**, Castellucci LA, Cuker A, Hansen JB, Klok FA, Langlois NJ, Levy JH, Middeldorp S, Righini M, Walters S; ISTH CDE Task Force. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. *J Thromb Haemost*. 2021 Jan;19(1):297-303. PMID: 33405381.
16. Budd AC, Rhodes M, Forster AJ, Noghani P, **Carrier M**, Wells PS. Prescribing patterns and outcomes of venous thromboembolism prophylaxis in hospitalized medical and cancer patients: Observations from the Ottawa Hospital. *Thromb Res*. 2021 Jan;197:144-152. PMID: 33217622.
17. Kumar V, Shaw J, Key NS, Ilich A, Mallick R, Wells P, **Carrier M**. D-dimer enhances risk targeted thromboprophylaxis in ambulatory cancer patients. *Oncologist*. 2020 Dec;25(12):1075-1083. PMID: 32969580.
18. Wang TF, Makar RS, Antic D, Levy JH, Douketis JD, Connors JM, **Carrier M**, Zwicker JI. Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. *J Thromb Haemost*. 2020 Dec; 3174-3183. DOI: 10.1111/jth.15074.pub
19. Shaw JR, Kumar V, Mallick R, **Carrier M**, Ilich A, Key NS, Wells P. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. *Thromb Res*. 2020 Dec;196:437-443. PMID: 33065408.
20. Shaw J, **Carrier M**, Dowlatshahi D, Chakraborty s, Tokessy M, Buyukdere H, Castellucci L. Activated Prothrombin Complex Concentrates for the Management of Direct Oral Anticoagulant-Associated Bleeding Events and Pre-Operative Administration for Urgent Surgery: Hemostatic and Thrombotic Outcomes. *Thromb Res*. 2020 Nov;195:21-28. PMID: 32645667.
21. McAlpine K, Breau R, **Carrier M**, Violette P, Knee C, Cagiannos I, Morash C, Lavallée L. Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre. *Can J Surg*. 2020 Nov 30;63(6):E562-E568. PMID: 33253514.
22. Kearon C, **Carrier M**, Gu CS, Schulman S, Bates SM, Kahn SR, Chagnon I, Nguyen DT, Wu C, Rudd-Scott L, Julian JA. Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. *Semin Thromb Hemost*. 2020 Nov;46(8):977-985. PMID: 33368114.
23. Khorana AA, Cohen AT, **Carrier M**, Meyer G, Pabinger I, Kavan P, Wells PS. Prevention of venous thromboembolism in ambulatory patients with cancer. *ESMO Open*. 2020 Nov;5(6):e000948. PMID: 33229505.
24. Ripsman D, Fergusson DA, Montroy J, Auer RC, Huang JW, Dobriyal A, Wesch N, **Carrier M**, Lalu MM. A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. *Thromb Res*. 2020 Nov;195:103-113. PMID: 32683148.

25. Chiasakul T, Patell R, Maraveyas A, **Carrier M**, Zwicker JI. Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. *J Thromb Haemost*. 2020 Nov 10. PMID: 33174368. Online ahead of print.
26. Xu Y, You D, Krzyzaniak H, Ponich B, Ronksley P, Skeith L, Salo P, Korley R, Schneider P, **Carrier M**. Effect of Oral Anticoagulants on hemostatic and thromboembolic complications in hip fracture: A systematic review and meta-analysis. *J Thromb Haemost*. 2020 Oct;18(10):2566-2581. PMID: 32574420.
27. Ng S, **Carrier M**. Prevention and treatment of cancer-associated thrombosis. *Curr Oncol*. 2020 Oct;27(5):275-278. PMID: 33173380.
28. McCurdy JD, Kuenzig ME, Smith G, Spruin S, Murthy SK, **Carrier M**, Nguyen GC, Benchimol EI. Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: A population-based study. *Inflamm Bowel Dis*. 2020 Oct 23;26(11):1761-1768. PMID: 31995204.
29. den Exter PL, Kroft LJM, Gonsalves C, Le Gal G, Schaefer-Prokop CM, **Carrier M**, Huisman MV, Klok FA, Meijboom L, Beenen LF, de Roos A, Hartmann I, Dennie C, Revel MP, Haramati L, van Beek E, Screatton N, Ferretti G, Ghaye B, Das M, White C, Pena Fernandez E, Paul N, Vlahos I, Renapurkar RD, Ravenel J, Kanne J, Abbara S, Rémy-Jardin M, Geurts B, Frauenfelder T, Sverzellati N, Prosch H, Goo JM, Vogel-Claussen J, MacMahon PJ, Bhalla S, Kahn S, Shivakumar S, Wells P, Rodger M, Castellucci L, Duffett L, Delluc A, Siegal D, Lazo-Langner A, Wu C, Lee A, Garcia D, Zwicker J, Aujesky D, Jimenez D, Righini M, Blondon M, Ay C, Barco S, Kamphuisen PW, Ferreira M, Sanchez O, Moores LK, Tromeur C, Ageno W, Hunt B, Prandoni P, Monreal M, Crowther M, Roy PM, Pabinger I, Donadini MP, Moustafa F, Jara-Palomares L, Pedroc R, Bertolotti L, Verhamme P, Eikenboom H, van der Meer F, Büller HR, van Es N. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts. *Res Pract Thromb Haemost*. 2020 Oct 1;4(8):1251-1261. PMID: 33313465.
30. Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, **Carrier M**, Dzavik V, Fergusson DA, Fowler RA, Galanaud JP, Gross PL, McDonald EG, Husain M, Kahn SR, Kumar A, Marshall J, Murthy S, Slutsky AS, Turgeon AF, Berry SM, Rosenson RS, Escobedo J, Nicolau JC, Zarychanski R. Anti-thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. *Clin Trials*. 2020 Oct;17(5):491-500. PMID: 32815416.

31. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothlin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC; Writing Committee for the REMAP-CAP Investigators, Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *JAMA*. 2020 Oct 6;324(13):1317-1329. PMID: 32876697.
32. Zhang J, Atalla M, Mallick R, Wells PS, **Carrier M**. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. *J Thromb Thrombolysis*. 2020 Oct 20. Online ahead of print. PMID: 33079379
33. Murthy SK, Robertson McCurdy AB, **Carrier M**, McCurdy JD. Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. *Thromb Res*. 2020 Oct;194:26-32. PMID: 32563061.
34. Mulder FI, Bosch FTM, Young AM, Marshall A, McBane RD, Zemla T, **Carrier M**, Kamphuisen PW, Bossuyt PM, Buller HR, Weitz JI, Middeldorp S, van Es N. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. *Blood*. 2020 Sep 17;136(12):1433-1441. PMID: 32396939.
35. Riva N, **Carrier M**, Gatt A, Ageno W. Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey. *Res Pract Thromb Haemost*. 2020 Sep 11;4(7):1192-1202. eCollection 2020 Oct. PMID: 33134784.
36. Moores LK, Tritschler T, Brosnahan S, **Carrier M**, Collen JF, Doerschug K, Holley AB, Jimenez D, LeGal G, Rali P, Wells P. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. *Chest*. 2020 Sep;158(3):1143-1163. PMID: 32502594.
37. Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V, Wahl D, Doré CJ, Cuker A, **Carrier M**, Pengo V, Devreese KMJ. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost*. 2020 Sep;18(9):2126-2137. PMID: 32881337
38. **Carrier M**, Wang TF. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some? *Blood*. 2020 Aug 6;136(6):669-673. PMID: 32575112.

39. Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. Cancer Associated Thrombosis in Everyday Practice: Perspectives From GARFIELD-VTE. *J Thromb Thrombolysis*. Aug;50(2):267-277. PMID: 32583306.
40. Hill K, Sucha E, Rhodes E, **Carrier M**, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll G, McArthur E, Sood MM. Risk of Hospitalization with Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. *JAMA Intern Med*. 2020 Aug 1;180(8):1052-1060. PMID: 32511684.
41. D'Astous J, **Carrier M**. Screening for Occult Cancer in Patients with Venous Thromboembolism. *J Clin Med*. 2020 Jul 27;9(8):E2389. PMID: 32726911.
42. Ilich A, Kumar V, Henderson M, Mallick R, Wells P, **Carrier M**, Key NS. Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. *Thromb Res*. 2020 Jul;191 Suppl 1:S31-S36. PMID: 32736776.
43. Mulder F, **Carrier M**, van Doormaal F, Robin P, Otten HM, Salaun PY, Büller HR, Le Gal G, van Es N. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: results from an individual patient data meta-analysis. *J Thromb Haemost*. 2020 Jul 12;18(10):2622-2628. PMID: 32654348.
44. **Carrier M**. Debate: Thromboprophylaxis should be considered in all patients with cancer - Yes. *Thromb Res*. 2020 Jul;191:142-144. PMID: 32386983. Review.
45. Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertolotti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, **Carrier M**, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. *Thromb Haemost*. 2020 Jul;120(7):1004-1024. PMID: 32473596.
46. Stephen MS, Castellucci L, **Carrier M**, Duffett L, Le Gal G, Rodger M, Wells PS, Delluc A. Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. *Haematologica*. 2020 Jun;105(6):e307-e309. PMID: 31582557.

47. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, **Carrier M**, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Review. *J Am Coll Cardiol*. 2020 Jun 16;75(23):2950-2973. PMID: 32311448.
48. Delluc A, Miranda S, den Exter P, Louzada M, Alatri A, Ahn S, Monreal M, Khorana A, Huisman MV, Wells PS, **Carrier M**. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. A systematic review and meta-analysis. *Haematologica*. 2020 May;105(5):1436-1442. doi: 10.3324/haematol.2019.222828.
49. Montroy J, Lalu MM, Auer RC, Grigor E, Mazzarello S, **Carrier M**, Kimmelman J, Fergusson DA. The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. *Thromb Haemost*. 2020 May;120(5):832-846. PMID: 32369854.
50. Legault K, Blostein M, **Carrier M**, Kahn S, Schulman S, Shivakumar S, Wu C, Crowther MA. Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. *Pilot Feasibility Stud*. 2020 May 18;6:67. PMID: 32477586. eCollection 2020.
51. Roberge G, **Carrier M**. How to manage patients with symptomatic subsegmental pulmonary embolism? *Pol Arch Intern Med*. 2020 Apr 30;130(4):310-316. PMID: 32091505.
52. Legault K, Blostein M, **Carrier M**, Khan S, Schulman S, Shivakumar S, Wu C, Crowther MA. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. *Pilot Feasibility Stud*. 2020 Apr 25;6:52. doi: 10.1186/s40814-020-00594-1. eCollection 2020.
53. Fulcher J, **Carrier M**. Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches? *Thromb Res*. 2020 Apr;188:100-102. PMID: 32120278.
54. Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, Garcia DA, Khorana AA, **Carrier M**, Lyman GH. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. *Cancer*. 2020 Apr 15;126(8):1736-1748. PMID: 31999844.
55. Fernando SM, Mok G, Castellucci LA, Dowlatshahi D, Rochweg B, McIsaac DI, **Carrier M**, Wells PS, Bagshaw SM, Fergusson DA, Tanuseputro P, Kyeremant K. Impact of anticoagulation on mortality and resource utilization among critically ill patients with major bleeding. *Crit Care Med*. 2020 Apr;48(4):515-524. PMID: 32205598

56. Wilk S, Kezadri-Hamiaz M, Amyot D, Michalowski W, Kuziemsy C, Catal N, Rosu D, **Carrier M**, Giffen R. An ontology-driven framework to support the dynamic formation of an interdisciplinary healthcare team. *Int J Med Inform.* 2020 Apr;136:104075. PMID: 31958670.
57. Galanaud JP, Righini M, Le Collen L, Douillard A, Robert-Ebadi H, Pontal D, Morrison D, Barrellier MT, Diard A, Guénnéguez H, Brisot D, Faisse P, Accassat S, Martin M, Delluc A, Solymoss S, Kassis J, **Carrier M**, Quéré I, Kahn SR. Long-term Risk of Post-Thrombotic Syndrome after Symptomatic Distal Deep-Vein Thrombosis: The CACTUS-PTS Study. *J Thromb Haemost.* 2020 Apr;18(4):857-864. PMID: 31899848.
58. Wang TF, **Carrier M**. How I Treat Obese Patients with Oral Anticoagulants. *Blood.* 2020 Mar 19;135(12):904-911. PMID: 31978224.
59. Staibano P, Perelman I, Lombardi J, Davis A, Tinmouth A, **Carrier M**, Stevenson C, Saidenberg E. Patient-centred outcomes in anaemia and renal disease: A systematic review. *Kidney Dis (Basel).* 2020 Mar;6(2):74-84. PMID: 32309289.
60. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, **Carrier M**, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G. Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study [Thromb. Res. vol. 185, January 2020, pages 13-19]. *Thromb Res.* 2020 Jul;191:156-159. PMID: 32151398.
61. Kraaijpoel N, **Carrier M**, Le Gal G, McInnes MDF, Salameh JP, McGrath TA, van Es N, Moher D, Büller HR, Bossuyt PM, Leeftang MMG. Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. *PLoS One.* 2020 Feb 11;15(2):e0228788. PMID: 32045437. eCollection 2020.
62. Zwicker JI, Wang TF, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, McMasters M, **Carrier M**. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. *J Thromb Haemost.* 2020 Feb;18(2):278-284. PMID: 31999063.
63. Mulder FI, Di Nisio M, Ay C, **Carrier M**, Bosch FTM, Segers A, Kraaijpoel N, Grosso MA, Zhang G, Verhamme P, Wang TF, Weitz JI, Middeldorp S, Raskob G, Beenen LFM, Büller HR, van Es N. Clinical implications of incidental venous thromboembolism in cancer patients. *Eur Respir J.* 2020 Feb 6;55(2):1901697. PMID: 31727694.
64. Shaw JR, Zhang T, Le Gal G, Douketis J, **Carrier M**. Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. *Res Pract Thromb Haemost.* 2020 Jan 20;4(1):131-140. PMID: 31989095.

65. Cantor N, **Carrier M**, Rodger MA, Veillet-Lemay G, Sabri E, Kovacs MJ. Predictors of long-term cancer diagnosis after an unprovoked thromboembolic event: A post-hoc analysis of the REVERSE cohort study. *Thromb Res.* 2020 Jan;185:132-134. PMID: 31812027.
66. Bikdeli B, **Carrier M**, Bates SM. Subsegmental pulmonary embolism: May not be a killer but indicates significant risk. *Thromb Res.* 2020 Jan;185:180-182. PMID: 31796210.
67. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, **Carrier M**, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. *Thromb Res.* 2020 Jan;185:13-19. PMID: 31733403.
68. Kimpton M, **Carrier M**. What's new in the prevention and treatment of cancer-associated thrombosis? *Hematology Am Soc Hematol Educ Program.* 2019 Dec 6;2019(1):158-166. PMID: 31808858.
69. Li A, Kuderer NM, Garcia DA, Khorana AA, Wells PS, **Carrier M**, Lyman GH. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. *J Thromb Haemost.* 2019 Dec;17(12):2141-2151. PMID: 31420937.
70. McAlpine K, Breau RH, Knee C, **Carrier M**, Violette PD, van Walraven C, McIsaac DI, Mallick R, Cagiannos I, Morash C, Lavallée LT. Venous thromboembolism and transfusion after major abdominopelvic surgery. *Surgery.* 2019 Dec;166(6):1084-1091. doi: 10.1016/j.surg.2019.05.050.
71. Kearon C, de Wit K, Parpia S, Schulman S, Afilalo M, Hirsch A, Spencer FA, Sharma S, D'Aragon F, Deshaies JF, Le Gal G, Lazo-Langner A, Wu C, Rudd-Scott L, Bates SM, Julian JA; PEGeD Study Investigators. Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. *N Engl J Med.* 2019 Nov 28;381(22):2125-2134. PMID: 31774957.
72. Di Nisio M, van Es N, **Carrier M**, Wang TF, Garcia D, Segers A, Weitz J, Buller H, Raskob G. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. *J Thromb Haemost.* 2019 Nov;17(11):1866-1874. doi: 10.1111/jth.14561.
73. Miranda S, Benhamou Y, Wells P, **Carrier M**. Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. *Thromb Haemost.* 2019 Nov;119(11):1886-1887. PMID: 31600806.
74. **Carrier M**, Altman AD, Blais N, Diamantouros A, McLeod D, Moodley U, Nguyen C, Young S, Schwenter F. Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. *Am J Surg.* 2019 Sep;218(3):537-550. doi: 10.1016/j.amjsurg.2018.11.046.

75. Fernandes A, Connors JM, **Carrier M**. Anticoagulation for Subsegmental Pulmonary Embolism. *N Engl J Med*. 2019 Sep 19;381(12):1171-1174. PMID: 31532966.
76. Douketis JD, Spyropoulos AC, Duncan J, **Carrier M**, Le Gal G, Tafur AJ, Vanassche T, Verhamme P, Shivakumar S, Gross PL, Lee AYY, Yeo E, Solymoss S, Kassis J, Le Templier G, Kowalski S, Blostein M, Shah V, MacKay E, Wu C, Clark NP, Bates SM, Spencer FA, Arnaoutoglou E, Coppens M, Arnold DM, Caprini JA, Li N, Moffat KA, Syed S, Schulman S. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. *JAMA Intern Med*. 2019 Aug 5; 179(11):1469-78. PMID: 31380891.
77. Shivji S, **Carrier M**. Screening for cancer in unprovoked venous thromboembolism. *HemaSphere Educational Updates in Hematology Book*. 24 Congress of the European Hematology Association Amsterdam, The Netherlands. June 13-16, 2019; 3(S2):22-23.
78. Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, Noble S, Khorana AA, **Carrier M**, Meyer G. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. *J Thromb Haemost*. 2019 Oct;17(10):1772-1778. doi: 10.1111/jth.14564.
79. Khan F, Rahman A, **Carrier M**, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA; MARVELOUS Collaborators. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. *BMJ*. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.
80. **Carrier M**, Soff G, Le Gal G. Treatment of venous thromboembolism in cancer. historical perspective and evolving role of the direct oral anticoagulants. *Cancer Treat Res*. 2019;179:103-115. doi: 10.1007/978-3-030-20315-3_7.
81. Rodger MA, Miranda S, Delluc A, **Carrier M**. Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next? *Thromb Res*. 2019 Aug;180:105-109. doi: 10.1016/j.thromres.2019.06.017. Review.
82. Delluc A, Wang TF, Yap ES, Ay C, Schaefer J, **Carrier M**, Noble S. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. *J Thromb Haemost*. 2019 Aug;17(8):1247-1252. doi: 10.1111/jth.14478.
83. Al Rawahi B, Almegren M, **Carrier M**. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A Systematic review and meta-analysis: Re-Abdulaziz Almulhim, Saad Fallatah, Ivo Abraham. Comparing incomparable with the wrong analytics: anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis. *Thrombosis Research Volume 178*, June 2019, Pages 110-111. *Thromb Res*. 2019 Aug;180:28. doi: 10.1016/j.thromres.2019.05.020.

84. **Carrier M**, Le Gal G, Wells PS. Preventing venous thromboembolism in patients with cancer. Reply. *N Engl J Med*. 2019 May 30;380(22):2181. doi: 10.1056/NEJMc1904003.
85. Ho ML, **Carrier M**. Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. *CJEM*. 2019 Jul;21(4):460-463. doi: 10.1017/cem.2019.345.
86. Suleman A, Jarvis V, Hadziomerovic A, **Carrier M**, McDiarmid S. Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study. *Thromb Res*. 2019 May;177:117-121. doi: 10.1016/j.thromres.2019.02.033.
87. McCurdy JD, Israel A, Hasan M, Weng R, Mallick R, Ramsay T, **Carrier M**. A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. Jun;49(12):1493-1501. doi: 10.1111/apt.15286.
88. Woodruff S, Lee AYY, **Carrier M**, Feugère G, Abreu P, Heissler J. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. *J Thromb Thrombolysis*. 2019 May;47(4):495-504. doi: 10.1007/s11239-019-01833-w.
89. Shaw JR, Douketis J, Le Gal G, **Carrier M**. Periprocedural interruption of anticoagulation in patients with cancer-associated VTE: An Analysis of Thrombotic and Bleeding Outcomes. *J Thromb Haemost*. 2019 Jul;17(7):1171-1178.. doi: 10.1111/jth.14468.
90. Kimpton M, **Carrier M**. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. *Expert Opin Drug Saf*. 2019 Apr;18(4):313-320. doi: 10.1080/14740338.2019.1601699.
91. Jara-Palomares L, van Es N, Praena-Fernandez JM, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Religa P, Rieu V, Rondina M, Beckers M, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Kraaijpoel N, Büller HR, **Carrier M**. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. *Thromb Res*. 2019 Apr;176:79-84. doi: 10.1016/j.thromres.2019.02.011.
92. Wang KL, van Es N, Cameron C, Castellucci LA, Büller HR, **Carrier M**. Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. *Heart*. 2019 Apr;105(7):545-552. doi: 10.1136/heartjnl-2018-313617.
93. Duffett L, Kearon C, Rodger M, **Carrier M**. Treatment of superficial vein thrombosis: A systematic review and meta-analysis. *Thromb Haemost*. 2019 Mar;119(3):479-489. doi: 10.1055/s-0039-1677793.
94. Chin-Yee N, Tanuseputro P, **Carrier M**, Noble S. Thromboembolic disease in palliative and end-of-life care: A narrative review. *Thromb Res*. 2019 Mar;175:84-89. doi: 10.1016/j.thromres.2018.12.028.

95. **Carrier M**, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. *N Engl J Med*. 2019 Feb 21;380(8):711-719. PMID: 30511879.
96. Kraaijpoel N, **Carrier M**. How I treat cancer-associated venous thromboembolism. *Blood*. 2019 Jan 24;133(4):291-298. doi: 10.1182/blood-2018-08-835595.
97. Staibano P, Perelman I, Lombardi J, Davis A, Tinmouth A, **Carrier M**, Stevenson C, Saitenberg E. Patient-centered outcomes in the management of anemia: A scoping review. *Transfus Med Rev*. 2019 Jan;33(1):7-11. doi: 10.1016/j.tmr.2018.07.001.
98. Li A, Garcia DA, Lyman GH, **Carrier M**. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. *Thromb Res*. 2019 Jan;173:158-163. doi: 10.1016/j.thromres.2018.02.144. PMID: 29506866.
99. Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, **Carrier M**, Crowther MA, Ghosh I, Lazo-Langner A, Zondag M; Study Investigators. Erratum to: Prothrombin Complex Concentrate for major bleeding on Factor Xa Inhibitors: A prospective cohort study. *Thromb Haemost*. 2018 Dec;118(12):2188. doi: 10.1055/s-0038-1675417.
100. Robin P, Eddy M, Sikora L, Le Roux PY, **Carrier M**, Couturaud F, Planquette B, Pesavento R, Rodger M, Salaun PY, Le Gal G. Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. *BMJ Open*. 2018 Nov 28;8(11):e023939. doi: 10.1136/bmjopen-2018-023939.
101. Johnston A, Hsieh SC, **Carrier M**, Kelly SE, Bai Z, Skidmore B, Wells GA. A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. *PLoS One*. 2018 Nov 9;13(11):e0207410. doi: 10.1371/journal.pone.0207410. eCollection 2018. PMID: 30412622.
102. Robin P, Otten HM, Delluc A, van Es N, **Carrier M**, Salaun PY, Le Gal G. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. *Thromb Res*. 2018 Nov;171:92-96. doi: 10.1016/j.thromres.2018.09.055.
103. **Carrier M**, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Tagalakis V, Wu C, Lee AYY. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. *Curr Oncol*. 2018 Oct;25(5):329-337. doi: 10.3747/co.25.4266.
104. Peleg M, Michalowski W, Wilk S, Parimbelli E, Bonaccio S, O'Sullivan D, Michalowski M, Quaglini S, **Carrier M**. Ideating mobile health behavioral support for compliance to therapy for patients with chronic disease: A case study of atrial fibrillation management. *J Med Syst*. 2018 Oct 13;42(11):234. doi: 10.1007/s10916-018-1077-4. PMID: 30317403.

105. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. *N Engl J Med*. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090.
106. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, **Carrier M**, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Gal GL, Templier GL, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for patients on a direct oral anticoagulant who need an elective surgery or procedure: Design and rationale. *Thromb Haemost*. 2018 Sep;118(9):1679-1680. doi: 10.1055/s-0038-1668582.
107. Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, **Carrier M**. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2018 Sep;16(9):1891-1894. doi: 10.1111/jth.14219.
108. Al Rawahi B, Almegren M, **Carrier M**. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis. *Thromb Res*. 2018 Sep;169:135-139. doi: 10.1016/j.thromres.2018.07.023.
109. Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, **Carrier M**, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. *Thromb Haemost*. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001.
110. Kraaijpoel N, van Es N, Raskob GE, Büller HR, **Carrier M**, Zhang G, Lin M, Grosso MA, Di Nisio M. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. *Thromb Haemost*. 2018 Jul;118(7):1270-1278. doi: 10.1055/s-0038-1649523.
111. Parker A, Peterson E, Lee AYY, de Wit C, **Carrier M**, Polley G, Tien J, Wu C. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. *J Thromb Haemost*. 2018 Jul;16(7):1321-1326. doi: 10.1111/jth.14139.
112. Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, **Carrier M**. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2018 Jun;16(6):1246-1249. doi: 10.1111/jth.14015.

113. Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, **Carrier M**. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. *Res Pract Thromb Haemost*. 2018 Jun 19;2(4):664-669. doi: 10.1002/rth2.12111. eCollection 2018 Oct. PMID: 30349884.
114. Ikesaka R, Langlois N, **Carrier M**, Kearon C, Le Gal G. Pilot trials in thrombosis: Purpose and pitfalls. *Res Pract Thromb Haemost*. 2018 Jun 13;2(3):572-579. doi: 10.1002/rth2.12117.
115. Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, **Carrier M**, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. *J Thromb Haemost*. 2018 Jun 7. PMID: 29978552. [Epub ahead of print]
116. Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, **Carrier M**, Crowther MA, Ghosh I, Lazo-Langner A, Zondag M; Study Investigators. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. *Thromb Haemost*. 2018 May;118(5):842-851. doi: 10.1055/s-0038-1636541.
117. Kimpton M, Wells PS, **Carrier M**. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. *Thromb Res*. 2018 Apr;164 Suppl 1:S124-S129. doi: 10.1016/j.thromres.2018.01.018.
118. Le Roux PY, Robin P, Tromeur C, Davis A, Robert-Ebadi H, **Carrier M**, Couturaud F, Le Gal G, Salaun PY. SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. *BMJ Open*. 2018 Apr 21;8(4):e022024. doi: 10.1136/bmjopen-2018-022024.
119. Robin P, **Carrier M**. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. *Thromb Res*. 2018 Apr;164 Suppl 1:S7-S11. doi: 10.1016/j.thromres.2017.12.024.
120. Shaw JR, Castellucci L, Siegal D, Stiell I, Syed S, Lampron J, Dorian P, Dhaliwal H, Stotts G, Wells PS, **Carrier M**. Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. *Thromb Res*. 2018 Mar;163:19-21. doi: 10.1016/j.thromres.2018.01.008.
121. van Es N, Louzada M, **Carrier M**, Tagalakakis V, Gross PL, Shivakumar S, Rodger MA, Wells PS. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. *Thromb Res*. 2018 Mar;163:41-46. doi: 10.1016/j.thromres.2018.01.009.
122. Husseinzadeh H, **Carrier M**. Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. *Thromb Res*. 2018 Mar;163:242-245. doi: 10.1016/j.thromres.2017.05.034.

123. Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W1 Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, **Carrier M**, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. *N Engl J Med*. 2018 Feb 22;378(8):699-707. doi: 10.1056/NEJMoa1712746.
124. Raskob GE, van Es N, Verhamme P, **Carrier M**, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med*. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948.
125. Skeith L, **Carrier M**, Shivakumar S, Langlois N, Le Gal G, Harris I, Gonsalves C. Guiding curriculum development of a national research training program in thrombosis medicine: A needs assessment involving faculty and trainees. *Thromb Res*. 2018 Feb;162:79-86. doi: 10.1016/j.thromres.2017.12.008.
126. Wan T, Rodger M, Zeng W, Robin P, Righini M, Kovacs MJ, Tan M, **Carrier M**, Kahn SR, Wells PS, Anderson DR, Chagnon I, Solymoss S, Crowther M, White RH, Vickars L, Bazarjani S, Le Gal G. Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. *Thromb Res*. 2018 Feb;162:104-109. doi: 10.1016/j.thromres.2017.11.020.
127. Shaw JR, Woodfine JD, Douketis J, Schulman S, **Carrier M**. Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. *Res Pract Thromb Haemost*. 2018 Feb 16;2(2):282-290. doi: 10.1002/rth2.12076
128. **Carrier M**, Klok FA. Symptomatic subsegmental pulmonary embolism: to treat or not to treat? *Hematology Am Soc Hematol Educ Program*. 2017 Dec 8;2017(1):237-241. doi: 10.1182/asheducation-2017.1.237. Review.
129. Di Nisio M, **Carrier M**. Incidental venous thromboembolism: is anticoagulation indicated? *Hematology Am Soc Hematol Educ Program*. 2017 Dec 8;2017(1):121-127. doi: 10.1182/asheducation-2017.1.121. Review.
130. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, **Carrier M**, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. *Thromb Haemost*. 2017 Dec;117(12):2415-2424. doi: 10.1160/TH17-08-0553.

131. Ikesaka RT, Kahn SR, Galanaud JP, Vazquez FJ, Roche-Nagle G, **Carrier M**, Le Gal G, Rodger M, Gandara E. The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians. *Thromb Res.* 2017 Nov;159:13-15. doi: 10.1016/j.thromres.2017.09.015.
132. Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, **Carrier M**. Occult cancer screening in patients with venous thromboembolism: Guidance from the SSC of the ISTH. *J Thromb Haemost.* 2017 Oct;15(10):2076-2079.. doi: 10.1111/jth.13791.
133. Khan F, Rahman A, **Carrier M**, Kearon C, Schulman S, Couturaud F, Prandoni P, Eichinger S, Becattini C, Agnelli G, Büller HR, Brighton TA, Palareti G, Pinede L, Sabri E, Hutton B, Wells GA, Rodger MA; MARVELOUS Collaborators. Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. *BMJ Open.* 2017 Sep 21;7(9):16950. doi: 10.1136/bmjopen-2017-016950.
134. van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Jara-Palomares L, Religa P, Rieu V, Rondina M, Beckers MM, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Büller HR, **Carrier M**. Screening for occult cancer in patients with unprovoked venous thromboembolism: A systematic review and meta-analysis of individual patient data. *Ann Intern Med.* 2017 Sep 19;167(6):410-417. doi: 10.7326/M17-0868.
135. Farren-Dai L, **Carrier M**, Kovacs J, Rodger M, Kovacs MJ, Le Gal G; REVERSE investigators. Association between remote major venous thromboembolism risk factors and the risk of recurrence after a first unprovoked episode. *J Thromb Haemost.* 2017 Oct;15(10):1977-1980. doi: 10.1111/jth.13796.
136. Baumann Kreuziger L, Jaffray J, **Carrier M**. Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. *Thromb Res.* 2017 Sep;157:64-71. doi: 10.1016/j.thromres.2017.07.002. Review
137. McDiarmid S, Scrivens N, **Carrier M**, Sabri E, Toye B, Huebsch L, Fergusson D. Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. *CMAJ Open.* 2017 Jun 30;5(3):E535-E539. doi: 10.9778/cmajo.20170010.
138. Khan F, Rahman A, **Carrier M**. Occult cancer detection in venous thromboembolism: The past, the present, and the future. *RPTH.* 2017 Jun 16;1(1):9-13. doi 10.1002/rth2.12007.
139. van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Jara-Palomares L, Regilia P, Rieu V, Rondina MT, Beckers MM, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Buller HR, **Carrier M**. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. *BMJ Open.* 2017 Jun 10;7(6):e015562. doi: 10.1136/bmjopen-2016-015562.
140. Al Megren M, De Wit C, Al Qahtani M, Le Gal G, **Carrier M**. Management of venous thromboembolism in patients with glioma. *Thromb Res.* 2017 Aug;156:105-108. doi: 10.1016/j.thromres.2017.06.010.

141. Fitzpatrick T, **Carrier M**, Le Gal G. Cancer, atrial fibrillation, and stroke. *Thromb Res.* 2017 May 9;155:101-105. doi: 10.1016/j.thromres.2017.05.006
142. Theberge I, Bowdridge J, Forgie MA, **Carrier M**, Louzada M, Siquiera L, Rhodes M, Wells PS. Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. *Thromb Res.* 2017 Apr;152:4-6. doi: 10.1016/j.thromres.2017.02.003.
143. Wilts IT, Le Gal G, Den Exter PL, Van Es J, **Carrier M**, Planquette B, Büller HR, Righini M, Huisman MV, Kamphuisen PW. Performance of the age-adjusted cut-off for D-dimer in patients with cancer and suspected pulmonary embolism. *Thromb Res.* 2017 Apr;152:49-51. doi: 10.1016/j.thromres.2017.02.007.
144. van Es N, Wells PS, **Carrier M**. Bleeding risk in patients with unprovoked venous thromboembolism: a critical appraisal of clinical prediction scores. *Thromb Res.* 2017 Apr;152:52-60. doi: 10.1016/j.thromres.2017.02.016.
145. Schulman S, Ritchie B, Nahirniak S, Gross PL, **Carrier M**, Majeed A, Hwang HG, Zondag M; Study investigators. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. *Thromb Res.* 2017 Apr;152:44-48.. doi: 10.1016/j.thromres.2017.02.010.
146. Angriman F, Vazquez FJ, Roy PM, Le Gal G, **Carrier M**, Gandara E. A new prognostic strategy for adult patients with acute pulmonary embolism eligible for outpatient therapy. *J Thromb Thrombolysis.* 2017 Apr;43(3):326-332.
147. Khan F, Vaillancourt C, **Carrier M**. Should we screen extensively for cancer following unprovoked venous thrombosis? *BMJ.* 2017 Mar 22;356:j1081. doi: 10.1136/bmj.j1081.
148. Shaw J, de Wit C, Le Gal G, **Carrier M**. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease. *J Thromb Haemost.* 2017 May;15(5):925-930. doi: 10.1111/jth.13670.
149. Jara-Palomares L, Otero R, Jimenez D, **Carrier M**, Tzoran I, Brenner B, Margeli M, Praena-Fernandez JM, Grandone E, Monreal M; RIETE investigators. Development of a risk prediction score for occult cancer in patients with venous thromboembolism. *Chest.* 2017 Mar;151(3):564-571.
150. Coyle K, **Carrier M**, Lazo-Langner A, Shivakumar S, Zarychanski R, Tagalakis V, Solymoss S, Routhier N, Douketis J, Coyle D. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. *Thromb Res.* 2017 Mar;151:67-71.
151. Khorana AA, Francis CW, Kuderer NM, **Carrier M**, Ortel TL, Wun T, Rubens D, Hobbs S, Iyer R, Peterson D, Baran A, Kaproth-Joslin K, Lyman GH. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. *Thromb Res.* 2017 Mar;151:89-95.

152. Skeith L, **Carrier M**, Robinson S, Alimam S, Rodger MA. Risk of venous thromboembolism in pregnant women with essential. *Blood*. 2017 Feb 23;129(8):934-939.
153. McAlpine K, Breau RH, Mallick R, Cnossen S, Cagiannos I, Morash C, **Carrier M**, Lavallée LT. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. *Urol Oncol*. 2017 Feb 14. pii: S1078-1439(17)30017-0. doi: 10.1016/j.urolonc.2017.01.015.
154. Wilk S, Michalowski M, Michalowski W, Rosu D, **Carrier M**, Kezadri-Hamiaz M. Comprehensive mitigation framework for concurrent application of multiple clinical practice guidelines. *J Biomed Inform*. 2017 Feb;66:52-71.
155. Roy PM, Corsi D, **Carrier M**, Theogene A, de Wit C, Dennie C, Le Gal G, Delluc A, Moumneh T, Rodger M, Wells P, Gandara E. Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. *J Thromb Haemost*. 2017 Apr;15(4):685-694. doi: 10.1111/jth.13629.
156. Duffett L, **Carrier M**. Inferior vena cava filters. *J Thromb Haemost*. 2017 Jan;15(1):3-12. Review.
157. Al Rawahi B, Le Gal G, Auer R, **Carrier M**. A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery. *Thromb J*. 2017 Jan 13;15:2.
158. **Carrier M**, Prandoni P. Controversies in the management of cancer-associated thrombosis. *Expert Rev Hematol*. 2017 Jan;10(1):15-22.
159. Douketis J, Ageno W, Carrier M, Kearon C. Managing challenging patients with venous thromboembolism: a practical, case-based approach. *Pol Arch Intern Med*. 2017 Jan 4;127(1):41-46.
160. Righini M, Galanaud JP, Guenneguez H, Brisot D, Diard A, Faisse P, Barrellier MT, Hamel-Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquet C, Accassat S, Robert-Ebadi H, **Carrier M**, Le Gal G, Mermillod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol*. 2016 Dec;3(12):e556-e562.
161. Zwicker JI, **Carrier M**. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: reply. *J Thromb Haemost*. 2016 Oct;14(10):2082.
162. Zwicker JI, Karp R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. *J Thromb Haemost*. 2016 Sep;14(9):1736-40.
163. Castellucci LA, Shaw J, Giulivi A, Edwards C, **Carrier M**, Patel R. Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency - The PACER pilot study. *Thromb Res*. 2016 Aug;144:69-71.

164. Bazzarelli AK, Scheer AS, Tai LH, Seth R, de Souza CT, Petreich W, Jonker DJ, Maroun JA, **Carrier M**, Auer RC. Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer. *Ann Surg Oncol*. 2016 Jul;23(7):2274-80.
165. de Moreuil C, Ianotto JC, Eveillard JR, **Carrier M**, Delluc A. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?] [Article in French]. *Rev Med Interne*. 2016 Jul;37(7):473-9.
166. Khan F, **Carrier M**, Rodger M. Cancer Screening After Unprovoked Venous Thromboembolism: A Teachable Moment. *JAMA Intern Med*. 2016 Jun 1;176(6):739-40.
167. Wilts IT, Le Gal G, den Exter PL, van Es J, **Carrier M**, Planquette B, Büller HR, Righini M, Huisman MV, Kamphuisen PW. PO-29 - Age-adjusted D-dimer cutoff level increases the number of cancer patients in who pulmonary embolism can be safely excluded without CT-PA imaging: The ADJUST-PE cancer substudy. *Thromb Res*. 2016 Apr;140 Suppl 1:S187.
168. Wells PS, Theberge IA, Bowdridge JC, Forgie MA, **Carrier M**. PO-41 - Rivaroxaban is effective therapy for high risk cancer patients with venous thromboembolic disease. *Thromb Res*. 2016 Apr;140 Suppl 1:S191-2.
169. Gheshmy A, **Carrier M**. Venous thromboembolism and occult cancer: impact on clinical practice. *Thromb Res*. 2016 Apr;140 Suppl 1:S8-S11.
170. Skeith L, **Carrier M**, Kaaja R, Martinelli I, Petroff D, Schleubner E, Laskin CA, Rodger MA. A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. *Blood*. 2016 Mar 31;127(13):1650-5.
171. Vazquez FJ, Gonzalez JP, Le Gal G, **Carrier M**, Gándara E. Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. *Thromb Res*. 2016 Feb;138:1-6.
172. Wilk S, Kezadri-Hamiaz M, Rosu D, Kuziemy C, Michalowski W, Amyot D, **Carrier M**. Using Semantic components to represent dynamics of an interdisciplinary healthcare team in a multi-agent decision support system. *J Med Syst*. 2016 Feb;40(2):42.
173. Ihaddadene R, Corsi DK, Lazo-Langner A, Shivakumar S, Zarychanski R, Tagalakis V, Solymoss S, Routhier N, Douketis J, Le Gal, G, **Carrier M**. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. *Blood*. 2016 Apr 21;127(16):2035-7.
174. Khorana AA, **Carrier M**, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. *J Thromb Thrombolysis*. 2016 Jan;41(1):81-91.
175. **Carrier M**. Cancer screening in unprovoked venous thromboembolism. *New Eng J Med*. 2015 Dec 17;373(25):2475.

176. Delluc A, **Carrier M**. Catheter-related thrombosis: Unresolved issues. *Thromb Res*. 2015 Dec;136(6):1055-6.
177. Tran T, Delluc A, de Wit C, Petrcich W, Le Gal G, **Carrier M**. The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. *Thromb Res*. 2015 Nov;136(5):962-5.
178. Ihaddadene R, **Carrier M**. The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: Implications for safety. *Expert Opin Drug Saf*. Jan;15(1):65-74.
179. Castellucci LA, Shaw J, van der Salm K, Erkens P, Le Gal G, Petrcich W, **Carrier M**. Self-Reported Adherence to Anticoagulation and Its Determinants Using the Morisky Medication Adherence Scale. *Thromb Res*. 2015 Oct;136(4):727-31.
180. Kezadri-Hamiaz M, Rosu D, Wilk S, Kuziemyky C, Michalowski W, **Carrier M**. A Framework for Modeling Workflow Execution by an Interdisciplinary Healthcare Team. *Stud Health Technol Inform*. 2015;216:1100.
181. van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Decousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso M, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer *Thromb Haemost*. 2015 Aug 13;114(6): 1268-76.
182. Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger M for the SOME Investigators. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. *NEJM*. 2015 Aug 20;373(8):697-704.
183. Vazquez F, Rodger M, **Carrier M**, Le Gal G, Reny JL, Sofi F, Nagpa S, Jetty P, Gandara E. Prothrombin G20210A mutation and lower extremity peripheral arterial disease. A systematic review and meta-analysis. *Eur J Vasc Endovasc Surg*. 2015 Aug;50(2):232-40.
184. Schulman S, **Carrier M**, Lee AYY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD, Periop Dabigatran Study Group. Perioperative management of dabigatran: a prospective cohort study. *Circulation*. 2015 Jul 21;132(3):167-73.
185. Le Gal G, Robert-Ebadi H, **Carrier M**, Kearon C, Bounameaux H, Righini M. Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis? *J Thromb Haemost*. 2015 Apr;13(4):563-6.
186. Ikesaka R, **Carrier M**. Clinical significance and management of subsegmental pulmonary embolism. *J Thromb Thrombolysis*. 2015 Apr;39(3):311-4.

187. van Gaal S, **Carrier M**, Rodriguez RA, Sharma M, Mallick R, Stotts G, Dowlatshahi D. A survey of the use of empiric novel anticoagulants during investigation of stroke. *Can J Neurol Sci*. 2015 Mar;42(2):135-7.
188. **Carrier M**, Lazo-Langner A, Shivakumar S, Tagalakis V, Gross PL, Blais N, Butts CA, Crowther M. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. *Curr Oncol*. 2015 Feb;22(1):49-59.
189. Di Nisio M, Lee AY, **Carrier M**, Liebman HA, Khorana AA; The Subcommittee on Haemostasis & Malignancy. Diagnosis and Treatment of Incidental Venous Thromboembolism in Cancer Patients: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2015 May;13(5):880-3.
190. Morretto P, Park J, Rodger M, Le Gal G, **Carrier M**. A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. *Thromb J*. 2015 Feb 14;13:10. doi: 10.1186/s12959-015-0040-6. eCollection 2015.
191. Delluc A, Le Gal G, Scarvelis D, **Carrier M**. Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. *Thromb Res*. 2015 Feb;135(2):298-302.
192. Delluc A, **Carrier M**, Meyer G, Le Gal G. [Should we treat unsuspected pulmonary embolism?] article in French. *Rev Med Interne*. 2014 Dec;35(12):775-8.
193. **Carrier M**, Kimpton M, Wells P, Langlois N, Kherani S, Le Gal G. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants. *Blood Coag Fibrinol*. 2014 Dec;25(8):812-5.
194. **Carrier M**, Khorana A, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer: Reply. *Am J Med*. 2014 Oct;127(10):e13.
195. **Carrier M**, Cameron C, Delluc A, Castellucci L, Khorana A, Lee AYY. Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. *Thromb Res*. 2014 Oct 8;134(6):1214-1219.
196. Di Nisio M, **Carrier M**, Lyman GH, Khorana AA; The SSC Subcommittee on Haemostasis and Malignancy. Prevention of Venous Thromboembolism in Hospitalized Medical Cancer Patients: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2014 Oct;12(10):1746-9.
197. Hogg K, Shaw J, Coyle D, Fallah P, **Carrier M**, Wells P. Validity of standard gamble estimated quality of life in acute venous thrombosis. *Thromb Res*. 2014 Oct;134(4):819-25.
198. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, **Carrier M**. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: A systematic review and meta-analysis. *JAMA*. 2014 Sep;312(11):1122-1135.

199. Vijenthira A, Le Gal G, Castellucci LA, **Carrier M**. Defining time in therapeutic range for busy clinicians: Frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. *Thromb Res*. 2014 Sep;134(3):584-6.
200. Delluc A, **Carrier M**. Venous thromboembolism in cancer patients: A call for more awareness. *Curr Oncol*. 2014 Aug;21(4):163-4.
201. Pena E, Ihaddadene R, **Carrier M**. The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus: Reply. Letter to the Editor. *J Thromb Haemost*. 2014 Aug;12(8):1374-6.
202. Ihadaddene R, Le Gal G, Delluc A, **Carrier M**. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. *Thromb Res*. 2014 Jul;134(1):93-5.
203. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, **Carrier M**, Coyle K, Bai A, Moulton K, Clifford T, Wells G. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. *BMJ Open*. 2014 Jun 2;4(6):e004301.
204. Douketis JD, **Carrier M**, Crowther MA. Unusual venous thrombosis. *CMAJ*. 2014 Jun 10;186(9):697-8.
205. Ihadaddene R, Yokom DW, Le Gal G, Moretto P, Canil CM, Delluc A, Reaume N, **Carrier M**. The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. *J Thromb Haemost*. 2014 Jun;12(6):855-9.
206. Gándara E, **Carrier M**, Rodger MA. Management of pregnancy associated venous-thromboembolism: a survey of practices. *Thromb J*. 2014 Jun 2;12:12.
207. Lee, AYY, **Carrier M**. Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. *Thromb Res*. 2014 May;133(S2):S167-S171.
208. Ikesaka R, Delluc A, Le Gal G, **Carrier M**. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. *Thromb Res*. 2014 Apr;133(4):682-7.
209. **Carrier M**, Lee AY. Thromboprophylaxis in cancer patients. *Semin Thromb Hemost*. 2014 Apr;40(3):395-400.
210. Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, Carson N, **Carrier M**, Rennicks White R, Shachkina S, Wen SW. Is Thrombophilia Associated with Placenta-Mediated Pregnancy Complications? A Prospective Cohort Study. *J Thromb Haemost*. 2014 Apr;12(4):469-78.
211. Yokom DW, Le Gal G, **Carrier M**. Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus: reply. *J Thromb Haemost*. 2014 Apr;12(4):579-80.

212. Ihadaddene R, **Carrier M**. Thromboprophylaxis for medical patients with cancer: what do the guidelines say? *Clin Pract*. 2014 March;11(2):155-168.
213. Castellucci LA, Le Gal G, Rodger MA, **Carrier M**. Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. *J Thromb Haemost*. 2014 Mar;12(3):344-8.
214. Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, **Carrier M**, Chande N, Marshall JK, Williams C, Kearon C. Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. *Gastroenterology*. 2014 Mar;146(3):835-848.e6.
215. Zwicker J, Connolly G, **Carrier M**, Kamphuisen P, Lee A. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2014 May;12(5):796-800.
216. Javidnia H, Hanna M, Li Y, Scheer A, Filion L, Eapen L, **Carrier M**, Auer R, Corsten M, Allan DS. Vascular progenitor clusters from peripheral blood in cancer patients following oncologic surgery. *J Surg Oncol*. 2014 Feb;109(2):151-7.
217. Rodger MA, **Carrier M**, Le Gal G, Martinelli I, Perna A, Rey E, de Vries JI, Gris JC. Meta-analysis of low molecular weight heparin to prevent recurrent placenta-mediated pregnancy complications. *Blood*. 2014 Feb 6;123(6):822-8.
218. Yokom D, Ihaddadene R, Moretto P, Canil C, Reaume N, Le Gal G, **Carrier M**. Increased risk of pre-operative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus. *J Thromb Haemost*. 2014 Feb;12(2):169-71.
219. Piran S, Ngo V, McDiarmid S, Le Gal G, Petrich W, **Carrier M**. Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients. *Thromb Res*. 2014 Jan;133(1):30-3.
220. **Carrier M**, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. *Am J Med*. 2014 Jan;127(1):82-86.
221. **Carrier M**, Khorana AA, Zwicker JI, Noble S, Lee AY; subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a reply to a rebuttal. *J Thromb Haemost*. 2014 Jan;12(1):116-7.
222. Gándara E, Kovacs J, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, **Carrier M**, Langlois N, Kovacs J, Little J, Carson N, Ramsay T, Rodger M. Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. *Thromb Haemost*. 2013 Dec;110(6):1172-9.

223. Gándara E, **Carrier M**, Rodger MA. Intermediate doses of low-molecular-weight heparin for the long-term treatment of pregnancy thromboembolism. A systematic review. *Thromb Haemost.* 2013 Dec 5;111(3): 559-61.
224. Piran S, Le Gal G, Wells PS, Gandara E, Righini M, Rodger MA, **Carrier M**. Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. *Thromb Res.* 2013 Nov;132(5):515-9.
225. **Carrier M**, Khorana AA, Zwicker JI, Noble S, Farge-Bancel D, Lee AYY on behalf of the subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of ISTH. *J Thromb Haemost.* 2013 Sep;11(9):1760-65.
226. Majeed H, Rodger M, Forgie M, **Carrier M**, Taljaard M, Scarvelis D, Gonsalves C, Rodriguez RA, Wells PS. Effect of 200 µG/day of vitamin k1 on the variability of anticoagulation control in patients on warfarin: A randomized controlled trial. *Thromb Res.* 2013 Sep;132(3):329-35.
227. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, **Carrier M**. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. *BMJ* 2013;347:f5133.
228. Seth R, Tai LH, T, Falls T, de Souza CT, Bell JC, **Carrier M**, Atkins H, Boushey R, Auer RA. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving Natural Killer cells in a murine model. *Ann Surg.* 2013 Jul;258(1):158-68.
229. Hogg K, Kimpton M, **Carrier M**, Coyle D, Forgie M, Wells P. Estimating quality of life in acute venous thrombosis. *JAMA Internal Medicine.* 2013 Jun 24;173(12):1067-1072
230. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, **Carrier M**, Vendittoli, PA. Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. *Ann Intern Med.* 2013 Jun 4;158(11):800-6.
231. Hogg K, Hinchliffe E, Haslam S, Sethi B, **Carrier M**, Lecky F. Predicting short term mortality after investigation for venous thromboembolism. *Throm Res.* 2013 Apr;131(4):e141-6.
232. Rodriguez RA, **Carrier M**, Wells PS. Non-Adherence to New Oral Anticoagulants: A reason for concern during long-term anticoagulation? *J Thromb Haemost.* 2013 Feb;11(2):390-4.
233. Gauthier K, Kovacs MJ, Wells PS, Gal GL, Rodger M; REVERSE investigators. Family history of venous thromboembolism (VTE) as a predictor for recurrent VTE in unprovoked VTE patients. *J Thromb Haemost.* 2013 Jan;11(1):200-3.

234. **Carrier M**, Khorana AA, Zwicker JJ, Lyman GH, Le Gal G and Lee AYY on behalf of the subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. *J Thromb Haemost.* 2012; 10: 2599–601.
235. Douma RA, Tan M, Schutgens R, Bates SM, Perrier A, Legnani C, Biesma DH, Ginsberg JS, Bounameaux H, Palareti G, **Carrier M**, Mol GC, Le Gal G, Kamphuisen PW, Righini M. Age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. *Haematologica.* 2012 Oct;97(10):1507-13.
236. Aw A, **Carrier M**, Kocerginski J, McDiarmid J, Tay J. Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. *Thromb Res.* 2012 Sep;130(3):323-6.
237. Le Gal, G, **Carrier M**, Rodger M. Clinical Decision Rules in Venous Thromboembolism. *Best Pract Res Clin Haematol.* 2012 Sep;25(3):303-317.
238. Carrier M, Righini M, Le Gal G. Symptomatic Sub-Segmental Pulmonary Embolism: What is the Next Step? *J Thromb Haemost.* 2012 Aug;10(8):1486-90.
239. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, Rodger MA, Zhang J, Lee AY, Meyer G, Wells PS. Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients with Cancer-Associated Venous Thromboembolism. *Circulation.* 2012 Jul 24;126(4):448-54.
240. Hopkins L, **Carrier M**, Plante M, Luna V, Gotlieb W, Rambout L. Surgical Venous Thromboprophylaxis: A Cross-sectional Survey of Canadian Gynaecologic Oncologists. *J Obstet Gynaecol Can.* 2012 Jul;34(7):673–677.
241. Erkens PM, Gandara E, Wells PS, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, **Carrier M**. Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? *Thromb Res.* 2012 Jun;129(6):710-4.
242. **Carrier M**, Cushman M. Assessing the Utility of Venous Thrombosis Prophylaxis in Orthopedic Surgery Patients. *Ann Intern Med.* 2012 May;156(10):748-9.
243. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med.* 2012 Apr;366(14):1287-97.
244. Pena E, Kimpton M, Dennie C, Peterson R, Le Gal G, **Carrier M**. Difference in Interpretation of Computed Tomography Pulmonary Angiography Diagnosis of Sub-Segmental Thrombosis in Patients with Suspected Pulmonary Embolism. *J Thromb Haemost.* 2012 Mar;10(3):496-8.

245. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO. Investigators. Semuloparin for thromboprophylaxis. *N Engl J Med*. 2012 Feb;366(7):601-9.
246. Hogg K, **Carrier M**. Treatment and prevention of venous thromboembolism in patients with cancer. *Ther Advances Hematol*. 2012 Feb;3(1):45-58.
247. Auer R, Sheer A, Wells P, Boushey R, Asmis T, Jonker D, **Carrier M**. The Use of Extended Perioperative Low Molecular Weight Heparin (Tinzaparin) to Improve Disease-Free Survival Following Surgical Resection of Colon Cancer: A Pilot Randomized Controlled Trial. *Blood Coagul Fibrinolysis*. 2011 Dec;22(8):760-2.
248. Hamadah A, Alwasaidi T, LE Gal G, **Carrier M**, Wells PS, Scarvelis D, Gonsalves C, Forgie M, Kovacs MJ, Rodger MA. Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence. *J Thromb Haemost*. 2011 Dec;9(12):2406-10.
249. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, **Carrier M**, Forgie M, Wells PS, Kim RB. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. *Blood*. 2011 Sep;118(11):3163-71.
250. **Carrier M**, Kimpton M, Le Gal G, Kahn SR, Kovacs MJ, Wells PS, Anderson DR, Rodger MA. The management of a sub-segmental pulmonary embolism: a cross-sectional survey of Canadian thrombosis physicians. *J Thromb Haemost*. 2011 Jul;9(7):1412-5.
251. Abou-Nassar K, **Carrier M**, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. *Thromb Res*. 2011 Jul;128(1):77-85.
252. **Carrier M**, Rodger MA, Wells PS, Righini M, LE Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. *J Thromb Haemost*. 2011 Jun;9(6):1119-25.
253. LE Gal G, **Carrier M**, Kovacs MJ, Betancourt MT, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Righini M, Delluc A, White RH, and Vickars L, Rodger M. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. *J Thromb Haemost*. 2011 Jun;9(6):1126-1132.
254. Rodger MA, Ramsay T, Le Gal G, **Carrier M**. Assessment of recurrence risk after unprovoked venous thromboembolism. *Ann Intern Med*. 2011 May;154(9):644.
255. Aw A, Carrier M. Thromboprophylaxis in High-Risk Patients: Medically Ill Hospitalized Patients and Major Orthopedic Surgery. *Can J Gen Intern Med*. Spring 2011;6(Sup 1).

256. **Carrier M**, LE Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. *J Thromb Haemost.* 2011 Apr;9(4):653-63.
257. Gandara E, Bose G, Erkens P, Rodgers M, **Carrier M**, Wells P. Outcomes of saddle pulmonary embolism: a nested case control study. *J Thromb Haemost.* 2011 Apr;9(4):867-9.
258. Erkens P, Gandara E, **Carrier M**, Wells, P, Rodger M, Le Gal G, Bose G. Safety of outpatient treatment in acute pulmonary embolism. *Thromb Haemost.* 2010 Nov;8(11):2412-7.
259. **Carrier M**, Le Gal G, Tao H, Wells P, Danovitch K, Mbanga-levac A, Rodger M. Should we screen patients with unprovoked venous thromboembolism for occult cancers? A pilot study. *Blood Coag Fibrinolysis.* 2010 Oct;21(7):709-10.
260. Le Gal G, Kovacs M, **Carrier M**, Do K, Kahn S, Wells P, Anderson D, Chagnon I, Solymoss S, Crowther M, Righini M, Lacut K, White R, Vickars L, Rodger M. Risk of recurrent venous thromboembolism after a first estrogen-associated episode. *Thromb Haemost.* 2010 Sep;104(3):498-503.
261. Rodger M, Le Gal G, **Carrier M**, Betancourt M, Kahn S, Wells P, Anderson A, Lacut K, Chagnon I, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, Kovacs M. Serum lipoprotein (a) Levels in patient with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE. *Thromb Res* 2010 Sept;126(3):222-226.
262. **Carrier M**, Righini M, Wells P, Perrier A, Anderson D, Rodger M, Pleasance S, Le Gal G. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. *J Thromb Haemost.* 2010 August;8:1716-1722.
263. Rodger M, **Carrier M**, Gandara E, Le Gal G. Unprovoked Venous Thromboembolism: Short term or Indefinite Anticoagulation? Balancing Long-Term Risk and Benefit. *Blood Rev.* 2010 July - September;24(4-5):171-178.
264. Rodger M, Betancourt M, Clark P, Lindqvist P, Dizon-Townson D, Said J, Seligsohn U, **Carrier M**, Salomon O, Greer I. The Association of Factor V Leiden and Prothombin Gene Mutation and Placenta-Mediated Pregnancy Complications: A Systematic Review and Meta-analysis of Prospective Cohort Studies. *PLoS Medicine.* 2010 Jun;7(6):1-12.
265. **Carrier M**, Lee, A. Screening for Occult Cancer in Patients with Venous Thromboembolism Patients. *eThrombosis.* 2010 June 1.
266. Shen AY, Le Gal G, Dennie C, Wells P, **Carrier M**. Incidence and clinical outcomes of occult cancers detected by computed tomographic pulmonary angiography in patients with acute pulmonary embolism. *J Thromb Haemost.* 2010 May;8(5):1128-9.

267. **Carrier M**, Le Gal G, Wells P, Rodger M. Systematic review: Case fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. *Ann Intern Med*. 2010 May;152(9):578-589.
268. Robert-Ebadi H, Le Gal G, **Carrier M**, Coutraud F, Perrier A, Bounameaux H, Righini M. Difference in clinical presentation of pulmonary embolism in women and men. *J Thromb Haemost*. 2010 Apr;8(4):693-8.
269. Le Gal G, **Carrier M**, Tierney S, Majeed H, Rodger M, Wells PS. Prediction of the warfarin maintenance dose after completion of the 10mg initiation nomogram- do we really need genotyping? *J Thromb Haemost*. 2010 Jan;8(1):90-94.
270. Wells PS, Le Gal G, Tierney S, **Carrier M**. Practical Application of the 10mg Warfarin Initiation Nomogram. *Blood Coag Fibrinolysis*. 2009 Sept;20(6):403-8.
271. Le Gal G, Kovacs MJ, **Carrier M**, Do K, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Perrier A, White RH, Rodger M. Validation of a diagnostic approach to exclude recurrent venous Thromboembolism. *J Thromb Haemost*. 2009 May;7(5):752-9.
272. **Carrier M**, Le Gal G, Cho R, Tierney S, Rodger M, Lee A. Dose Escalation of Low Molecular Weight Heparin to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation in Cancer Patients. *J Thromb Haemost*. 2009 May;7(5):760-5.
273. **Carrier M**, Righini M, Karami Djurabi R, Huisman MV, Perrier A, Wells PS, Rodger M, Wuillemin W, Le Gal G. VIDAS© D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of the management outcome studies. *J Thromb Haemost*. 2009;101:886-892.
274. **Carrier M**, Lee AY. Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. *Nat Clin Pract Oncol*. 2009 Feb;6(2):74-84.
275. **Carrier M**, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients venous thromboembolism? *Ann Intern Med*. 2008 Sept 2;149(5):323-33.
276. Gonsalves A, **Carrier M**, Wells PS, McDiarmid S, Huebsch L, Allan DS. Increased incidence of venous thromboembolism following allogeneic compared with autologous hematopoietic stem cell transplantation. *J Thromb Haemost*. 2008 Sep;6(9):1468-73.
277. **Carrier M**, Le Gal G, Bates S, Anderson D, Wells PS. D-dimer Testing is Useful to Exclude Deep Vein Thrombosis in Elderly Patients. *J Thromb Haemost*. 2008;6:1072-6.
278. **Carrier M**, Lee AY, Bates S, Anderson D, Well PS. Accuracy and Usefulness of a Clinical Prediction Rule and D-dimer Testing in Excluding Deep Vein Thrombosis in Cancer Patients. *Thromb Res*. 2008;123(1):177-183. Jun 16.
279. **Carrier M**, Rodger MA, Fergusson D, Doucette S, Kovacs MJ, Moore J, Knoll GA. Increased Mortality in Patients with Antibodies to the Platelet Factor 4-Heparin Complex on Chronic Hemodialysis. *Kidney Int*. 2008;73:213-9.

280. **Carrier M**, Wells PS. Should we regionalize the management of pulmonary embolism? [Commentary]. *CMAJ*. 2008;178:58-59.
281. Descourt R, Righini M, **Carrier M**, Le Gal G. Place of cancer among the risk factors in venous thromboembolism. *Pathol Biol (Paris)*. 2008;56:178-83.
282. **Carrier M**, Tay J, Fergusson D, Well PS. Thromboprophylaxis for Catheter-Related Thrombosis in Patients with Cancer: A Systematic Review of Randomized Controlled Trials. *J Thromb Haemost*. 2007;5:2552-2554.
283. **Carrier M**, Knoll GA, Fergusson D, Doucette S, Kovacs MJ, Moore J, Rodger MA. The Prevalence of Antibodies to the Platelet Factor 4-Heparin Complex and Association with Venous Access Thrombosis in Patients on Chronic Hemodialysis. *Thromb Res*. 2007;120(2):215-20.
284. **Carrier M**, Wells P, Rodger MA. Excluding Pulmonary Embolism at the Bedside with Low Pre-test Probability and D-Dimer: Safety and Clinical Utility of 4 Methods to Assign Pre-Test Probability. *Thromb Res*. 2006;117(4):469-74.
285. Rodger MA, **Carrier M**, Rock G. The Use of Functional Protein S Assays in the Diagnosis of Protein S Deficiency. *Pathophysiol Haemos Thromb*. 2003 Jul-2004 Aug; 33(4):202-5.
286. Rodger MA, Gagné-Rodger C, Howley HE, **Carrier M**, Coyle D, Wells PS. The Outpatient treatment of Deep Vein Thrombosis Delivers Cost Savings to Patients and their Families, Compared to Inpatient Therapy. *Thromb Res*. 2003;112:13-8.
287. Rodger MA, **Carrier M**, Keely E, Karovitch A, Walker M, Nimrod C, Wells PS. The Management of Thrombophilia during Pregnancy- A Canadian Survey. *J Obstet Gynaecol Can*. 2002;24:946-52.
288. Rodger MA, **Carrier M**, Gwynne NJ, Rasuli P, Raymond F, Djunaedi H, Wells PS. Diagnostic Value Of Arterial Blood Gas Measurement in Suspected Pulmonary Embolism. *Am J Respir Crit Care Med*. 2000 Dec;162(6):2105-8.

Presentations

Invited Presentations – International Conferences

1. Debate with Dr. M. Di Nisio: Incidental VTE: to treat or not to treat? Chairs: S. Siragusa (Italy), S. Middeldorp (The Netherlands) 10th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 26, 2021. Virtual. Bergamo, Italy
2. Direct oral anticoagulants for the treatment of VTE in cancer patients. Korean Society of Hematology (ICKSH) International Conference & 62nd Annual Meeting. Apr 2, 2021.
3. Covid och venös trombos [Covid and venous thrombosis]. Swedish Society of Thrombosis and Haemostasis. Virtual presentation Mar 18, 2021.
4. Management of unusual site thrombosis. 1st Kuwait Thrombosis & Hemostasis Congress. Webinar series Mar 20-28, 2021.

5. The changing landscape of cancer-associated venous thromboembolism. THSNA 2020 Virtual Conference. Thrombosis & Hemostasis Summit of North America. Oct 28, 2020.
6. American Society of Hematology 2020 Guidelines for Prevention and Treatment in Patients with Cancer. American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting. Virtual. Oct 26, 2020.
7. Updates in Cancer Associated Thrombosis. Thrombosis UK, Let's Talk Clots virtual conference. Oct 12, 2020.
8. Recherche de cancer post-TVP: non, oui, mais? Société Marocaine des Maladies Vasculaires (SMMV) Virtual Symposium. May 22, 2020.
9. The treatment of thrombosis in patients with cancer. Cancer and Thrombosis Symposium. Société Marocaine des Maladies Vasculaires (SMMV) Virtual Symposium. May 21, 2020.
10. Thromboprophylaxis in patients with cancer. Ambulatory patients under cancer treatment. VTE Safety Zone 2020. Virtual/Madrid, Spain. Feb 21, 2020.
11. Update from the Clinic: Cancer-associated thrombosis. 61st ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL. Dec 5, 2019.
12. New scenarios in screening for hidden cancer on VTE. 6th International Pneumological Biennial. Sevilla, ES. Nov 7, 2019.
13. Utility of meta-analysis in daily clinical practice what do they contribute to the management of our patients? 6th International Pneumological Biennial. Sevilla, ES. Nov 7, 2019.
14. Primary prevention of cancer associated thrombosis (CAT). VTE Dublin 2019: Diagnostic and therapeutic advances in venous thromboembolism (VTE). Mater Misericordiae University Hospital. Sep 27, 2019. Dublin, Ireland.
15. Cancer-associated thrombosis, Master Class. The 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 65th Annual Scientific and Standardization Committee (SSC) Meeting., Melbourne, Australia, July 9, 2019.
16. Modern treatment of cancer-associated thrombosis. The 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 65th Annual Scientific and Standardization Committee (SSC) Meeting., Melbourne, Australia, July 7, 2019.
17. Management of cancer-associated thrombosis in patients with thrombocytopenia: Guidance from the SSC of the ISTH. The 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 65th Annual Scientific and Standardization Committee (SSC) Meeting., Melbourne, Australia, July 7, 2019.
18. Importance of risk prediction. The 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 65th Annual Scientific and Standardization Committee (SSC) Meeting., Melbourne, Australia, July 6, 2019.
19. Tips and pitfalls for systematic reviews and meta-analyses. The 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 65th Annual Scientific and Standardization Committee (SSC) Meeting., Melbourne, Australia, July 6, 2019.

20. RAMs for CAT prevention. European and Mediterranean League Against Thromboembolic Disease (EMLTD) 50th Anniversary International Congress on Thrombosis. Athens, Greece. Jun 20, 2019.
21. Screening for cancer in unprovoked venous thromboembolism. 24th Congress of the European Hematology Association (EHA). Jun 15 and 16, 2019. Amsterdam.
22. Diagnostic imaging dilemmas in VTE. 15th National Conference on Anticoagulant Therapy (AC Forum). April 12, 2019. Fort Lauderdale, Florida
23. DOACs for the treatment of cancer-associated thrombosis (Case Based Presentation). Session title: Are the direct oral anticoagulants changing the landscape in the management of venous thromboembolism? 64th Annual Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH). Dublin, Ireland. Jul 21, 2018.
24. AVERT Study. Plenary Session 6: Ongoing clinical and experimental studies on thromboprophylaxis. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Bergamo, Italy. OS-02. Apr 14, 2018.
25. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Plenary Session 1: Epidemiology of thrombosis in cancer. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Bergamo, Italy. Apr 13, 2018. PL-01.
26. Subsegmental pulmonary embolism: To treat or not to treat. *Keynote*. 59th ASH Annual Meeting and Exposition. American Society of Hematology. Atlanta, GA. Dec 10, 2017
27. Chair Session: How Long to Anticoagulate my patient with VTE. 59th ASH Annual Meeting and Exposition. American Society of Hematology. Atlanta, GA. Dec 9, 2017.
28. What is the role of cancer screening for patients with VTE? ISTH webinar on Cancer Detection in VTE Patients. International Society on Thrombosis and Haemostasis. May 24, 2017.
29. Moderate State-of-the-Art Lecture: Update on DOACs. Hemostasis & Thrombosis Research Society (HTRS) 2017 Scientific Symposium. Scottsdale, AZ. Apr 8, 2017.
30. Moderate Session: Engaging topics in thrombosis. Hemostasis & Thrombosis Research Society (HTRS) 2017 Scientific Symposium. Scottsdale, AZ. Apr 8, 2017.
31. Occult Cancer Screening in Unprovoked VTE. *Keynote*. Hemostasis & Thrombosis Research Society (HTRS) 2017 Scientific Symposium. Scottsdale, AZ. Apr 7, 2017.
32. Moderate Session: Thrombosis: Prevention and Management. Hemostasis & Thrombosis Research Society (HTRS) 2017 Scientific Symposium. Scottsdale, AZ. Apr 7, 2017.
33. Moderate Session: Debates: Diagnostic Dilemmas in Hemostasis and Thrombosis. Hemostasis & Thrombosis Research Society (HTRS) 2017 Scientific Symposium. Scottsdale, AZ. Apr 6, 2017.
34. Thromboembolism and cancer, new practices. TAO-Cancer Toxicity Management Meeting. Paris, France. Dec 9, 2016.

35. Venous thrombosis and Cancer. 2016 Annual Meeting of the Swedish Society of Thrombosis and Hemostasis. Linköping, Sweden. April 21, 2016.
36. Managing Patients at High Risk for Bleeding and High Risk for Thrombosis. Third Biennial Thrombosis and Hemostasis Summit of North America. Thrombosis and Hemostasis Societies of North America (THSNA). Chicago, IL. Apr 15, 2016.
37. Venous thromboembolism and occult cancer: impact on clinical practice. Plenary Session Epidemiology of thrombosis in cancer. *Keynote*. 8th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC). Bergamo, Italy. April 8, 2016.
38. Subsegmental pulmonary embolism: To treat or not to treat. PENN-CHOP Blood Center for Patient Care and Discovery, Perelman School of Medicine, University of Pennsylvania. Philadelphia, PA. Mar 9, 2016.
39. Diagnosing small clots: SSPE. SSC on Predictive and Diagnostic Variables in Thrombotic Disease. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 20, 2015.
40. Occult VTE: Do new trials result in changing practice. SSC Meeting on Malignancy and Thrombosis. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 20, 2015.
41. The risks and benefits of thromboprophylaxis (tp) among hospitalized medically ill cancer patients. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015.
42. Symptomatic and incidental sub-segmental PE. 13th National Conference of the Anticoagulation Forum. Washington, DC. Apr 24, 2015.
43. Subsegmental Pulmonary Embolism. Session V: Venous Thrombosis: To Treat or Not to Treat. Hemostasis & Thrombosis Research Society (HTRS) 2015 Scientific Symposium. New Orleans. Apr 18, 2015.
44. Predicting VTE in cancer patients – Is it clinically relevant? 60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Milwaukee, WI. Jun 24, 2014.
45. Is there a role for NOACs in treatment of cancer-associated thrombosis? 60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Milwaukee, WI. Jun 24, 2014.
46. Treatment of recurrent VTE and bleeding concerns. Scientific and Standardization Committee (SSC), XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. June 29, 2013.
47. The Inpatient thromboprophylaxis conundrum. Scientific and Standardization Committee (SSC), XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. June 29, 2013.
48. Incidental PE in cancer, to treat or not to treat? 4th International Symposium on Thrombosis & Haemostasis. King Saud University, Riyadh, Saudi Arabia. May 13, 2013.

49. Cancer and thrombosis (with focus on recurrent VTE, bleeding, thrombocytopenia). 4th International Symposium on Thrombosis & Haemostasis. King Saud University, Riyadh, Saudi Arabia. May 13, 2013.
50. Thromboprophylaxis in medically-ill patients. 4th International Symposium on Thrombosis & Haemostasis. King Saud University, Riyadh, Saudi Arabia. May 14, 2013.
51. Controversias en Anticoagulación. 2^o Congreso de Medicina Interna de la Costa Atlántica, Mar del Plata, Argentina. March 22, 2013.
52. TVP/TEP idiopático. Screening para trombofilia – cancer. 2^o Congreso de Medicina Interna de la Costa Atlántica, Mar del Plata, Argentina. March 22, 2013.
53. Standardization of VTE outcome in cancer trials. 58th Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH), Liverpool, UK June 27-30, 2012.
54. Screening for occult malignancy: where does the evidence stand? 58th Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH), Liverpool, UK June 27-30, 2012.
55. Satellite symposium Cancer and Thrombosis: The Quest for Optimal Care. Title: Unanswered Clinical Questions: Incidental VTE, Recurrent Thrombosis, Catheter-Related VTE. Sixth International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy. April 20-22, 2012. Invited speaker.
56. Thrombosis and Cancer. Symposia on Thrombosis and special patients and Masterclasses on the same subject. Stockholm, Sweden. Feb 9, 2012.
57. Thrombosis and Cancer. Symposia on Thrombosis and special patients and Masterclasses on the same subject. Copenhagen, Denmark. Feb 8, 2012
58. Diagnosis of Isolated Sub-Segmental Pulmonary Embolism on Computed Tomography Pulmonary Angiography; How Sure Are We of the Diagnosis? American Society of Hematology (ASH) 53rd Annual Meeting and Exposition, San Diego, CA Dec 9, 2011. Participant.
59. Enfermedad tromboembólica y disección aórtica. 1^o Congreso de Medicina Interna de la Costa Atlántica. Residencias de Clínica Médica de Mar del Plata. Mar del Plata, Argentina. Oct 14, 2011.
60. Standardizing VTE in Oncology Trials. SCC Cancer & Thrombosis. XXII Congress of the International Society of Thrombosis and Haemostasis (ISTH). Kyoto, Japan. Jul 25, 2011. Invited speaker.
61. Venous Thromboembolism and Cancer: Prevention and Treatment. American Society of Hematology (ASH), 52nd Annual Meeting, Meet the Expert Series. Orlando, Florida. December 4-7, 2010. Invited speaker.
62. Thromboprophylaxis in Multiple Myeloma: How strong is the evidence? 56th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) Cairo, Egypt May 22-25, 2010. Invited speaker.

63. Trousseau's Syndrome Revisited: Should We Screen Extensively for Malignancy in Patients with Venous Thromboembolism? A Systematic Review and Meta-Analysis. Abstract 403. American Society of Hematology (ASH) 50th Annual Meeting and Exposition. San Francisco. Dec 6-9, 2008.
64. Heparin Induced Thrombocytopenia in Patients with End Stage Renal Disease. Frenesius Medical Care Conference. Dallas. May 1, 2008. Invited speaker.
65. Management of Anticoagulation using Warfarin. Annual Champlain Region Stroke Update. Ottawa. 2008. Invited speaker.
66. Increased Mortality in Patients with Antibodies to the Platelet Factor 4-Heparin Complex on Chronic Hemodialysis. American Society of Hematology (ASH) 48th Annual Meeting and Exposition. Orlando. Dec 9-12, 2006.

Invited Presentations – National/Provincial:

1. Update on the treatment of cancer associated thrombosis and AF in cancer patients. Hematology Lecture Rounds. McGill University Health Center. Montreal, QC. Virtual. Feb 3, 2021.
2. Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. Provincial Gyne Oncology Journal Club. Saskatchewan Cancer Agency. Regina SK. Virtual. Jan 27, 2021.
3. Chair, ASH Highlights Program. Thrombosis Canada Webex. Dec 16, 2020
4. Malignancy screening in patients with unprovoked VTE. CanVECTOR National Thrombosis Seminar. Virtual. Nov 24, 2020.
5. Use of NOAC in Cancer-Associated Thrombosis. Mumbai Hematology Group Webinar Oct 24, 2020. Mumbai, India.
6. Thrombose et COVID-19. Colloque Neurovasculaire 2020. Société des sciences vasculaires du Québec (SSVQ). Virtual symposium. Oct 23, 2020.
7. ASH Highlights: Canadian Perspectives. Thrombosis Canada Webex. Dec 18, 2019
8. Primary thromboprophylaxis in ambulatory cancer patients. Medical Grand Rounds, Dalhousie University. Halifax, NS Oct 22, 2019.
9. Paradigm shift: Direct oral anticoagulants for the prevention and treatment of cancer-associated thrombosis. Thrombosis Canada Annual Education Conference. Toronto, ON. Oct 19, 2019.
10. 5th Annual Pulmonary Embolism Symposium (PERT). Boston, MA. Oct 4-5, 2019.
11. Cancer Associated Thrombosis. Canadian Hematology Conference. Toronto. Sep 21, 2019.
12. Challenges in thrombosis management. Thrombosis Canada Live Webinar. Jun 25, 2019.
13. Clinical Expert for "Tale of Two Heparins" webinar. he Canadian Agency for Drugs and Technologies in Health, (CADTH), and Horizon Health Network, New Brunswick Regional Health Authority. Jun 10, 2019.

14. Reversal of Anticoagulants. Evening Symposium: Choosing plasma wisely: when and when not to use plasma. Ontario Regional Blood Coordinating Network (ORBCoN). Toronto, ON. May 2, 2019.
15. Diagnostic Imaging Dilemmas in VTE. 15th National Conference on Anticoagulant Therapy (AC Forum). Fort Lauderdale, FL. Apr 12, 2019.
16. TEV et Cancer: la nouvelle place des AOD. Société des sciences vasculaires du Québec (SSVQ) visioconférences: Nouveautés en anticoagulation 2019: cancer, coronaires et interactions. Montreal, QC. Mar 22, 2019.
17. Long Term Management and Thrombosis in the Cancer Patient. Symposium on Hepatic Oncology at Whistler (SHOW). Whistler, BC. Jan 31, 2019.
18. Risk and Epidemiology of VTE in Cancer Patients. Symposium on Hepatic Oncology at Whistler (SHOW). Whistler, BC. January 31, 2019.
19. Moderator of Panel Discussion: CAT & Cancer. Symposium on Hepatic Oncology at Whistler (SHOW). Whistler, BC. January 31, 2019.
20. Moderator of Panel Discussion: CAT & Cancer. Symposium on Hepatic Oncology at Whistler (SHOW). Whistler, BC. January 31, 2019.
21. Panel Member. SHOW Case Discussion. Symposium on Hepatic Oncology at Whistler (SHOW). Whistler, BC. January 31, 2019.
22. New development in CAT. Medical Oncology Grand Rounds. Lakeridge Health Oshawa Oshawa, ON. Oct 12, 2018.
23. CAT - What is new and practice changing. 15th Annual CAGPO Conference. The Canadian Association of General Practitioners in Oncology. Quebec, QC. Sep 28, 2018.
24. CAT 101. 15th Annual CAGPO Conference. The Canadian Association of General Practitioners in Oncology. Quebec, QC. Sep 28, 2018.
25. An Update on the New/Direct Oral Anti-coagulants (DOACs). Thrombosis and Anticoagulation Newfoundland and Labrador (TANL) Conference 2018. Memorial University of Newfoundland. St. John's, NL Sep 22, 2018. Keynote.
26. An Overview of Cancer Associated Thrombosis. Thrombosis and Anticoagulation Newfoundland and Labrador (TANL) Conference 2018. Memorial University of Newfoundland. St. John's, NL Sep 22, 2018. Keynote
27. Complex Pulmonary Embolism Cases. Presentation to family physicians. St. John's, NL Sep 21, 2018.
28. Controversies in Management of Venous Thromboembolism. Eastern Health Hematology Rounds. St. John's, NL Sep 21, 2018.
29. Primary prophylaxis in ambulatory cancer patients. Société des sciences vasculaires du Québec (SSVQ) Video Symposium. Montreal Heart Institute. Montreal, QC Jun 15, 2018.
30. Cancer-associated thrombosis update. Niagara Health System Thrombosis Update. Keynote. St. Catharine's, ON. May 9, 2018.

31. What's new in VTED. New Brunswick Hematology Day 2018. Saint John Regional Hospital. Moncton, NB. May 4, 2018
32. Case Discussion: Managing patients with AF and renal impairment, Renfrew Victoria Hospital. Renfrew, ON. Mar 26, 2018.
33. Management of cancer-associated thrombosis. Canadian Association of Pharmacy in Oncology (CAPHO). Plenary. Gatineau, QC. May 6, 2018.
34. Catheter-related thrombosis. Canadian Vascular Access Association. Toronto, ON. Apr 27, 2018.
35. Facilitator, Cardiovascular Function and Cancer Treatment Roundtable. American College of Cardiology (ACC). Washington, DC, Feb 15, 2018.
36. Venous Thromboembolism. 2018 Highlights of ASH in North America, American Society of Hematology (ASH). Miami, FL. Jan 20, 2018.
37. Venous Thromboembolism. 2018 Highlights of ASH in North America, American Society of Hematology (ASH). Chicago, IL. Jan 27, 2018.
38. Cancer and Venous Thromboembolism. Haematology and Oncology Rounds. CancerCare Manitoba. Winnipeg, MB Nov 28, 2017.
39. Subsegmental Pulmonary Embolism. Department of Internal Medicine Grand Rounds. University of Manitoba. Winnipeg, MB, Nov 28, 2017.
40. Cancer and Thrombosis. Dalhousie University Hematology Symposium. Halifax, NS. Nov 4, 2017.
41. Perioperative management of oral anticoagulation. Regional Surgical Network, Meno Ya Win Health Centre. Sioux Lookout. Sep 22, 2017.
42. Post-operative thromboprophylaxis. Regional Surgical Network, Meno Ya Win Health Centre. Sioux Lookout. Sep 22, 2017.
43. Which VTE Doesn't Need Treatment. 18th Annual Antithrombotic Therapy Symposium: Improving Anticoagulation in Detroit. Dearborn, MI. Apr 28, 2017.
44. Screening for Occult Cancer in Patients with Thrombosis. Combined Oncology and Medicine Rounds. Queen's University. Kingston, ON. Apr 20, 2017.
45. Reversal of direct oral anticoagulants in the patient with GI bleeding. Ontario Regional Blood Coordinating Network's 12th Annual Transfusion Videoconference Symposium: Blood and Guts: Management of the GI Bleed. Sudbury, ON. Apr 12, 2017.
46. Anticoagulant therapy for symptomatic calf DVT (CACTUS). Anticoagulation Forum. Webinar Ottawa, ON. Jan 11, 2017.
47. Cancer Associated Thrombosis, Meet the Expert Workshop, Thrombosis Pearls & Perils for Primary Care, Thrombosis Canada. Vancouver, BC. Nov 13, 2016.
48. Q&A with expert about blood clots and cancer, World Thrombosis Day Educational webinar, Thrombosis Canada. Oct 13, 2016.

49. DVT prophylaxis in cancer patients. Clinical and Translational Research Symposium University of Vermont Cancer Centre. Burlington, Vermont. Apr 29, 2016.
50. Thrombosis and Cancer. 15e Congrès annuel de la SSVQ. Société des sciences vasculaires du Québec. Quebec, QC. Nov 21, 2015.
51. Cancer associated venous thromboembolism. 11th Annual McMaster Update in Thromboembolism & Hemostasis, Hamilton, ON. Oct 30, 2015.
52. AF and VTE on the Front Lines: There's a NOAC For That! CAEP 2015 Conference. Canadian Association for Emergency Physicians (CAEP). Edmonton, AB. Jun 2, 2015.
53. How long should I anticoagulate after DVT or PE? CancerCare Manitoba, Blood Day for Primary Care, University of Manitoba. Winnipeg, MB. Feb 6, 2015.
54. Anticoagulation, including the use of novel oral anticoagulants in CVT/PE and atrial fibrillation. CancerCare Manitoba, Blood Day for Primary Care, University of Manitoba. Winnipeg, MB. Feb 6, 2015.
55. Challenging cases of cancer-associated thrombosis. CBMTG 2014 Conference. Canadian Blood and Marrow Transplant Group. Halifax, NS. Jun 13, 2014.
56. Venous thromboembolism treatment in patients with cancer: Review of the New ASCO Clinical Practice Guidelines. The Society of Gynecologic Oncology of Canada (SGOC), 14th Annual Continuing Professional Development Meeting. Toronto, ON. May 2, 2014.
57. Indications of anticoagulants; which agent to use for your patient? Canadian Blood Services and Ontario Regional Blood Coordinating Network's Ninth Annual Transfusion Medicine Symposium: Bleeding Issues in the Anticoagulated Patient. North Bay, ON. Apr 9, 2014.
58. Cancer-Associated Thrombosis: Review of Challenging Cases. The Ottawa Hospital Cancer Center, National Oncology Fellows' Webinar Program. Ottawa, ON. Feb 26, 2014.
59. New oral anticoagulants: breakthrough or just another bleeding mess? Family Medicine Forum 2013. Vancouver, BC. Nov 8, 2013.
60. Nouveaux agents anticoagulants oraux : Quoi de neuf ? Association des médecins hématologues et oncologues du Québec (AMHOQ) 38^e Congrès Annuel. Quebec. May 4, 2013.
61. Thrombosis and cancer. Canadian Society of Internal Medicine Annual Meeting, Quebec City, QC. Oct 17, 2012.
62. New anticoagulants in the real world: A focus on starting and interrupting their use. 8th Annual McMaster Update in Thromboembolism & Hemostasis, Hamilton, ON Oct 12, 2012
63. Cancer and thrombosis. Hematology/Oncology Rounds. Cancer Centre of Southeastern Ontario, Kingston, ON. Jun 14, 2012.
64. Traitement et prévention de la TEV chez les patients avec cancer. Oncology, Rounds. Centre de recherche clinique et évaluative en oncologie (CRCEO) de l'Hôtel-Dieu de Québec, Québec City. May 16, 2012.

65. Thromboprophylaxis in hospitalized patients. VTE Noon Rounds, Renfrew Victoria Hospital, Renfrew, ON. Apr 7, 2012.
66. Thromboprophylaxis in Surgical patients. Surgical Grand Rounds. Belleville General Hospital. Belleville, ON. Nov 24, 2011.
67. Screening for occult malignancy in patients with venous thromboembolism. Internal Medicine Grand Rounds. CancerCare Manitoba Dept of Medical Oncology & Hematology. Winnipeg, MB. Nov 22, 2011.
68. Anti-metastatic properties of LMH: Truth or Myth?. Hematology/Oncology Regional Grand Rounds. CancerCare Manitoba Dept of Medical Oncology & Hematology. Winnipeg, MB. Nov 22, 2011.
69. Anti-neoplastic effects of low-molecular-weight-heparin: truth or myth? Grand Rounds. Fletcher Allen Hospital, University of Vermont, Vermont. Nov 8, 2011.
70. Occult cancer screening. Grand Rounds. Hôpital du Sacré-Coeur de Montréal. Montréal, QC. Nov 2, 2011.
71. Propriétés anti-méetastatiques des HFPM. Medical Oncologists and Surgeons at Gatineau Hospital. Gatineau, QC. Nov 3, 2011.
72. Propriétés anti-cancéreuses des HFPM. Grand Rounds. CHUS-Fleurimont Sherbrooke. Sherbrooke, QC. Oct 28, 2011.
73. Propriétés anti-cancéreuses des HFPM. Hematology Rounds. Hôpital Charles LeMoine. Greenfield Park, QC. Oct. 28, 2011.
74. Propriétés anti-cancéreuses des HFPM. Hematology Rounds. Hôpital du Sacré-Coeur de Montréal. Montréal, QC. Oct. 27, 2011.
75. Propriétés anti-cancéreuses des HFPM. Réunion d'hématologie-oncologie Centre intégré de cancérologie. Cité de la Santé de Laval. Laval, QC. Oct 26, 2011.
76. Propriétés anti-cancéreuses des HFPM. Hematology Rounds. Hôpital Maisonneuve-Rosemont. Montreal, QC. Oct 26, 2011.
77. Quand faut-il rechercher un cancer chez un patient avec une MTEV idiopathique? Hematology Rounds. CHUM Hôpital Notre Dame. Montreal, QC. Oct 26, 2011.
78. A critical appraisal of VTE prophylaxis and treatment in patients with cancer. Oncology Rounds, Saint John Hospital. Saint John, NB. Apr 20, 2011.
79. A critical appraisal of VTE prophylaxis and treatment in patients with cancer. Oncology Rounds, Moncton Hospital. Moncton, NB. Apr 19, 2011.
80. Rounds, Renfrew Victoria Hospital, Renfrew, ON. Apr 7, 2011.
81. ICU Noon Rounds, Belleville General Hospital. Belleville, ON. Mar 9, 2011.
82. Screening for occult malignancy in patients with idiopathic venous thromboembolism. 10th Annual Quebec Society Vascular Sciences Symposium. Nov 2010.
83. Novel antithrombotics: their current & future roles. 5th McMaster update in Thromboembolism Conference. Oct 3-5, 2009. Speaker.

84. Venous thromboembolism prophylaxis and treatment in patients with cancer. The Canadian Oncology Societies and Canadian Association of Medical Oncologist, Webinar. Presenter. 2009.

Invited Presentations – Local:

1. Perles cliniques en matière de thromboembolie veineuse (TEV). Mise à Jour pour l'hospitaliste 2020. Montfort Hospital, University of Ottawa. Oct 30, 2020.
2. Prevention and treatment of VTE in patients with ALL on asparaginase therapy. Thrombosis Rounds. Division of Hematology, University of Ottawa at The Ottawa Hospital. Ottawa, ON. May 21, 2020.
3. Updates in VTE – Cases in the ER. Emergency Department Rounds. Montfort Hospital, Ottawa, ON. Mar 10, 2020.
4. Rôle émergent des anticoagulants oraux directs (OAD) pour la thrombose ou la FA associée au cancer. l'Hôpital de LaSalle. LaSalle, QC. Jan 29, 2020
5. Rôle émergent des anticoagulants oraux directs (OAD) pour la thrombose ou la FA associée au cancer. Hôpital Pierre-Le Gardeur. Terrebonne, QC. Jan 28, 2020
6. A practical approach to the management of VTE & latest 2019 ASH update, a Canadian Perspective. Internal Medicine Rounds. Queensway Carleton Hospital, Ottawa, ON. Jan 21, 2020
7. Update in anticoagulation: Challenging patients and New Indications. UOHI webinar series for family physicians. University of Ottawa Heart Institute. Ottawa, ON Jan 20, 2020.
8. Updates in DOACS in special populations and complicated cases. Combined Oncology and Medicine Rounds. Queen's University. Kingston, ON Sep 12, 2019.
9. Primary thromboprophylaxis in cancer patients: The CASSINI and AVERT trials. Clinical Epidemiology Rounds, University of Ottawa at The Ottawa Hospital. Ottawa, ON. May 17, 2019.
10. The AVERT Trial. Thrombosis Rounds. Division of Hematology, University of Ottawa at The Ottawa Hospital. Ottawa, ON. Jan 17, 2019.
11. Journal Club: Can we use rivaroxaban for the treatment of cancer-associated thrombosis. A critical appraisal of the SELECT-D trial. Thrombosis Rounds. Division of Hematology, University of Ottawa at The Ottawa Hospital. Ottawa, ON. Jun 21, 2018.
12. Staibano P, Perelman I, Lombardi J, Davis A, Timmouth A, **Carrier M**, Stevenson C, Saidenberg E. Use of patient-centred outcomes in the management of anaemia: A systematic review. Ottawa Blood Disease Centre Trainee Research Symposium, Division of Hematology, University of Ottawa at The Ottawa Hospital. Ottawa, ON. May 10, 2018.
13. Direct Oral anticoagulants for the management of cancer-associated thrombosis. The Ottawa Hospital Cancer Program Grand Rounds. Ottawa, ON. Apr 26, 2018.

14. Occult cancer detection in patients with venous thromboembolism (VTE): The past, the present and the future. Division of Hematology Grand Rounds. The Ottawa Hospital, University of Ottawa. Ottawa, ON. Mar 9, 2018.
15. Anticoagulation in oncology patients. Cardio Oncology Preceptorship, The Ottawa Hospital. Ottawa, ON Oct 17, 2017.
16. Venous thromboembolism and Cancer. Oncology Nursing lunch & learn. The Ottawa Hospital Cancer Program. Ottawa, ON. May 23, 2017.
17. Update on novel oral anticoagulants: A review of clinical use and patient management. Montfort Hospital, Ambulatory Care Group. Jun 15, 2016, Ottawa, ON.
18. Occult cancer detection in patients with unprovoked venous thromboembolism. The SOME Trial. Clinical Epidemiology Rounds, The Ottawa Hospital: Ottawa ON. Jun 3, 2016.
19. Peri-operative anticoagulation. Division of Urology, The Ottawa Hospital, University of Ottawa. Ottawa, ON. Feb 3, 2016.
20. Perioperative management of Thrombosis. Montfort Hospital, Department of Anaesthesia. Ottawa, ON. Jan 7, 2016.
21. Occult Cancer detection in patients with unprovoked VTE. Department of Medicine Grand Rounds, The Ottawa Hospital, University of Ottawa. Ottawa, ON Nov 10, 2015.
22. Screening for cancer in thrombosis patients. World Thrombosis Day, Patient Symposium. Ottawa Blood Disease Centre at The Ottawa Hospital. Ottawa, ON. Oct 13, 2015.
23. New oral anticoagulants - Are they safe to use in the elderly. The Ottawa Hospital, Geriatric Medicine Academic Rounds. Ottawa, ON. Apr 9, 2015.
24. VTE Prophylaxis in Surgery. The Ottawa Hospital, Department of Surgery. Ottawa, ON. Apr 2, 2015.
25. How to be a successful researcher. The Ottawa Hospital, Department of Medicine Medical Education Retreat. Ottawa, ON. Sep 19, 2014.
26. Perioperative management of the direct oral anticoagulants. Cornwall Community Hospital, Departments of Anesthesiology and Surgery. Cornwall, ON Jun 18, 2014.
27. Lecture: New oral anticoagulants – are they safe to use in the elderly? University of Ottawa Primary Care Geriatric Education Day. Ottawa, ON Jun 6, 2014.
28. Update on VTE treatment & bleed management protocols at The Ottawa Hospital. Medicine Rounds. Renfrew Victoria Hospital. Renfrew, ON. Dec 16, 2013.
29. Deep vein thrombosis / pulmonary embolism. Respiriology Pneumo Club. The Ottawa Hospital, Ottawa, ON Dec 3, 2013.
30. Thromboprophylaxis in medically ill patients. Grand Rounds. Queensway Carleton Hospital, Ottawa, ON Oct 25, 2013.
31. Budget development for Grants. Clinical Research Training Course. The Ottawa Hospital Research Institute. Ottawa, ON. Oct 23, 2013.

32. Update on VTE treatment & bleed management protocols. Noon Rounds. Brockville General Hospital. Brockville, ON. Oct 23, 2013.
33. Venous thromboembolism treatment in patients with cancer: review of the New ASCO Clinical Practice Guidelines. TOHCP Grand Rounds, The Ottawa Hospital, Ottawa, ON. Sep 26, 2013.
34. Thromboprophylaxis in ambulatory cancer patients undergoing chemotherapy. TOH Cancer Centre Nursing Education session. The Ottawa Hospital, Ottawa, ON. Jun 21, 2013.
35. Nouveaux agents anticoagulants oraux: répondre aux questions cliniques les plus fréquentes entourant leurs utilisations. Journées Montfort 2013. L'hôpital Monfort, Ottawa, ON. Apr 19, 2013.
36. Screening for occult malignancies in patients with unprovoked venous thromboembolism (VTE): Update on SOME Trial. Clinical Epidemiology Rounds, The Ottawa Hospital: Ottawa ON. Apr 5, 2013.
37. Thromboprophylaxis in the gynecologic patient. Gynecology/Oncology Nursing Education session. The Ottawa Hospital, Ottawa, ON. Apr 3, 2013.
38. VTE prophylaxis and the CHEST Guidelines. Ottawa Valley Regional Drug Information Service (OVRDIS), Ottawa, ON. Oct 13, 2012.
39. DVT's in the cancer population. Hematology Nursing Education Day. Malignant Hematology and BMT Foundation. Ottawa, ON May 4, 2012.
40. New anticoagulants for atrial fibrillation. Mise à Jour 2012 Update. The Ottawa Valley Regional Drug Information Service (OVRDIS). Ottawa, ON Mar 24, 2012.
41. Management of potentially clinically unimportant venous thromboembolism: Do we need to treat all pulmonary embolism? Clinical Epidemiology Rounds, The Ottawa Hospital: Ottawa ON. Mar 23, 2012.
42. VTE Update. ICU Nurses. The Ottawa Hospital. Mar 7, 2012.
43. New oral anticoagulants for stroke prevention in patients with atrial fibrillation. Neurology Academic Day, University of Ottawa. Ottawa, ON. Dec 20, 2011.
44. Cancer and thrombosis. Nursing In-Service. The Ottawa Hospital. Nov 18, 2011.
45. Occult cancer detection in patients with venous thromboembolism. Clinical Epidemiology Rounds, The Ottawa Hospital, Ottawa ON. Sep 16, 2011.
46. Hematology-Fatigue. Mini-Med Goes to the Family Doctor. Ottawa, ON Jun 2, 2011.
47. La thromboprophylaxie. Réunion médecine familiale. Montfort Hospital. May 10, 2011.
48. Title: Grand Rounds, Winchester District Memorial Hospital. Apr 27, 2011.
49. New antithrombotic medications. 60th Annual Refresher Course for Family Physicians. University of Ottawa. Ottawa, ON. Apr 13, 2011.
50. Thromboprophylaxis. Kingston General Hospital. Kingston, ON. Sep 21, 2010.

51. Cancer-related VTE: Treatment and prevention and differences in LMWH. Mise à Jour Update. The Ottawa Valley Regional Drug Information Service (OVRDIS). Ottawa, ON. Apr 2, 2010.
52. Thromboprophylaxis (Medical, ICU and Surgical). Hematology Rounds, The Ottawa Hospital. Ottawa, ON. Apr 27, 2009.
53. Cancer and thrombosis research update. Medical Grand Rounds, The Ottawa Hospital. Ottawa, ON. Sep 25, 2008.
54. Cancer and thrombosis-management. Medical Grand Rounds, The Ottawa Hospital. Ottawa, ON. Apr 27, 2008.

Abstract Oral Presentations – National Conferences

1. Michalowski M, Michalowski W, O'Sullivan D, Wilk S, and **Carrier M**. AF guide system to support personalized management of atrial fibrillation. 2017 AAAI Joint Workshop on Health Intelligence (W3PHIAI 2017). San Francisco, CA. Feb 5, 2017.

Abstract Oral Presentations – International Conferences

1. Bosch FTM, Wang TF, Di Nisio M, Segers A, Connors JM, Garcia D, Mulder FI, Weitz J, Büller HR, **Carrier M**, Verhamme P, Grosso M, Raskob G, van Es N. Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study. 10th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 26, 2021. Virtual. Bergamo, Italy. OC-14.
2. Shaw JR, Mallick R, **Carrier M**, Ilich A, Key NS, Wells PS. Enhanced VTE risk stratification in ambulatory patients with cancer. 62nd ASH Annual Meeting & Exposition. American Society of Hematology. Orlando, FL. Dec 9, 2019. Abstract No.634.
3. Kimpton M, Kumar S, Wells, PS, **Carrier M**, Thavorn K. Cost-utility analysis of apixaban compared to usual care for the primary thromboprophylaxis of ambulatory cancer patients initiating chemotherapy. 62nd ASH Annual Meeting & Exposition. American Society of Hematology. Orlando, FL. Dec 7, 2019. Abstract No. 329.
4. Mulder F, van Es N, Kraaijpoel N, Di Nisio M, **Carrier M**, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Büller HR, Raskob GE. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE cancer randomized trial. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 15, 2018. Bergamo, Italy. OC-17.

5. Kraaijpoel N, Bleker SM, van Es N, Mahé I, Muñoz A, Meyer G, Planquette B, Sanchez O, Bertoletti L, Accassat S, de Magalhaes E, Baars J, Rutten A, Lalezari F, Beyer–Westendorf J, Endig S, Marten S, Porreca E, Rutjes AW, Russi I, Constans J, Boulon C, Kleinjan A, Beenen LFM, Iosub D, Piovella F, Couturaud F, Tromeur C, Biosca M, Assaf JD, Helfer H, Pinson M, Lerede T, Falanga A, Lacroix P, Désormais I, Maraveyas A, G. Bozas G, Aggarwal A, Rickles FR, Girard P, Caliandro R, Martinez del Prado P, de Prado Maneiro C, García Escobar I, González Santiago S, Schmidt J, Dublanchet N, Aquilanti S, Confrere E, Paleiron N, Grange C, Sevestre MA, Ferrer Pérez AI, Salgado Fernández M, Falvo N, Thaler J, Otten HM, **Carrier M**, Bergmann JF, Büller HR, Di Nisio M. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 15, 2018. Bergamo, Italy. OC-16.
6. Lazo-Langner A, Kahn SR, Wells PS, Anderson D, Rodger M, **Carrier M**, Bosco AA, Kovacs J, Corpuz R, Kovacs JM. Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 4, 2016. OR417.
7. Khorana AA, Francis CW, Kuderer NM, **Carrier M**, Ortel TL, Wun T, Peterson D, Iyer R, Lyman GH. Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. 57th ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL. Dec 7, 2015. OR427.
8. Ihaddadene R, Corsi DJ, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis JD, **Carrier M**. Risk Factors Predictive of Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism. 57th ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL. Dec 7, 2015.
9. Lazo-Langner A, Kahn SR, Wells PS, Anderson D, Rodger M, **Carrier M**, Bosco AA, Kovacs J, Corpuz R, Kovacs MJ. A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. 57th ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL. Dec 7, 2015.
10. **Carrier M**, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Ramsay T, Coyle D, Chagnon I, Kassam K, Taves D, Rodger MA and Tao H for the SOME Investigators. Screening for occult malignancy in patient with unprovoked venous thromboembolism: an open randomized controlled trial using a comprehensive abdomen/pelvis computed tomography (SOME TRIAL). XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 22, 2015. Abstract No: ISTH15LB-1848.
11. **Carrier M**, Controversies in cancer-associated thrombosis. *Keynote*. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 25, 2015. Abstract No: AS080-THU.

12. **Carrier M**, Wu C, Peterson E, de Wit C, Ma M, Tien J, Polley G, Lee A. The risks and benefits of thromboprophylaxis (TP) among hospitalized medically ill cancer patients. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: OR295-WED.
13. **Duffett L**, **Carrier M**, Le Gal G, Rodger M, Gándara M. The impact of optical density cut-off on sensitivity and specificity for the diagnosis of heparin induced thrombocytopenia: a systematic review and meta-analysis. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 22, 2015. Abstract No: OR053-MON
14. **Tran T**, de Wit C, Delluc A, Petrcich W, Le Gal G, **Carrier M**. Impact of oral anticoagulation on time to procedure in patients admitted for hip fracture. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: OR281-WED.
15. **Castellucci LA**, Shaw J, Acres S, Porteous R, Gomes B, Watpool I, Edwards C, Giulivi A, **Carrier M**, Patel R. Prophylactic enoxaparin in critically ill patients with severe renal insufficiency. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: OR310-WED.
16. **Righini M**, Galanaud JP, Guenneguez H, Brisot D, Diard A, Faisse P, Barrelier MT, Hamel Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquenot C, Accassat S, **Carrier M**, Le Gal G, Mermillod B, Laroche JP, Bounameaux H, Perrier A, Kahn S, Quéré I. Anticoagulant therapy for symptomatic distal deep vein thrombosis: the cactus randomized placebo-controlled trial. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: AS137-WED.
17. **Schulman S**, **Carrier M**, Lee A, Shivakumar S, Blostein M, Spencer F, Solymoss S, Barty R, Wang G, Heddle N, Douketis J. Perioperative management of dabigatran: a prospective cohort study. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: OR282-WED.
18. **Roy PM**, Corsi D, Theogene A, de Wit C, Dennie C, Le Gal G, Rodger M, Wells P, **Carrier M**, Gandara E. Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 25, 2015. Abstract No: OR384-THU.
19. Kezadri-Hamiaz M, Rosu D, Wils S, Kuziemy C, Michalowski W, Amyot D, Carrier M. Cadre formel pour la modélisation de la gestion des processus métier par une équipe médicale interdisciplinaire. Healthcare Informatics, Supply Chain, and Organizational Transformation Session. 15th IFAC Symposium on Information Control Problems in Manufacturing. Ottawa, Canada. May 11, 2015.

20. Moretto P, Le Gal G, **Carrier M**. A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. Abstract OC-11. 7th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy, May 10, 2014.
21. Kimpton M, Le Gal G, Kherani K, **Carrier M**. Defining time in therapeutic range for clinicians: Frequency of dose changes and INR testing as surrogate markers for adequate vitamin K antagonist management. Abstract AS 38.2. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 4, 2013. Abstract No: AS 38.2
22. Le Gal G, **Carrier M**, Kelling D, Penalzoza A, Douma R, Righini M. Age-adjusted D-Dimer for venous thromboembolism exclusion in the elderly: systematic review and meta-analysis. Abstract AS 42.1 A. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands Abstract. July 4, 2013. Abstract No: as 42.1.
23. Castellucci L, Le Gal G, Wells P, Gandara E, Rodger M, **Carrier, M**. Secondary prevention of recurrent venous thromboembolism: Systematic review and meta-analysis of bleeding complications among patients receiving anticoagulation. Abstract OC 12.1. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. Abstract No: OC 12.1.
24. Le Gal G, Robert-Ebadi H, **Carrier M**, Kearon C, Bounameaux H, Righini M. Is it useful to image both legs in patients with suspected deep vein thrombosis? A retrospective chart review. Abstract OC 20.1. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. Abstract No: OC 20.1.
25. Outpatient Treatment of Symptomatic Pulmonary Embolism: A Systematic Review and Meta-Analysis. American Society of Hematology (ASH). 54th Annual Meeting and Exposition. Dec 8-11, 2012. Atlanta, GA. Abstract #361.
26. Louzada, ML, Lazo-Langner A, Dao V, Zhang J, Kovacs MJ, **Carrier M**, Rodger M, Wells P. Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients with Cancer-Associated Venous Thromboembolism. 53rd ASH Annual Meeting and Exposition, San Diego, CA. Dec 6, 2010. Abstract No. 475.
27. Le Gal G, **Carrier M**, Rodger M. Should we classify women who develop venous thrombosis on estrogen as having provoked or unprovoked venous thromboembolism? results from the reverse study. XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA. July 13, 2009. Abstract No. OC-MO-087.
28. Le Gal G, Kovacs MJ, **Carrier M**, Do K, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Perrier A, White RH, Rodger M. Validation of a diagnostic approach to exclude recurrent venous. XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA. July 14, 2009. Abstract No. OC-TU-011.

29. Rodger MA, Betancourt M, **Carrier M**. The association of FvI and PGM and placenta mediated pregnancy complications. a systematic review and meta-analysis of prospective cohort studies. Abstract No. XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA. July 15, 2009. AS-WE-022.
30. Le Gal G, **Carrier M**, Tierney S, Majeed H, Rodger M, Wells PS. Prediction of the warfarin maintenance dose after completion of the 10mg initiation nomogram- do we really need genotyping? XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA. July 16, 2009. Abstract No. OC-TH-012.

Poster Presentations – International Conferences

1. Kumar V, Key NS, Ilich A, Shaw J, Mallick R, Wells P, **Carrier M**. Using the CAT Score to improve thromboprophylaxis in ambulatory cancer patients. 10th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 24, 2021. Virtual. Bergamo, Italy. Poster No. PO-02.
2. Ladha D, Mallick R, Wells P, **Carrier M**. Efficacy and Safety of Apixaban for the Primary Prevention of VTE among Patients with Gastrointestinal Cancers: A Post-hoc Analysis of the AVERT Trial. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12, 2020. Poster No. PB2378.
3. Weitz JI, Ageno W, Farjat AE, Turpie AGG, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, **Carrier M**, Dalsgaard Nielsen J, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK, on Behalf of the GARFIELD-VTE Investigators. Influence of Body Mass Index on Outcomes in Patients with Venous Thromboembolism: Insights from GARFIELD-VTE. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12, 2020. Poster No. PB2311.
4. Ikesaka R, Siegal D, Witham D, Webb C, **Carrier M**. Thromboprophylaxis with Rivaroxaban in Patients with Malignancy and Central Venous Lines (TRIM-line): A Multi-centre Open-label Pilot Randomized Controlled Trial. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12, 2020. Poster No. PB2137.
5. Nayak AL, Zahrai A, Mallick R, **Carrier M**, Wells P. Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12, 2020. Poster No. PB2105.
6. Xu Y, You D, Ponich B, Krzyzaniak H, Ronksley P, Skeith L, Schneider P, **Carrier M**. Effect of Oral Anticoagulant Use on Surgical Delay and Outcomes in Hip Fracture Patients: A Systematic Review and Meta-Analysis. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12, 2020. Poster No. PB1113.

7. Shaw J, **Carrier M**, Dowlatshahi D, Chakraborty s, Tokessy M, Buyukdere H, Castellucci L. Activated Prothrombin Complex Concentrates for the Management of Direct Oral Anticoagulant-Associated Bleeding Events and Pre-Operative Administration for Urgent Surgery: Hemostatic and Thrombotic Outcomes. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12, 2020. Poster No. PB1111.
8. Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, Garcia DA, Khorana AA, **Carrier M**, Lyman GH. Meta-analysis and cost-effectiveness analysis of low-dose direct oral anticoagulant for the prevention of cancer associated thrombosis. 62nd ASH Annual Meeting & Exposition. American Society of Hematology. Orlando, FL. Dec 9, 2019. Poster No. 4669.
9. Atalla M, Zhang J, Mallick R, Wells PS, **Carrier M**. Thromboprophylaxis for patients with newly diagnosed VS. Recurrent cancers: A post-hoc analysis of the Avert Trial. 62nd ASH Annual Meeting & Exposition. American Society of Hematology. Orlando, FL. Dec 9, 2019. Poster No. 3660.
10. Knoll W, Mallick R, Wells PS, **Carrier M**. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A subgroup analysis of the Avert trial. 62nd ASH Annual Meeting & Exposition. American Society of Hematology. Orlando, FL. Dec 7, 2019. Poster No. 1140.
11. Kraaijpoel N, van Es N, Raskob GE, Büller HR, **Carrier M**, Zhang G, Lin M, Grosso MA, Di Nisio M. Risk scores for occult cancer in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 14, 2018. Bergamo, Italy. PO-55.
12. Kraaijpoel N, Di Nisio M, Mulder F, van Es N, **Carrier M**, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Segers A, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob GE. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 14, 2018. Bergamo, Italy. PO-53.
13. Samuleson Bannow B, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, **Carrier M**. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 14, 2018. Bergamo, Italy. PO-16.
14. Legault K, Hillis C, Yeung C, Iorio A, Crowther M, Akl E, **Carrier M**, Ceervera R, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl J, Moffat K, O'Brien S, Pengo V, Rand J, Rodriguez Pinto I, Thom L, Schunemann H. Annual European Congress of Rheumatology. Madrid, Spain Jun 15 2017. Poster THU0561.
15. Shaw J, de Wit C, Le Gal G, **Carrier M**. Bleeding and Thrombotic Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants in Patients with Prior Venous Thromboembolic Disease. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 4, 2016. Poster 2614.

16. Skeith L, **Carrier M**, Robinson S, Alimam S, Rodger M. The Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Skeith L, Carrier M, Robinson S, Alimam S, Rodger M. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 4, 2016. Poster 2595
17. Gupta S, Gandara E, **Carrier M**, Castellucci LA. Systematic Review of Treatment for Massive and Submassive Pulmonary Embolism. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 4, 2016. Poster 2612.
18. Kimpton M, Buyting R, Corsi DJ, Rupani N, **Carrier M**, McCurdy A. Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 4, 2016. Poster 2624.
19. Parker A, Peterson EA, Lee AYY, de Wit C, **Carrier M**, Polley G, Tien J, Wu C. Risk Stratification for the Development of Venous Thromboembolism in Hospitalized Patients with Cancer. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 5, 2016. Poster 4728.
20. Taylor J, Ahghel A, Corsi D, **Carrier M**, Tinmouth A, Saidenberg E. Risk of Venous Thromboembolism in Hospitalized Patients with Sickle Cell Disease. 58th Annual Meeting of the American Society of Hematology. San Diego, CA USA. Dec 4, 2016. Poster 4755.
21. Castellucci L, Shaw J, Le Gal G, Hawken S, McIntyre L, **Carrier M**. Delayed Major Bleeding in Critically Ill Trauma Patients. 57th Annual Meeting of the American Society of Hematology. Orlando, FL, USA. Dec 5, 2015. PO1098.
22. Farren-Dai L, Le Gal G, **Carrier M**, Rodger M, Kovacs MJ. Association between venous thromboembolism (VTE) minor risk factors and the risk of recurrence after a first unprovoked episode. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: PO630-WED.
23. Vazquez F, Gonzalez J, **Carrier M**, Le Gal G, Gandara E. Risk of major bleeding in patients treated with vitamin K antagonists or Aspirin. A systematic review and meta-analysis. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 24, 2015. Abstract No: PO664-WED.
24. Castellucci LA, Shaw J, Le Gal G, Tokessy M, Cober N, Saidenberg E, **Carrier M**. Use of prothrombin complex concentrate and activated prothrombin complex concentrate for reversal of direct oral anticoagulant associated bleeding. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 23, 2015. Abstract No: PO320-TUE.
25. Kimpton M, **Carrier M**, Tay J, Davis A, Le Gal G. Rates of venous thromboembolism despite thromboprophylaxis in multiple myeloma patients receiving lenalidomide or pomalidomide: A systematic review and meta-analysis. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 23, 2015. Abstract No: PO101-TUE.

26. Wilts D, Le Gal G, den Exter P, van Es J, **Carrier M**, Planquette B, Büller H, Righini M, Huisman M, Kamphuisen P. Age-adjusted d-dimer cut-off level increases the number of cancer patients in whom pulmonary embolism can be safely excluded without CTPA imaging: the ADJUST-PE cancer substudy. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 23, 2015. Abstract No: PO100-TUE.
27. Ikesaka RT, Kahn S, Galanaud JP, Vazquez F, Roche-Nagle G, **Carrier M**, Le Gal G, Rodger M, Gandara E. Is post thrombotic syndrome perceived to be a clinically relevant outcome?: A survey of physician priorities. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 22, 2015. Abstract No: PO473-MON.
28. Ikesaka RT, Kahn S, Galanaud JP, Vazquez F, Roche-Nagle G, **Carrier M**, Le Gal G, Rodger M, Gandara E. Practice variation in the treatment of DVT and prevention of post thrombotic syndrome between internists and vascular surgeons: A Canadian survey of physician practices. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada Jun 22, 2015. Abstract No: PO467-MON.
29. Delluc A, Le Gal G, Scarvelis D, Carrier M. 4260 Outcomes of Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients Session 332. 56th ASH Annual Meeting & Exposition. Orlando, FL, December 8, 2014.
30. Shaw J, Le Gal G, Tokessy M, Cober N, Saidenberg E, **Carrier M**, Castellucci L. 4259 FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery. Session 332. 56th ASH Annual Meeting & Exposition. Orlando, FL, December 8, 2014.
31. Shaw J, Le Gal G, Tokessy M, Cober N, Saidenberg E, **Carrier M**, Castellucci L. 1540 FEIBA™ for Reversal of Direct Oral Anticoagulant Associated Major Bleeding Clinically Relevant Abstract. Session: 332. 56th ASH Annual Meeting & Exposition. Orlando, FL, December 6, 2014.
32. Vijenthira A, Le Gal G, **Carrier M**. Defining time in therapeutic range for clinicians: Frequency of dose changes is a good surrogate marker for identifying patients with suboptimal anticoagulation with Warfarin. 60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Milwaukee, WI. Jun 23, 2014. Poster No. COA06.
33. Castellucci LA, Cameron C, Le Gal G, **Carrier M**. Efficacy and safety outcomes of treatment of acute venous thromboembolism: A systematic review and network meta-analysis. Poster COA20. 60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Milwaukee, WI. Jun 23, 2014.

34. Castellucci LA, Shaw J, van der Salm K, Erkens P, Carrier M. Determinants of anticoagulation adherence using Morisky Medication Adherence Scale. 60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Milwaukee, WI. Jun 23, 2014. Poster No. COA36.
35. Ihadaddene R, Le Gal G, Delluc A, **Carrier M**. Dose escalation of low molecular weight heparin in cancer patients with recurrent venous thromboembolism. 7th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy, May 11, 2014. Poster No. 12708
36. Ikesaka R, Le Gal G, **Carrier M**. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 4, 2013. ePoster No. PA 4.10-3.
37. **Carrier M**, Moretto P, Khorana A, Le Gal G, Zwicker J. Low molecular weight heparin in hospitalized cancer patients: A systematic review and pooled analysis of placebo-controlled randomized trials. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 3, 2013. ePoster No. PB 3.61-2.
38. Piran S, Ngo V, McDiarmid S, Le Gal G, Petreich W, **Carrier M**. Incidence and Predictive Factors of Symptomatic Venous Thromboembolism Related to Port-a-cath in Cancer Patients. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 2, 2013. ePoster No. PA 2.16-1.
39. Ihaddadene R, Yokom D, Le Gal G, Moretto P, Canil C, Reaume N, **Carrier M**. Survival in renal cell carcinoma patients with venous tumor thrombus: a retrospective case-control study. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 2, 2013. ePoster No. PB 2.61-3.
40. Ikesaka I, Le Gal G, **Carrier M**. Efficacy and safety of weight-adjusted dosing of low-molecular-weight-heparin for prevention and treatment of acute VTE in obese patients: a systematic review and meta-analysis. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 2, 2013. ePoster No. PB 2.71-4.
41. **Carrier M**, van der Salm K, Wells P, Rodriguez R, Duchesnes L, Erkens P. Self-reported adherence with warfarin and new oral anticoagulants in patients on chronic oral anticoagulant therapy. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 2, 2013. Poster No. PB 2.48-2.
42. Le Gal G, Zeng W, Righini M, Kovacs M, Tan M, **Carrier M**, Bazarjani M, Rodger M. Residual pulmonary embolism as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. The REVERSE Study Group. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 2, 2013. ePoster No. PB 2.71-5.

43. Yokom D, Ihaddadene R, Le Gal G, Moretto P, **Carrier M**. Incidental venous thromboembolism in kidney cancer patients: a case-control study. Poster. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. ePoster No. PA 1.16-4.
44. Yokom D, Ihaddadene R, Le Gal G, Moretto P, **Carrier M**. Increased incidence of VTE prior to surgery in patients with renal cell carcinoma and tumor thrombus. Poster. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. ePoster No. PB 1.70-5.
45. Ihaddadene R, Yokom D, Le Gal G, Moretto P, **Carrier M**. The risk of venous thromboembolism in renal cell carcinoma patients with residual and non-resected tumor thrombus. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. ePoster No. PA 1.20-5.
46. Tan M, **Carrier M**, Huisman M, Rodger M. Complication rates among patients treated for upper extremity thrombosis: A meta-analysis and systematic review. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. Poster No. PA 1.20-4.
47. Gonsalves C, Bates S, Wells P, Kahn S, **Carrier M**, Douketis J, Rodger M. Development and accreditation of a standardized training program in thrombosis and vascular medicine - a Canadian initiative. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 1, 2013. Poster No. PB 1.64-5.
48. Hogg K, Shaw J, Fallah P, Coyle D, **Carrier M**, Wells P. Measuring quality of life in acute venous thromboembolism. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands. July 2013. Poster No. PO 397.
49. Bazzarelli AK, Scheer AS, Tai L-H, Seth R, de Souza CT, Jonker DJ, Maroun JA, **Carrier M**, Auer RAC. Association of tissue factor pathway inhibitor gene polymorphism -33T→C with disease-free survival in colorectal cancer. American Society of Clinical Oncology (ASCO), 2013 Gastrointestinal Cancers Symposium. Jan 24-26, 2013, San Francisco, CA. Poster No. 395.
50. Hogg K, Kimpton M, , **Carrier M**, Coyle D, Wells P. Quality of life in acute deep vein thrombosis and pulmonary embolism. 58th Annual Meeting of The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Jun 2012. Poster No. PE16.
51. **Carrier M**, Le Gal G, Kahn S, Kovacs M, Wells P, Anderson D, Rodger M. The Management of sub-segmental pulmonary embolism: A cross-sectional survey of Canadian Thrombosis Physicians. Abstract. XXII Congress of the International Society of Thrombosis and Haemostasis (ISTH). Kyoto, Japan. Jul 23, 2011. Poster No. P-MO-308.

52. Carrier M, Rodger MA, Wells PS, Righini M, Le Gal G. Residual Vein Obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: A systematic Review and Meta-analysis. Abstract. XXII Congress of the International Society of Thrombosis and Hemostasis (ISTH). Kyoto, Japan. Jul 23, 2011. Poster No. P-MO-283.
53. **Carrier M**, Le Gal G, Tay J, Wu CM, Lee AY. Thromboprophylaxis in Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide and Lenalidomide: A Systematic Review and Meta-Analysis. 52nd ASH Annual Meeting and Exposition, Orlando, FL. Dec 4, 2010. Poster No. 1090.
54. **Bose G**, Gandara E, **Carrier M** Erkens PMG, Rodger M Wells P. Outcome of Saddle Pulmonary Embolism: A Nested Case-Control Study. 52nd ASH Annual Meeting and Exposition, Orlando, FL. Dec 4, 2010. Poster No. 1102.
55. **Bose G**, Gandara E, **Carrier M** Erkens PMG, Rodger M Wells P. Outcomes of Pulmonary Embolism In Surgical Patients: A Retrospective Cohort Study. 52nd ASH Annual Meeting and Exposition, Orlando, FL. Dec 5, 2010. Poster No. 3180.
56. **Louzada ML**, Lazo-Langner A, **Carrier M**, Dao V, Zhang J, Rodger MA, Kovacs MJ, Wells P. Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period. 52nd ASH Annual Meeting and Exposition, Orlando, FL. Dec 6, 2010. Poster No. 4202.
57. Aw A, Kocerginski J, McDiarmid S, **Carrier M**, Tay J. Incidence and Predictive Factors of Symptomatic Thrombosis Related to Peripherally Inserted Central Catheters In Chemotherapy Patients. 52nd ASH Annual Meeting and Exposition, Orlando, FL. Dec 6, 2010. Poster No. 4206.
58. **Louzada ML**, **Carrier M**, Lazo-Langner A, Dao V, Zhang J, Kovacs MJ, Lee AY, Levine MN, Meyer G, Rodger M, Wells P. Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. 52nd ASH Annual Meeting and Exposition, Orlando, FL. Dec 7, 2010. Poster No. 4209.
59. **Erkens PMG**, Gandara E, Wells P, Yi-Hao Shen A, Bose G, Le Gal G, Rodger MA, Prins MH, **Carrier M**. Safety of Outpatient Treatment in Acute Pulmonary Embolism. American Society of Hematology (ASH), 52nd Annual Meeting. Orlando, Florida. December 6, 2010. Poster No. 3796.
60. The Use of Extended Perioperative Low Molecular Weight Heparin to Improve Disease-Free Survival Following Surgical Resection of Colon Cancer: A Pilot Randomized Controlled Trial. Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), April 23-25, 2010 Stresa Italy. Poster presentation.
61. Surgical Stress Promotes the Development of Metastatic Disease by a Coagulation-Dependent mechanism. International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC). April 23-25, 2010 Stresa Italy. Poster Presentation.

62. Subsegmental Pulmonary Embolism Diagnosed by Computed Tomography: Incidence and Clinical Implications. A Systematic Review and Meta-Analysis of the Management Outcome Studies. American Society of Hematology (ASH) 51st Annual Meeting. New Orleans, Dec 5-8, 2009. Poster presentation.
63. Incidence and Clinical Outcomes of Occult Malignancies Detected by Computed Tomographic Pulmonary Angiography in Patients with Acute Pulmonary Embolism. American Society of Hematology (ASH) 51st Annual Meeting. New Orleans, Dec 5-8, 2009. Poster presentation.
64. Incidence and Management of Subsegmental Pulmonary Embolism. American Society of Hematology (ASH) 51st Annual Meeting. New Orleans, Dec 5-8, 2009. Poster presentation.
65. **Carrier M**, Le Gal G, Cho R, Tierney S, Rodger MA, Lee AY. Dose Escalation of Low Molecular Weight Heparin to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation in Cancer Patients. XXII Congress of the International Society of Thrombosis and Hemostasis (ISTH). Boston. Jul 16, 2009. Poster No. PP-TH-489.
66. **Carrier M**, Le Gal G, Wells PS, Rodger MA. Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Episodes During and Following Anticoagulation Therapy. XXII Congress of the International Society of Thrombosis and Hemostasis (ISTH). Boston. Jul 16, 2009. Poster No. PP-TH-292.
67. Case Fatality Rates of Recurrent Venous Thromboembolism during and Following Anticoagulation Therapy. American Society of Hematology (ASH) 50th Annual Meeting and Exposition. San Francisco. Dec 6-9, 2008. Abstract 3032.
68. VIDAS D-Dimer in Combination with Clinical Pre-Test Probability to Rule out Pulmonary Embolism. A Systematic Review of the Management Outcome Studies. American Society of Hematology (ASH) 50th Annual Meeting and Exposition. San Francisco. Dec 6-9, 2008. Abstract 1811.
69. Thromboprophylaxis for Catheter-Related Thrombosis in Patients with Cancer: A Systematic Review of randomized Controlled Trials. American Society of Hematology (ASH) 49th Annual Meeting and Exposition. Atlanta. Dec 8-11, 2007. Poster presentation.
70. Accuracy and Usefulness of a Clinical Prediction Rule and D-dimer Testing in Excluding Deep Vein Thrombosis in Cancer Patients. XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH). Geneva. Jul 6-12, 2007. Poster presentation.
71. Accuracy of Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism Evaluation (SOME): a Prospective Pilot Cohort Study using Comprehensive Abdomen/pelvis Computed Tomography. XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH). Geneva. Jul 6-12, 2007. Poster presentation.

72. The Prevalence of Antibodies to the Platelet Factor 4-Heparin Complex and Association with Venous Access Thrombosis in Patients on Chronic Hemodialysis. Canadian Society of Nephrology meeting and at the Kidney Research Center Research Day. 2006. Poster presentation.
73. High Prevalence of Antibodies to the Heparin-Platelet Factor 4 Complex in Hemodialysis Patients. American Society of Nephrology. Philadelphia. 2005. Poster presentation.
74. Excluding Pulmonary Embolism at the Bedside with Low Pre-test Probability and D-Dimer: Safety and Clinical Utility of 4 Methods to Assign Pre-Test Probability. American Society of Hematology (ASH) 46th Annual Meeting and Exposition. San Diego. December 4-7, 2004. Poster presentation.
75. Factor V Deficient Activated Protein C Resistance Assay or Factor V Leiden PCR: Which Test When? A Cost Effectiveness Analysis. American Society of Hematology (ASH) 41st Annual Meeting, New Orleans. Dec 3-7, 1999. Poster presentation.

Poster Presentations – National Conferences

1. Michalowski M, Wilk S, Michalowski W, **Carrier M**. Representing drug classes for mitigating concurrently applied CPGs. American Medical Informatics Association (AMIA) Annual Symposium. San Francisco, CA. Nov 5, 2018. Poster 034.
2. Yokom D, Ihaddadene R, Le Gal, G, Moretto P, Reaume N, Canil C, Carrier M. Increased incidence of venous thromboembolism in patients with renal cell carcinoma and tumor thrombus prior to surgery. Canadian Association of Medical Oncologists (CAMO) 2013 Annual Scientific Meeting. Toronto, ON. Apr 25, 2013. Poster.
3. Ryma Ihaddadene R, Yokom DW, Le Gal G, Moretto P, M. Reaume MN, Canil CM, Carrier M. Reduced overall survival in renal cell carcinoma patients with venous tumor thrombus. Canadian Association of Medical Oncologists (CAMO) 2013 Annual Scientific Meeting. Toronto, ON. Apr 25, 2013. Poster.
4. Yokom D, Ihaddadene R, Le Gal, G, Moretto P, Reaume N, Canil C, Carrier M. Symptomatic and incidental venous thromboembolism are not associated with worsened survival in kidney cancer patients. Canadian Association of Medical Oncologists (CAMO) 2013 Annual Scientific Meeting. Toronto, ON. Apr 25, 2013. Poster.

Teaching/Lectures

*University of Ottawa
Undergraduates, Year 1*

Semaine 6 CBL: Aberration de l'hémostase – Partie 1, Coagulation and transfusion. Foundations Unit (2 hrs)

Oct 23, 2020

Semaine 5 CBL: Hémoglobinopathies – Part 1, Red blood cells. Foundations Unit (2 hrs)	Oct 16, 2020
TBL Maladie thrombo-embolique aiguë et chronique. Lymphome/Thrombose Unit 1 (2 hrs)	Apr 9, 2019
Lecture Microscopie: Maladie des Globules blanc Foundations Unit (1.5 hrs)	Nov 1, 2018
CBL Lymphoma Part 1, Francophone stream (2 hrs)	Apr 3, 2018
Semaine 6 CBL: Aberration de l'hémostase – Partie 1, Coagulation and transfusion. Foundations Unit (2 hrs)	Oct 24, 2017
Semaine 5: Hémoglobinopathies, APC 1, Foundations Unit, Group 5 (2 hrs)	Oct 17, 2017
Semaine 13: Maladie thrombo-embolique aiguë et chronique, APC Partie 2 (2 hrs)	Apr 4, 2017
Lecture Microscopie: Maladie des Globules blanc Foundations Unit (1.5 hrs)	Nov 3, 2016
Semaine 7: Leucémie, APC 1, Foundations Unit Group 5 (2 hrs)	Nov 1, 2016
Semaine 6 CBL: Aberration de l'hémostase – Partie 1, Coagulation and transfusion. Foundations Unit (2 hrs)	Oct 25, 2016
Semaine 5 CBL: Hémoglobinopathies – Part 1, Red blood cells. Foundations Unit (2 hrs)	Oct 18, 2016
Semaine 4 CBL: Pancytopenie – Part 1, Introduction to Blood. Foundations Unit (2 hrs)	Oct 11, 2016
Semaine 5: Hémoglobinopathies, APC 1, Foundations Unit, Group 5 (2 hrs)	Oct 13, 2015
Semaine 12: Lymphome – Partie 2. Unit 1 APC 2 (3 hrs)	Apr 2, 2015
Semaine 12: Lymphome – Partie 1. Unit 1 APC 2 (2 hrs)	Mar 31, 2015
Week 6 CBL: Aberration of hemostasis – Part 2, Coagulation and transfusion. Foundations Unit (3 hrs)	Oct 24, 2014
Week 6 CBL: Aberration of hemostasis – Part 1, Coagulation and transfusion. Foundations Unit (2 hrs)	Oct 21, 2014
Week 5 CBL: Hemoglobinopathies – Part 2, Red blood cells. Foundations Unit (3 hrs)	Oct 17, 2014
Week 5 CBL: Hemoglobinopathies – Part 1, Red blood cells. Foundations Unit (2 hrs)	Oct 14, 2014
Week 4 CBL: Pancytopenia – Part 1, Introduction to Blood. Foundations Unit (2 hrs)	Oct 7, 2014
Week 13 CBL: Acute and Chronic Thromboembolic Disease, Thrombotic Disorders Unit 1 (Year 1) (3 hrs)	Apr 11, 2014
Week 13 CBL: Acute and Chronic Thromboembolic Disease, Thrombotic Disorders Unit 1 (Year 1) (2 hrs)	Apr 8, 2014

Lecture: Cours: Hémostase anormale - 06 - Coagulation et transfusion sanguine - Foundation Unit (Year 1) (2 hrs)	Oct 21, 2013
Lecture: Venous Thromboembolism in the Surgical Patient & Perioperative Anticoagulation, PGY1 and PGY2, Surgical Foundations (2 hrs)	Dec 4, 2012
Semaine 7: Leucémie, APC 2, Foundations Unit Group 5 (3 hrs)	Nov 2, 2012
Microscopie: Maladie des Globules blanc Foundations Unit (1.5 hrs)	Nov 1, 2012
Semaine 7: Leucémie, APC 1, Foundations Unit Group 5 (2 hrs)	Oct 30, 2012
Semaine 6: Coagulation intravasculaire disséminée (CIVD) APC 2, Foundations Unit Group 5 (3 hrs)	Oct 26, 2012
Semaine 6: Coagulation intravasculaire disséminée (CIVD) APC 1, Foundations Unit Group 5 (2 hrs)	Oct 23, 2012
Hémostase anormale: Coagulation et transfusion sanguine – Foundations Unit (2 hrs)	Oct 22, 2012
Semaine 5: Hémoglobinopathies, APC 2, Foundations Unit, Group 5 (3 hrs)	Oct 19, 2012
Semaine 5: Hémoglobinopathies, APC 1, Foundations Unit, Group 5 (2 hrs)	Oct 16, 2012
Semaine 4: Anémie aplastique, APC 1, Foundations Unit Group 5 (2 hrs)	Oct 9, 2012
Semaine 13: CBL Maladie thrombo-embolique aiguë et chronique, APC 2, Group 2 (3 hrs)	Apr 5, 2012
Semaine 13: CBL Maladie thrombo-embolique aiguë et chronique, APC 1, Group 2 (2 hrs)	Apr 3, 2012
Semaine 13: Thrombose veineuse profonde (TVP) et embolie pulmonaire. Course 242802, Unit 1 (1 hr)	Apr 2, 2012
Semaine 13: Prévention des caillots: Pharmacologie et anticoagulation. Course 242802, Unit 1 (1 hr)	Apr 2, 2012
Semaine 12: APC 1: Lymphoma. Group 2, Unit 1 (2 hrs)	Mar 27, 2012
Semaine 7: Leucémie (OBLIGATOIRE). Course 29453: APC 2 (3 hrs)	Nov 4, 2011
Semaine 07: Leucémie. Cours 29499: Microscopie: Hématologie – <i>Maladies des globules blancs</i> . Groups A-F. Foundations Unit (1.5 hrs)	Nov 3, 2011
Semaine 7: Leucémie (OBLIGATOIRE). Course 29447: APC 1 Foundations Unit (2 hrs)	Nov 1, 2011
Semaine 6: CIVD Coagulation et transfusion sanguine (OBLIGATOIRE). Course 28846: APC 1 Foundations Unit (2 hrs)	Oct 25, 2011
Semaine 6: Coagulation et transfusion sanguine. Cours 241761: Hémostase anormale. Foundations Unit (2 hrs)	Oct 24, 2011
Semaine 5: Globules rouge. Cours 28790: APC 2. Hémoglobinopathies (OBLIGATOIRE). Foundations Unit (3 hrs)	Oct 21, 2011

Course 28837: Lab microscopie: Hématologie - <i>Sang normal et maladies du sang et de la moelle osseuse</i> - 05 - Globules rouges - Foundations Unit (1.5 hrs)	Oct 21, 2011
Semaine 5: Globules rouge. Microscopie – Hématologie. <i>Sang normal et maladies du sang et de la moelle osseuse</i> -Groupes A-F (1 hr)	Oct 20, 2011
Course 28784: APC 1 - Semaine 5: Hémoglobinopathies (OBLIGATOIRE) - 05 - Globules rouges - Foundations Unit (2 hrs)	Oct 18, 2011
Course 27011: APC 1 - Semaine 4: Anémie aplastique (OBLIGATOIRE) - 04 - Introduction au sang Foundations Unit (2 hrs)	Oct 11, 2011
APC 2: Maladie thromboembolique aigue et chronique (3 hrs)	Aug 4, 2011
APC 1: Maladie thromboembolique aigue et chronique (2 hrs)	May 4, 2011
Semaine 13: Maladie thromboembolique aiguë et chronique (OBLIGATOIRE). Course 16135: Unit 1 APC 2 (3 hrs)	Apr 8, 2011
Semaine 13: Maladie thromboembolique aiguë et chronique (OBLIGATOIRE). Course 16129: Unit 1 APC 1 (2 hrs)	Apr 5, 2011
Semaine 12: Lymphome. Course 15576: Unit 1 APC 2 (OBLIGATOIRE) (3 hrs)	Apr 1, 2011
Semaine 12: Lymphome. Course 15570: Unit 1 APC 1 - (OBLIGATOIRE) (2 hrs)	Mar 29, 2011
Semaine 11 : Oncologie. Course 15565: Unit 1 Activité spécifique à l'unité: <i>Statistiques canadiennes sur le cancer et traitement systémique</i> (1 hr)	Mar 21, 2011
Semaine 7: Leucémie (OBLIGATOIRE). Course 7130: APC 2 (3 hrs)	Nov 5, 2010
Course 7147: Lab microscopie: Hématologie - Maladies des globules blancs - 07 - Leucémie Foundations Unit (1.5 hrs)	Nov 4, 2010
Course 7153: Activité spécifique à l'unité: Troubles myéloprolifératifs et myélodysplasie - 07 - Leucémie Foundations Unit (2 hrs)	Nov 3, 2010
Semaine 7: Leucémie (OBLIGATOIRE). Course 7124: APC 1 Foundations Unit (2 hrs)	Nov 2, 2010
Unit 1 - FR - weeks 17 and 18 - APC 1 - semaine 17: Maladie thromboembolique aiguë et chronique (OBLIGATOIRE) - 17 - Troubles thrombotiques - (INTÉGRATION I) (2 hrs)	May 7, 2010
Unit 1 - FR - weeks 17 and 18 - APC 2 - semaine 17: Maladie thromboembolique aiguë et chronique (OBLIGATOIRE) - 17 - Troubles thrombotiques -- (INTÉGRATION I) (3 hrs)	May 7, 2010
Unit 1 - FR - Weeks 17 and 18 - Activité spécifique à l'unité: Qu'est-ce qui fait coaguler un patient? - 17 - Troubles thrombotiques - (INTÉGRATION I) (2 hrs)	May 6, 2010

Unit 1 - FR - Weeks 17 and 18 - Cours: Thrombose veineuse profonde (TVP) et embolie pulmonaire - 17 - Troubles thrombotiques -- (INTÉGRATION I) (1 hr)	May 3, 2010
Unit 1 - FR - Weeks 17 and 18 - Cours: Prévention des caillots: Pharmacologie et anticoagulation - 17 - Troubles thrombotiques - (INTÉGRATION I) (1 hr)	May 3, 2010
Instructor - Year 1 - Fr - Unit 1 - Weeks 11 and 12 - APC semaine 12 - Lymphome (OBLIGATOIRE) - 12 - Lymphome (3 hrs)	Apr 9, 2010
Immunologie-leucemie (3 hrs)	Nov 6, 2009
Fr-Session-Cours: Leucemie (1 hr)	Nov 3, 2009
Fr-Leucemie (2 hrs)	Nov 3, 2009
06 - Coagulation et transfusion sanguine - ACP: 2 Semaine 6: CIVT (OBLIGATOIRE) (3 hrs)	Oct 30, 2009
Lab microscopie: Hematologie-Sang normal et maldies du sang et de la moelee osseuse-05-Globules rouges (1.5 hrs)	Oct 22, 2009
Lab microscopie: Hematologie-Sang normal et maldies du sang et de la moelee osseuse-05-Globules rouges (1.5 hrs)	Oct 22, 2009
Coagulation et transfusion sanguine - ACP: 1 Semaine 6: CIVT (OBLIGATOIRE) (2 hrs)	Oct 20, 2009
ACP: 2 Semaine 4: Immunodeficiency Anemie aplastique (OBLIGATOIRE) -04-Introduction au sang (2 hrs)	Oct 16, 2009
ACP: 1 Semaine 4: Immunodeficiency Anemie aplastique (OBLIGATOIRE) -04-Introduction au sang (2 hrs)	Oct 13, 2009
Activite specifique a l'unite: Troubles myeloproliferatifs et myelodysplasie - 05 globules rouge (1.5 hrs)	Oct 22, 2009
Tutor - Case Base Learning (CBL) (3 hrs)	Jan 16, 2009
Tutor - Case Base Learning (CBL) (6 hrs)	Jan 13, 2009
Tutor - Case Base Learning (CBL) (3 hrs)	Jan 9, 2009
Directed Activities - Globules rouges (1.5 hrs)	Jan 8, 2009
Syndromes myeloproliferatifs et myelodysplasique (3 hrs)	Jan 8, 2009
Laboratory lecture: Anemie (3 hrs)	Jan 8, 2009
Hemoglobinopathies/CIVD (10 hrs)	Jan 6, 2009
Tutor - Case Base Learning (CBL) (3 hrs)	Dec 9, 2008
Tutor - Case Base Learning (CBL) (3 hrs)	Dec 5, 2008
Laboratory lecture: moelle normal et globule blancs (3 hrs)	Dec 4, 2008
Leucemie (1 hr)	Dec 1, 2008
Leucemie aigue (3 hrs)	Nov 26, 2008

Tutor - Case Base Learning (CBL) (2 hrs)	Nov 28, 2008
Tutor - Case Base Learning (CBL) (2 hrs)	Nov 25, 2008
4 APC semaine 9 et 11: Mono/Lymphome et Leucemie (CBL) (3 hrs)	Nov 21, 2008
4 APC semaine 9 et 11: Mono/Lymphome et Leucemie (3 hrs)	Nov 18, 2008

*University of Ottawa
Graduates*

Examiner, MSc Thesis Defense for Vignan Yogendrakumar Improving our Ability to Define and Predict Hematoma Expansion in Intracerebral Hemorrhage: A Detailed Analysis of Prospective Intracerebral Hemorrhage Cohorts	Aug 30, 2019
Chair, MSc Epidemiology Thesis Defense for Shunichiro Nakao Title: Evaluating the impact of point-of-care ultrasonography on patients with suspected acute heart failure or chronic obstructive pulmonary disease in the Emergency Department: A prospective observational study.	Jul 16, 2018
Examiner, PhD Comprehensive Exam for Ariel Weir	Apr 13, 2017
Examiner, MSc Epidemiology Thesis Defense for Sean Bennett. Title: The Use of Perioperative Red Blood Cell Transfusions and their Appropriateness in Liver Resection.	Apr 25, 2017
Examiner, MSc Epidemiology Thesis Defense for Mohammad Golfam Title: Optimization of Lung Scintigraphy in Pregnant Women at the Ottawa Hospital	Mar 7, 2017
Examiner, PhD. Thesis Defense for Ghazi Saud Alotaibi Title: The Epidemiology of Venous Thromboembolism in Alberta, Canada: A Population Based Cohort Study. University of Alberta	Feb 19, 2016
Chair, MSc. Thesis Defense for Jon-David Schwalm Title: Revascularization strategies in multi-vessel coronary artery disease: Analysis of influencing factors. Supervisor, Dr. Jeremy Grimshaw.	Jan 12, 2015
Examiner, MSc Epidemiology. Thesis Defense for Edward Clark Title: The implementation of a computerized decision support system for oral anticoagulant dosing in hemodialysis patients: a study of effectiveness and safety in high-risk population. Co-Supervisors, Dr. Marc Rodger and Dr. Greg Knoll.	Dec 2014
Examiner, MSc Epidemiology. Thesis Defence for Leigh Jonah Title: The Clinical Validity of Family History in Risk Classification of Colorectal Cancer. Supervisor, Dr. Brenda Wilson.	May 2014
Examiner, MSc. Epidemiology Thesis Defence for Abdulhakeem Mohammed Alobaid Title: Bariatric Surgery for Obesity: A Systematic Review and Meta-Analysis	Apr 2013
Examiner, MSc. Epidemiology Thesis Defence for Fahad Alkherayf Title: Restarting Oral Anticoagulation Therapy in Patients with Mechanical Heart Valve and Intracranial Haemorrhages.	Nov 2012

Other Graduates

Examiner, PhD Thesis Defense for Philippe Robin, Centre Hospitalier Universitaire de Brest, Brest (CHU Brest) Jan 11, 2019

Other Academic/Teaching Experience

Application Mentor. Clinical Research Training Institute (CRTI) of the American Society of Hematology.	2020-2021
Presenter: Introduction to trial design. ASH CRTI Webinar. Clinical Research Training Institute of the American Society of Hematology.	Jul 29, 2019
Lecturer: Systematic Reviews and Meta-Analysis and How to Search the Literature Workshop. 2018 CRTI Summer Workshop, Clinical Research Training Institute of the American Society of Hematology. La Jolla, CA	Jul 31, 2018
Lecturer: Overview of Trial Design. 2018 CRTI Summer Workshop, Clinical Research Training Institute of the American Society of Hematology. La Jolla, CA	Jul 30, 2018
Presenter: Malignant Hematology & Thrombosis. Palliative Medicine Academic Half Day. The Ottawa Hospital, University of Ottawa. Ottawa, ON.	May 14, 2019
Presenter: DVT/PE focus on diagnosis. Division of Hematology Academic Half Day. The Ottawa Hospital, University of Ottawa. Ottawa, ON.	Jun 7, 2018
Presenter: Malignant Hematology & Thrombosis. Palliative Care Academic Half Day. The Ottawa Hospital, University of Ottawa. Ottawa, ON.	May 8, 2018
Lecturer: Overview of Trial Design and Systematic Reviews and Meta-Analysis Workshops. 2017 CRTI Summer Workshop, Clinical Research Training Institute of the American Society of Hematology. La Jolla, CA	Aug 5-11, 2017
Keynote Session: Global Impact of Ottawa Research. The Ottawa Hospital Department of Medicine Research Day.	Jun 7, 2017
Presenter: Malignancy-Associated Thrombosis. Palliative Care Academic Half Day. The Ottawa Hospital, University of Ottawa. Ottawa, ON.	May 9, 2017
Moderator Oral Session: Outcomes Research – Non-Malignant Conditions: Hemostasis and Thrombosis. 58th ASH Annual Meeting and Exposition. American Society of Hematology. San Diego, CA.	Dec 4, 2016
Presenter: DVT prophylaxis: Who, when and how for outpatient oncology patients. Medical and Radiation Oncology Residents Academic Half Day. The Ottawa Hospital, University of Ottawa. Ottawa, ON.	Nov 16, 2016
Facilitate Session: DVT/PE: Clinical Applications and Treatment Division of Hematology Academic Half Day. University of Ottawa	May 12, 2016

Moderator Oral Session: Antithrombotic Therapy: Therapy in Cancer Patients 57th ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL.	Dec 7, 2015
Moderator Oral Session: Health Services and Outcomes Research – Non- Malignant Conditions: Venous Thromboembolism in Malignancy 57th ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL.	Dec 7, 2015
Presenter: DVT/PE diagnosis and management, including NOACs. Division of Cardiology Academic Half Day. The Ottawa Hospital, University of Ottawa. Ottawa, ON.	Dec 2, 2015
Moderator: Cancer and Thrombosis Session. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada.	Jun 24, 2015
Moderator: Superficial Venous Thrombosis, Session V: Venous Thrombosis: To Treat or Not to Treat. Hemostasis & Thrombosis Research Society (HTRS) 2015 Scientific Symposium. New Orleans.	Apr 18, 2015
Moderator: Distal Deep Venous Thrombosis. Session V: Venous Thrombosis: To Treat or Not to Treat. Hemostasis & Thrombosis Research Society (HTRS) 2015 Scientific Symposium. New Orleans.	Apr 18, 2015
Chair, MSc. Thesis Defense for Trang Nguyen Title: Acceptance of an Emergently Released Vaccine by the General Public: 2009 H1N1 Influenza Pandemic Vaccine. Supervisor, Dr. Jamie Brehaut.	Sep 2012
Presenter: Perioperative bridging/reversal/thromboprophylaxis. Hematology Residency Training Program Academic Half Day, University of Ottawa. Ottawa, ON (with Dr. Janet Lui). Ottawa, ON.	Aug 23, 2012
Chair, PhD Comprehensive Exam for Chris Cameron University of Ottawa	Feb 2012
Presenter: New oral anticoagulants. Internal Medicine Academic Half Day, University of Ottawa. Ottawa, ON.	Jan 18, 2012
Abstract Reviewer, Cancer and Thrombosis. XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Amsterdam, The Netherlands, June 29-July 4, 2013.	2013
Moderator ePoster session: Angicoagulant Agents. XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Amsterdam, The Netherlands, June 29-July 4, 2013.	2013.
Abstract Reviewer Annual Meeting of the American Society of Hematology San Diego, California, December 6, 2011	2011

Supervisor of Clinical Research to Second Year Medical Student Undergraduate Research Opportunity Program Award University of Ottawa, Winter 2011	2011
Examiner, Oral Examinations Annual Canadian Hematology Resident Retreat Sunnybrook Health Sciences Centre, Toronto, ON July 15, 2011	2011
Presenter: Cancer-associated-thrombosis. Hematology Residency Training Program Half day, University of Ottawa. Ottawa, ON.	Jul 14, 2011
Presenter: Peri-operative management of anticoagulation. General Surgery-Half Day, University of Ottawa, Ottawa, ON.	Feb 1, 2011
Moderator, Oral Session: Antithrombotic Therapy: Changing Practice through Clinical Trials – Antithrombotics and Reversing Agents.” Annual Meeting of the American Society of Hematology Orlando, Florida, December 6, 2010	2010
Application Reviewer Internal Medicine CaRMS, University of Ottawa, December 2010	2010
Grant Reviewer, Fonds de la recherche en santé Québec Clinical Research in Partnership with the Pharmaceutical Industry November 2010	2010
Reviewer, The Physicians’ Services Incorporated Foundation PE METRICS: Pulmonary Embolism: Methodology, Epidemiology & Treatment in Critical Care Study	2009
Author, Bayer HealthCare Educational Tool From Efficacy to Effectiveness: Novel Advances in VTE Practice	2009
Reviewer, American College of Physicians, Physician Information and Education Resource (PIER) Module: “Venous Thromboembolism Prophylaxis in the Surgical Patient	2009
Member, Adjudication Committee Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)	2012-present
Presenter: HIT and Cancer and Thrombosis. Internal Medicine Half Day, University of Ottawa. Ottawa, ON.	Oct 8, 2008
Member, Adjudication Committee Extended Prophylaxis Comparing Low Molecular Weight Heparin to Aspirin Following Total Hip Arthroplasty (EPCAT)	2008-2011
Member, Adjudication Committee Venous Thromboembolism Natural History Incidence and Outcome in the Elderly (VENICE)	2008-2009

Abstract reviewer and Moderator American Society of Hematology (ASH) Annual Meeting and Exposition Antithrombotic Therapy – Special Populations and Management Issues Session	2008-2009
Member, Data Safety and Monitoring Board Committee Randomized Trial of Tenecteplase to Treat Patients with Severe Submassive Pulmonary Embolism (US)	2008-present
Tutor, Years 1 and 2 Physical Skills Development Course University of Ottawa	2002-2005

Clinical Electives:

Jennifer Lymer, PGY2 Neurology, University of Ottawa (8 hrs)	May 12, 19, 2021
Daniel Fadare, PGY1 Internal Medicine, University of Ottawa (4 hrs)	May 5, 2021
Henry Liu, PGY1 Ophthalmology, University of Ottawa (4 hrs)	Apr 7, 2021
Kathryn Sullivan, PGY1 Internal Medicine, University of Ottawa (4 hrs)	Dec 16, 2020
Milani Sivapragasam, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Dec 2, 9, 2020
Dennys Avecilla, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Nov 18, 25, 2020
Melissa Lepage-Ratte, PGY1 Internal Medicine, University of Ottawa (4 hrs)	Nov 4, 2020
Kevin Chin, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Oct 21, 28, 2020
Micaela Jacobson, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Oct 7, 14, 2020
Hamza Mahmood, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Sep 23, 30, 2020
David Aziz, PGY2 Internal Medicine, University of Ottawa (8 hrs)	Sep 9, 16, 2020
Gabrielle Bourque, PGY3 Internal Medicine, University of Ottawa (8 hrs)	Aug 26, Sep 2
Kelsey Uminski, PGY4 Hematology, University of Ottawa (4 hrs)	Jul 8, 2020
Robert Kay, PGY3 Internal Medicine, University of Ottawa (4 hrs)	May 20, 2020
Kooroush Dehghan, PGY1 Internal Medicine, University of Ottawa (4 hrs)	May 6, 2020
Jessica Evans, PGY4 Internal Medicine, University of Ottawa (4 hrs)	Apr 22, 2020
Annie Hung, PGY1 Internal Medicine, University of Ottawa (4 hrs)	Apr 15, 2020
David Spillane, PGY2, McGill University (4 hrs)	Feb 26, 2020
Jimmy Zhang, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Feb 12, 19, 2020
Yan Xu, PGY4 Hematology, uOttawa (4 hrs)	Jan 15, 2020
Anthony Grieco, PGY5 Hematology, University of Ottawa (8 hrs)	Dec 18, 2019, Jan 8, 2020

Sheryl Hodgson, PGY4 Internal Medicine, University of Ottawa (16 hrs)	Nov 20, 27, Dec 4, 11, 2019
Frank Battaglia, MS 4, University of Ottawa (4 hrs)	Nov 20, 2019
Kevin Hill, PGY2 Internal Medicine, University of Ottawa (4 hrs)	Nov 13, 2019
Luke Gagnon, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Oct 23, 20, 2019
Christopher Mansour, PGY2 Internal Medicine, University of Ottawa (8 hrs)	Oct 9, 16, 2019
Qazi Sohail, PGY3 Internal Medicine, University of Ottawa (4 hrs)	Oct 2, 2019
Michael D'Aquila, PGY4 Internal Medicine, University of Ottawa (8 hrs)	Sep 11, 18, 2019
Sonia Poenaru, PGY2 Internal Medicine, University of Ottawa (4 hrs)	Sep 4, 2019
Natasha Rupani, PGY5, Queen's University (4 hrs)	Aug 28, 2019
Chris Picheca, PGY2 Neurology, University of Ottawa (8 hrs)	Aug 14, 21, 2019
Hely Shah, PGY2 Internal Medicine, University of Ottawa (8 hrs)	Jul 31, Aug 7, 2019
James Zhang, PGY5 Internal Medicine, University of Ottawa (8 hrs)	Jun 12, 26, 2019
Kelsey Uminski, PGY2, University of Manitoba (4 hrs)	May 15, 2019
Wilson Stephenson PGY3 Internal Medicine, University of Ottawa (4 hrs)	May 8, 2019
Ian Pitcher, PGY3 Internal Medicine, University of Ottawa (8 hrs)	Apr 24, May 1, 2019
Hamza Mahmood, PGY1 Internal Medicine, University of Ottawa (4 hrs)	Apr 10, 2019
Emily Curley, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Mar 27, Apr 3, 2019
Joshua Bowridge, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Feb 27, Mar 6, 2019
Mohammed Abdoli, PGY2 Neurology, University of Ottawa (8 hrs)	Feb 13, 20, 2019
Rudy Unni, PGY5 Internal Medicine, University of Ottawa (4 hrs)	Jan 30, 2019
James Zhang, PGY5 General Internal Medicine, University of Ottawa (4 hrs)	Jan 9, 2019
Weiwei Beckerleg, PGY4 General Internal Medicine, University of Ottawa (4 hrs)	Nov 21, 2018
Stefan Rodic, PGY1 Internal Medicine, University of Ottawa (4 hrs)	Nov 9, 2018
Abid Ismail, PGY4 General Internal Medicine, McMaster University (4 hrs)	Oct 17, 2018
Liz Irish, PGY2 Neurology, University of Ottawa (4 hrs)	Oct 3, 2018
Danielle Moorman, PGY3 Internal Medicine, University of Ottawa (4 hrs)	Sep 26, 2018
Joseph Aziz, PGY1 Internal Medicine, University of Ottawa (4 hrs)	Sep 5, 2018
Manika Gupta, PGY4 Hematology, McMaster University (8 hrs)	Aug 29, Sep 19, 2018
Jieging Xu, PGY1 Internal Medicine, University of Ottawa (8 hrs)	Jul 11, 25, 2018
Kyle Murphy, PGY3 Critical Care, University of Ottawa (8 hrs)	Jun 20, 27, 2018
Daniel Chan, MS1 Internal Medicine Student Exposure week, University of Ottawa (4 hrs)	Jun 13, 2018

Maggie Moores, PGY2 Neurology, Dalhousie University (8 hrs)	May 16, 30, 2018
Marc Reeson, PGY5 General Internal Medicine, University of Saskatchewan (4 hrs)	Apr 25, 2018
Asma Atfeesh, PGY4 Hematology, Univeristy of Saudi Arabia (8 hrs)	Apr 18, May 2, 2018
Nicholas Chin-Yee, PGY3 Internal Medicine, University of Ottawa (4 hrs)	Apr 4, 2018
Rocky Wang, PGY5 Hematology, University of Ottawa (8 hrs)	Mar 21, Apr 4, 2018
Samantha Cremer, MS4 University of Ottawa (4 hrs)	Mar 7, 2018
Ayel Yahya, Clinical Fellow, Saudi Arabia (8 hrs)	Feb 28, Mar 7, 2018
Saleh Fadel, MS4 University of Ottawa (4 hrs)	Nov 29, 2017
Monica Gad, MS4 University of Ottawa (4 hrs)	Nov 22, 2017
Michael Wong, PGY2 Internal Medicine, University of Alberta (4 hrs)	Nov 8, 2017
Yousef Alhumanna, PGY2 Critical Care, University of Ottawa (8 hrs)	Sep 27, Oct 11, 2017
Matthew Cohen, MS4 University of Montreal (4 hrs)	Sep 6, 2017
Salma Shivji, PGY5 Hematology, University of Alberta (12 hrs)	Aug 30, Sep 13, 20, 2017
James England, PGY3 Internal Medicine, University of Toronto (4 hrs)	Aug 23, 2017
Yamilée Hebert, MS 2 University of Ottawa (8 hrs)	Aug 22, 25, 2017
Roy Khalife, PGY4 Hematology, University of Ottawa (8 hrs)	Aug 16, 23, 2017
Alison Castle, PGY1 Genetics, University of Ottawa (4 hrs)	Aug 16, 2017
Manika Gupta, PGY3 Internal Medicine, McMaster University (4 hrs)	Aug 2, 2017
Xing Jian Liu, PGY3 Internal Medicine, McGill University (4 hrs)	Jul 5, 2017
Osman Radwhi, PGY4 Hematology, King Abdulaziz University (4 hrs)	Jul 5, 2017
Justin Graveline PGY2 Neurology (8 hrs)	Jun 1, 21, 2017
Aimee Li PGY4 Internal Medicine, University of Ottawa (4 hrs)	May 3, 2017
Jacques Maillet, PGY3 Internal Medicine, Dalhousie University (4 hrs)	Apr 26, 2017
Lydia Richardson, MS3 University of Ottawa (4 hrs)	Apr 19, 2017
Gauruv Bose, PGY2 Internal Medicine, University of Ottawa (4 hrs)	Apr 4, 2017
Shen Li, PGY2 Internal Medicine, McGill University (4 hrs)	Mar 29, 2017
Nily Osman, PGY2 Neurology, University of Ottawa (8 hrs)	Mar 8, 22, 2017
Kyle Murphy, PGY4 Critical Care, University of British Columbia (4 hrs)	Feb 22, 2017
Andrea Cervi, PGY3 Internal Medicine, University of Ottawa (8 hrs)	Feb 8, 15, 2017
Talia Abecassis, MS4 University of Ottawa (4 hrs)	Feb 8, 2017
Houman Rashidian, MS4 (4 hrs)	Jan 4, 2017
Stacey Tokar, Neurology resident (4 hrs)	Jan 4, 2017
Junghyun Park, MS4 University of Ottawa (4 hrs)	Nov 23, 2016

Ayman Mukhtar, PGY5 Hematology, King Abdul Aziz University (8 hrs)	Nov 16, 30, 2016
Asma Atfeesh, PG, Saudi (4 hrs)	Nov 16, 2016
Mohammed Marei, PGY6 Hematology, University of Ottawa, (16 hrs)	Oct 19, 26, Nov 2, 9
Mary-Pat Schlosser, PGY6 Pediatric Hematology, Univ of Ottawa (8 hrs)	Oct 14, 19, 2016
w/Shipa Gupta, PGY 3 Internal Medicine, University of Ottawa (4 hrs)	Sep 27, 2016
Noelle Ma, Med Student Y4 University of Toronto (4 hrs)	Sep 23, 2016
Maggie Eddy, PGY 4 Internal Medicine, University of Ottawa (12 hrs)	Sep 2, 9, 16, 2016
Janique Dyba, PGY3 Internal Medicine, Queen's University (4 hrs)	Jul 22, 2016
Erica Blimkie, MS2 University of Ottawa (4 hrs)	Jul 15, 2016
Danielle Hammond, Med Student University of Ottawa (4 hrs)	May 20, 2016
Adam Bryant, PGY5 Hematology, University of Ottawa (8 hrs)	Mar 11, Apr 1, 2016
Miriam Kimpton, PGY3 Internal Medicine, University of Ottawa (4 hrs)	Mar 11, 2016
Chaoran Zhang, MS4 University of Ottawa (4 hrs)	Jan 15, 2016
J. Ding, PGY2 Neurology, University of Ottawa (4 hrs)	Dec 18, 2015
Aimee Li, PG Internal Medicine, University of Ottawa (4 hrs)	Dec 11, 2015
Natalie Satkunum, PGY, Internal Medicine, University of Ottawa (4 hrs)	Nov 27, 2015
Zahra Alshamassi, Hematology, University of Ottawa (8 hrs)	Nov 20, 27, 2015
Jaelyn Ernst, PGY4 Internal Medicine, University of Ottawa (8 hrs)	Aug 11, 14, 2015
Nabeel Syed, PGY2 Internal Medicine, University of Ottawa (4 hrs)	Aug 7, 2015
Miriam Kimpton PGY2, Internal Medicine, University of Ottawa (4 hrs)	May 19, 2015
Julie Tien, PGY4 Internal Medicine, University of Alberta (12 hrs)	Mar 13-27, 2015
Manal Alsagaff, PGY 4 Internal Medicine, University of Alberta (16 hrs)	Feb 13-Mar 6, 2015
Afshan Gheshmy, Internal Medicine, University of Ottawa (4 hrs)	Oct 31, 2014
I Medrea, PGY2 Neurology, University of Ottawa (4 hrs)	Jul 18, 2014
Mary Salib, McMaster University (8 hrs)	Jul 4, 11, 2014
Émilie Meyers, MS1 University of Ottawa (12 hrs)	Feb 19-22, 2013

Supervisory Activities

Post Graduate

Co-Supervision:

Joseph Shaw, MSc, Clinical Epidemiology	2020-
Shira Strauss, MSc, Clinical Epidemiology	2019-present
Optimizing Anti-thrombotic Regimens in Females with Symptomatic Lower Extremity Arterial Disease	

Miriam Kimpton, MSc, Clinical Epidemiology Myeloproliferative disorders and thrombosis	2018-2020
Rick Ikesaka, MSc, Clinical Epidemiology Upper extremity thrombosis	2016-2018
Leslie Skeith, MEd Area of focussed competency in adult thrombosis medicine	2015-2017
Lisa Duffett, MSc, Clinical Epidemiology Management of superficial venous thrombosis: Defining event rates and designing a pilot randomized trial of anticoagulant therapy.	2012-2017
Lana Castellucci, MSc, Clinical Epidemiology Safety and efficacy of venous thromboembolism prophylaxis in severe traumatic brain injury.	2013-2015
Patricia Moretto, MSc, Clinical Epidemiology Use of thromboprophylaxis in hospitalized medically ill cancer patients	2010-2014
Esteban Gandara, MSc, Clinical Epidemiology Is a quarter dose reduction of low molecular weight Heparin effective for secondary prevention in pregnant patients diagnosed with deep vein thrombosis or pulmonary embolism?	2009-2012

Research Projects

Co-Supervision

Bader Al-Rawahi, MSc, Clinical Epidemiology Efficacy and safety of aspirin for venous thromboembolism primary prophylaxis after major abdominal surgery. Co-Supervisor: G. Le Gal	Aug 2013- Sep 2015
--	-----------------------

Supervision:

Ryan Buyting, Undergraduate Student, University of Ottawa Research Project: Venous thromboembolism in multiple myeloma.	Jun-Aug, 2016
Bader Al-Rawahi, MSc, Clinical Epidemiology Efficacy and safety of aspirin for venous thromboembolism primary prophylaxis after major abdominal surgery.	Aug 2013-Jun 2017
Joseph Shaw, Medical Student, ASH HONORS Award Research Project: Evaluating risk of delayed bleeding in critically ill trauma patients.	2014-2015
Turki Alshuaibi, Hematology Residency Training Program, University of Ottawa PGY4 Elective, Block 3	2013
Daniel Yokum, Internal Medicine Resident, University of Ottawa Research Project: Incidental venous thromboembolism in kidney cancer patients.	2012-2014
Ryma Ihaddadene, Graduate Student, University of Ottawa Research Project: Incidental venous thromboembolism in cancer patients. It is a retrospective chart review of patient records with kidney, pancreas and lung cancers.	2012-present
Miriam Kimpton, PGYI Internal Medicine Resident, University of Ottawa Research Project: Venous thromboembolism in multiple myeloma.	2014-present

Undergraduate Research Opportunity Program Award: Research Project: Determination of time in therapeutic range for patients on long-term anticoagulation.	2011-present
Miriam Kimpton, Medical Student, ASH Trainee Research Award Research Project: Does the frequency of INR testing correspond to Time in Therapeutic Range in patients receiving warfarin?	2012 and 2015
Vincent Ngo, Research Summer Student, University of Ottawa Research Project: Incidence and predictive factors of symptomatic thrombosis related to port-a-cath in chemotherapy patients	2012-2013
Siavash Piran, Internal Medicine Resident University of Ottawa, and ASH Trainee Research Award Research Project: Incidence and predictive factors of symptomatic thrombosis related to port-a-cath in chemotherapy patients.	2011-2013
Rick Ikesaka, Internal Medicine Resident, University of Ottawa Research Project: Systematic review of weight-based dosing of heparin.	2011-present
Katrien van der Salm, Medical Student, MMed, Maastricht University Research Project: Closing the communication gap between thrombosis clinics and patients on anticoagulation for venous thrombosis in Canada: Survey on preference for wireless or landline medication reminders.	Sep-Dec 2012
Melanie Tan, Post Doctorate Fellowship, Leiden University Medical Center Research Project: Systematic on the risk of recurrence and major bleeding for patients with upper extremity DVT.	Oct 2011-Sep 2012
Andrew Aw, Internal Medicine Resident, University of Ottawa Research Project: Systematic review on compliance with anticoagulant medications	2010-2012
Jamila Al-Faris, Internal Medicine Resident, University of Ottawa Research Project: Prophylactic IVIG and antibiotics in CLL: a systematic review	2010-2013
Gauruv Bose, Research Summer Medical Student, University of Ottawa Research Project: Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? Research Project: Outcomes of saddle pulmonary embolism: a nested case-control study. Research Project: Safety of outpatient treatment in acute pulmonary embolism.	2010
Petra Erkens, Graduate Student (research project), University of Ottawa	2010-2011
Josh Koczerginski, Research Summer Medical Student, University of Ottawa	2010
Yi-Hao Shen, Research Summer Medical Student, University of Ottawa	2009
Kimberly Do, Research Summer Student, University of Ottawa	2008
Sarah Tierney, Research Summer Student, University of Ottawa	2008
Marika Armstrong, Resident Elective, University of Ottawa	2013
Jesse Nault, Clinical Elective, First Year Medical Student, University of Ottawa	2013
Josée Sylvain, Clinical Elective PGY1, Queen's University	2013
Émilie Meyers, Clinical Elective, 1st year Medical Student, University of Ottawa	2013
Lisa Falvo, Resident Elective	2011

Jessica Roy, Elective 1st year Medical Student, University of Ottawa	2009
Marie-Eve Berube, Elective 1st year Medical Student, University of Ottawa	2009
Marie-Eve Murray, Elective 1st year Medical Student, University of Ottawa	2009

Consultations, Workshops, Seminars

1. CanVECTOR National Thrombosis Seminar: Bleeding & Anticoagulation. Virtual. Apr 27, 2021
2. 10th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 22-26, 2021. Virtual. Bergamo, Italy.
3. Essentials for Academic Leadership Workshop Phase II. University of Ottawa, Faculty of Medicine. Ottawa, ON. Feb-May 2021.
4. Put the oxygen mask on yourself first: Looking after yourself so that you can look after others. Leadership Development Institute (LDI), The Ottawa Hospital. Ottawa. Nov 19, 2020.
5. Colloque neurovasculaire 2020 Société des sciences vasculaires du Québec (SSVQ). Oct 23, 2020.
6. Growth Mindset. CBD Webinar Series. Royal College of Physicians and Surgeons of Canada. Oct 7, 2020.
7. CanVECTOR National Thrombosis Seminar: COVID-19 and Thrombosis – Concept of Immunothrombosis. Virtual. Sep 21, 2020.
8. ISTH 2020 Virtual Congress. International Society on Thrombosis and Haemostasis. Jul 12-14, 2020.
9. Leading in challenging times: Covid-19 and the changing face of leadership at TOH. Leadership Development Institute (LDI), The Ottawa Hospital. Ottawa. Jun 11, 2020.
10. 61st ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL. Dec 7-10, 2019.
11. CanVECTOR 4th Annual Conference. Toronto, ON Oct 17-18, 2019.
12. Thrombosis Canada Annual Education Conference. Toronto, ON. Oct 19, 2019.
13. Diagnosis of VTE. Canadian AFC Adult Thrombosis Medicine Half Day. University of Ottawa, McMaster University, McGill University. Ottawa, ON. Oct 3, 2019.
14. VTE Dublin 2019: Diagnostic and therapeutic advances in venous thromboembolism (VTE). Mater Misericordiae University Hospital. Sep 25-27, 2019. Dublin, Ireland.
15. Canadian Hematology Conference. Toronto. Sep 20-21, 2019.
16. The 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 65th Annual Scientific and Standardization Committee (SSC) Meeting., Melbourne, Australia, July 6 - 10, 2019.

17. European and Mediterranean League Against Thromboembolic Disease (EMLTD) 50th Anniversary International Congress on Thrombosis. Athens, Greece. Jun 19-22, 2019
18. 24th Congress of the European Hematology Association (EHA). Jun 13-16, 2019. Amsterdam.
19. Department of Medicine Resident Research Day. University of Ottawa at The Ottawa Hospital. Ottawa, ON. May 29, 2019.
20. Association des Spécialistes en Médecine Interne du Québec (ASMIQ). Montreal, QC. May 25, 2019
21. Evening Symposium: Choosing plasma wisely: when and when not to use plasma. Ontario Regional Blood Coordinating Network (ORBCoN). May 2, 2019. Toronto, ON.
22. 15th National Conference on Anticoagulant Therapy (AC Forum). April 11-13, 2019. Fort Lauderdale, Florida
23. Symposium on Hepatic Oncology at Whistler (SHOW). Jan 31-Feb 1, 2019. Whistler, BC.
24. CANVECTOR 3rd Annual Conference. Montreal, QC. Oct 25-26, 2018.
25. Thrombosis Canada Annual Education Conference. Montreal, QC. Oct 27, 2018.
26. 64th Annual Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH). Jul 18-21, 2018. Dublin, Ireland.
27. Department of Medicine Resident Research Day. University of Ottawa at The Ottawa Hospital. Ottawa, ON. Jun 7, 2018.
28. Ottawa Blood Disease Centre Trainee Research Symposium, Division of Hematology, University of Ottawa at The Ottawa Hospital. Ottawa, ON. May 10, 2018.
29. CAPHO Conference 2018. Canadian Association of Pharmacy in Oncology. May 3-6, 2018. Gatineau, QC.
30. 43rd Annual CVAA Conference. Canadian Vascular Access Association. Apr 25-27, 2018. Toronto, ON.
31. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC). Apr 13-15, 2018. Bergamo, Italy.
32. 59th ASH Annual Meeting and Exposition. American Society of Hematology. Dec 9-12, 2017. Atlanta, GA.
33. Thrombosis Canada, Annual Conference and General Meeting. Toronto, ON. Nov 11, 2017.
34. CanVECTOR 2nd Annual Conference. Nov 10, 2017. Toronto, ON.
35. The Ottawa Hospital Research Institute Research Day. Ottawa, ON. Nov 9, 2017.
36. Dalhousie University Hematology Symposium. Halifax, NS. Nov 4, 2017.
37. University of Ottawa, Department of Internal Medicine Academic Research Half Day. Ottawa, ON. Nov 1, 2017.

38. XXVI Congress and 63 Annual SSC Meeting of the International Society on Thrombosis and Haemostasis (ISTH). Berlin, Germany. July 8-13, 2017.
39. The Ottawa Hospital, Department of Medicine Research Day. Ottawa, ON. Jun 7, 2017.
40. University of Ottawa, Division of Hematology Trainee Research Day. May 4, 2017
41. 18th Annual Antithrombotic Therapy Symposium: Improving Anticoagulation in Detroit. Dearborn, MI. Apr 28, 2017.
42. Ontario Regional Blood Coordinating Network's 12th Annual Transfusion Videoconference Symposium: Blood and Guts: Management of the GI Bleed. Sudbury, ON. Apr 12, 2017.
43. Hemostasis & Thrombosis Research Society (HTRS) 2017 Scientific Symposium. Scottsdale, AZ. Apr 6-8, 2017.
44. Essentials for Academic Leadership Workshop. University of Ottawa, Faculty of Medicine. Ottawa, ON. Jan-May, 2017.
45. Thrombosis Pearls & Perils for Primary Care, Thrombosis Canada. Vancouver, BC. Nov 13, 2016.
46. CanVECTOR 1st Annual Conference. Jun 7-9, 2016. Toronto, ON.
47. 62nd Annual Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Montpellier, France. May 25–28, 2016. Chair.
48. Third Biennial Thrombosis and Hemostasis Summit of North America. Thrombosis and Hemostasis Societies of North America (THSNA). Chicago, IL. Apr 13-16, 2016.
49. 8th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC). Bergamo, Italy. April 8-10, 2016.
50. 57th ASH Annual Meeting and Exposition. American Society of Hematology. Orlando, FL. Dec 5-8, 2015.
51. 15e Congrès Annuel, Symposium et Exposition de la Société des sciences vasculaires du Québec (SSVQ). Quebec, QC . Nov 21, 2015.
52. Thrombosis Canada Annual Conference and General Meeting. Ottawa, ON. Nov 7, 2015.
53. 11th Annual McMaster Update in Thromboembolism & Hemostasis. McMaster University. Hamilton, ON. Oct 30, 2015.
54. Meeting of the CanVECTOR Investigators Group (CIG). Montreal, QC. Sep 21, 2015.
55. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, ON. Jun 20-25, 2015
56. CAEP 2015 Conference. Canadian Association for Emergency Physicians (CAEP). Jun 2, 2015. Edmonton, AB.
57. 13th National Conference of the Anticoagulation Forum. Washington, DC. Apr 23-25, 2015.

58. Hemostasis & Thrombosis Research Society (HTRS) 2015 Scientific Symposium. New Orleans. Apr 16-18, 2015.
59. Biannual meeting of the Venous Thrombosis Clinical Trials Organisation (VECTOR). Ottawa, ON. Jan 23, 2015.
60. 56th ASH Annual Meeting & Exposition. American Society of Hematology San Francisco, CA. December 6-9, 2014.
61. Biannual meeting of the Venous Thrombosis Clinical Trials Organisation (VECTOR). London, ON. Sep 29, 2014
62. Conflict Management and Negotiation course. Canadian Medical Association, Physician Management Institute (PMI). Sep 7-9, 2014.
63. 60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Milwaukee, WI. Jun 23-26, 2014.
64. Biannual meeting of the Venous Thrombosis Clinical Trials Organisation (VECTOR). Halifax, NS. Jun 13, 2014
65. Geriatric Challenges in Primary Care. University of Ottawa, Continuing Professional Development. Ottawa, ON. Jun 6, 2014.
66. American Society of Hematology (ASH) 55th Annual Meeting and Exposition in New Orleans, LA. Dec 7-10, 2013.
67. Family Medicine Forum. The College of Family Physicians of Canada. Vancouver, BC. Nov 7-9, 2013.
68. Scientific Highlights: Post-ISTH 2013. Hematology Grand Rounds, The Ottawa Hospital. Oct 24, 2013.
69. Canadian Society of Internal Medicine (CSIM) Annual Meeting. Toronto, ON. Oct 2-5, 2013.
70. XXIVth Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands Jun 29-Jul 4, 2013.
71. 2nd Advanced course on Thrombosis and Haemostasis. College of Medicine, King Saud University, Riyadh, Saudia Arabia. May 14, 2013.
72. Atlantic Hematology Symposium 2013. Halifax, NS. May 11, 2013.
73. Association des médecins hématologues et oncologues du Québec (AMHOQ) 38^e Congrès Annuel. Quebec. May 2-5, 2013.
74. Journées Montfort 2013. April 19, 2013. Participant.
75. 2^o Congreso de Medicina Interna de la Costa Atlántica, Mar del Plata, Argentina. March 21-23, 2013.
76. American Society of Hematology (ASH) 54rd Annual Meeting and Exposition, Atlanta, GA Dec 8-11, 2012. Participant.

77. 58th Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH). Liverpool, UK. June 27-30, 2012. Participant.
78. Sixth International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy. April 20-22, 2012. Participant.
79. American Society of Hematology (ASH) 53rd Annual Meeting and Exposition, San Diego, CA Dec 10-13, 2011. Participant.
80. Workshop For New Program Directors. Sep 2011. Participant.
81. XXIII Congress of International Society on Thrombosis & Haemostatis (ISTH) and 57th Annual SSC meeting. Kyoto, Japan. Jul 23-28, 2011. Participant.
82. 4th International Symposium to be on Women's Health Issues in Thrombosis and Haemostasis. Feb 2011. Participant.
83. CHEO - Fellowship Academic Half Day. Jan 2011. Participant.
84. American Society of Hematology (ASH), 52nd Annual Meeting. Orlando, Florida. December 4-7, 2010. Participant.
85. 56th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) Cairo, Egypt May 22-25, 2010. Participant.
86. Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), April 23-25, 2010 Stresa Italy. Participant.
87. Time Management Workshop. Apr 2010. Participant.
88. American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Dec 5-8, 2009 New Orleans. Participant.
89. Investigator Training Program. Nov 2009. Participant.
90. New Faculty Orientation. Sep 2009. Participant.
91. American Society of Hematology (ASH) 50th Annual Meeting and Exposition. San Francisco. Dec 6-9, 2008. Participant.

Peer Reviewer

Elsevier, Outstanding Reviewer Status award

2014

	Journal	# Articles Reviewed
2021	Blood	1
	European Journal of Internal Medicine	1
	JAMA	1
	Research and Practice in Thrombosis and Haemostasis	1
2020	Annals of Internal Medicine	1

	Journal	# Articles Reviewed
	Blood	2
	Blood Advances	1
	CMAJ	2
	Internal Medicine Journal	1
	Journal of Clinical Oncology	1
	NEJM	4
	Research and Practice in Thrombosis and Haemostasis	4
	Thrombosis and Haemostasis	5
	Thrombosis Research	9
2019	American Journal of Hematology	1
	Blood	1
	BMJ Supportive & Palliative Care	1
	Circulation	1
	Haematologica	1
	NEJM	4
	Thrombosis and Haemostasis	2
	Thrombosis Research	5
2018	American Journal of Perinatology	1
	Blood	2
	Blood Advances	1
	European Respiratory Journal	1
	Haematologica	2
	JAMA Internal Medicine	1
	JAMA Oncology	1
	NEJM	3
	Research and Practice in Thrombosis and Haemostasis	1
	Trials	1
	The Lancet	1
	Thrombosis and Haemostasis	6
	Thrombosis Research	11
2017	Annals of Internal Medicine	2
	Blood	2
	Blood Reviews	1
	BMJ	1
	Chest	1
	Cochrane Library	1
	Haematologica	1

	Journal	# Articles Reviewed
	Journal of Thrombosis and Haemostasis	1
	NEJM	1
	Research and Practice in Thrombosis and Haemostasis	3
	Supportive Care in Cancer	1
	Thrombosis (Hindawi)	1
	Thrombosis and Haemostasis	5
	Thrombosis Research	4
2016	Annals of Internal Medicine	1
	Annals of Oncology	1
	Blood	5
	BMJ Open	1
	British Medical Journal	1
	Chest	2
	Current Oncology	1
	Haematologica	2
	Journal of the American Medical Association	1
	Journal of Thrombosis and Haemostasis	1
	PLOS One	2
	Thrombosis and Haemostasis	5
	Thrombosis Research	7
2015	Annals of Internal Medicine	1
	Annals of Oncology	1
	Blood	5
	BMJ	1
	Canadian Medical Association Journal	1
	Clinical and Applied Thrombosis/Hemostasis	1
	Dove Medical Press	1
	Expert Opinion On Drug Safety	1
	Haematology	1
	Journal of the American Medical Association	1
	Journal of the National Comprehensive Cancer Network	1
	Journal of Thrombosis and Haemostasis	5
	New England Journal of Medicine	1
	Swiss Medical Weekly	1
	Thrombosis and Haemostasis	6
	The Lancet Hematology	1
	The Lancet Oncology	1
	Thrombosis and Haemostasis	1

	Journal	# Articles Reviewed
	Thrombosis Research	7
2014	Annals of Internal Medicine	1
	Annals of the American Thoracic Society	2
	British Medical Journal	1
	Blood	4
	Canadian Medical Association Journal	2
	Chest	1
	Clinical and Applied Thrombosis/Hemostasis	1
	Cochrane Peripheral Vascular Diseases (PVD) Group	2
	Circulation	1
	Future Medicine	1
	Hospital Practice	1
	Journal of Arteriosclerosis, Thrombosis, and Vascular Biology	2
	Journal of Cancer Research and Clinical Oncology	1
	Journal of Internal Medicine	1
	Journal of Thrombosis and Haemostasis	9
	Journal of Thrombosis and Thrombolysis	1
	Thrombosis and Haemostasis	2
	Thrombosis Research	10
	PLOS One	1
2013	Annals of Internal Medicine	1
	Annals of Medicine	1
	Annals of Surgery	1
	Blood	3
	British Medical Journal	1
	Canadian Medical Association Journal	1
	Chest	2
	Clinical and Applied Thrombosis/Hemostasis	1
	Clinical Lung Cancer	1
	Current Oncology	1
	European Journal of Internal Medicine	1
	The Journal of the American Medical Association	1
	Journal Arteriosclerosis, Thrombosis and Vascular Biology	1
	Journal of Thrombosis and Haemostasis	9
	Thrombosis and Haemostasis	1
	Thrombosis Research	4
	Portuguese Journal of Pulmonology	1

	Journal	# Articles Reviewed
2012	Blood	1
	Chest	2
	European Journal of Internal Medicine	1
	JAMA	1
	Journal of Thrombosis and Haemostasis	17
	Journal of Thrombosis and Thrombolysis	1
	Lung Cancer	1
	Thrombosis and Haemostasis	1
	Thrombosis Research	2
2011	Journal of Thrombosis and Haemostasis	2